ATTENUATED HERPES VIRUSES, HERPES VIRUSES WHICH INCLUDE FOREIGN DNA ENCODING AN AMINO ACID SEQUENCE AND VACCINES CONTAINING SAME

Abstract: The present invention provides a recombinant fusion protein comprising an antigenic amino acid sequence fused to at least a portion of the gpX glycoprotein from pseudorabies virus. Such a protein may be formulated into a vaccine and delivered to an animal using a live herpes virus vector adapted to express the fusion protein.

Description: ATTENUATED HERPESVIRUSES, HERPESVIRUSES WHICH INCLUDE FOREIGN DNA ENCODING AN AMINO ACID SEQUENCE AND VACCINES CONTAINING SAME This application is a continuation-in-part of U.S. Sferial No. 078,519, filed July 27, 1987, U.S. Serial No. 933,107, filed November 20, 1986, U.S. Serial No. 902,877, filed September 2, 1986, U.S. Serial No. 887,140, filed July 17, 1986, U.S. Serial No. 823,102, filed January 27, 1986, and U.S. Serial No. 773,403, filed September 6, 1985, the contents of each of which are hereby incorporated by reference into the present application. Background of the Invention Within this application several publications are refer- enced by Arabic numerals within parentheses. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entirety are hereby incorporated by reference into this applica- tion in order to more fully describe the state of the art to which this invention pertains. The advent of recombinant DNA techniques has made it possible to manipulate the naturally occurring DNA sequences within an organism (the genome) in order to change in some manner the functions of the organism through genetic engineering. The present invention concerns organisms defined as viruses that infect ani¬ mals and contain DNA as their genetic material; specif- icall viruses belonging to the herpesvirus group (her- pesviruses) (23). This group of viruses comprise a number of pathogenic agents that infect and cause dis¬ ease in a number of target species∑ swine, cattle, chickens, horses, dogs, cats, etc. Each herpesvirus is specific for its host species, but they are all related in the structure of their genomes, their mode of replication, and to some extent in the pathology they cause in the host animal and in the mechanism of the host immune response to the virus infection. The types of genetic engineering that have been per¬ formed on these herpesviruses consist of cloning parts of the virus DNA into plasmids in bacteria, recon¬ structing the virus DNA while in the cloned state so that the DNA contains deletions of certain sequences, and furthermore adding foreign DNA sequences either in place of the deletions or at sites removed from the deletions. The usual method is to make insertions of the foreign DNA into the viral sequences, although the foreign DNA could be attached to the end of the viral DNA as well. One utility of the addition of foreign sequences is achieved when the foreign sequence encodes a foreign protein that is expressed during viral infec¬ tion of the animal. A virus with these characteristics is referred to as a vector, because it becomes a living vector which will carry and express the foreign protein in the animal. In effect it becomes an elaborate de¬ livery system for the foreign protein. The prior art for this invention stems first from the ability to clone and analyze DNA while in the bacterial plasmids. The techniques that are available for the most part are detailed in Maniatis et al. (1). This publication gives state-of-the-art general recombinant DNA techniques. The application of recombinant DNA techniques to animal viruses has a relatively recent history from about 1980. The first viruses to be engineered have been the smallest ones - the papovaviruses. These viruses contain 3000-4000 base pairs (bp) of DNA in their genome. Their small size makes analysis of their genomes relatively easy and in fact most of the ones studied (SV40, polyoma, bovine papilloma) have been entirely sequenced. Because these virus particles are small and cannot accommodate much extra DNA, and because their DNA is tightly packed with essential ' sequences (that is, sequences required for replication) , it has not been possible to engineer these viruses as live vectors for foreign gene expression. Their entire use in genetic engineering has been as defective replicons for the expression of foreign genes in animal cells in culture (roughly analogous to plasmids in bacterial systems) or to their use in mixed populations of virions in which wild type virus acts as a helper for the virus that has replaced an essential piece of DNA with a foreign gene. The studies on papovaviruses do not suggest or teach the concept of living virus vectors as delivery systems for host animals. The next largest DNA animal viruses are the adenovi¬ ruses. In tnese viruses there is a small amount of nonessential DNA that can be replaced by foreign se¬ quences. The only foreign genes that seem to have been expressed in adenoviruses are the T-antigen genes from papovaviruses (2,3,4,5), and the herpes simplex virus thy idine kinase gene (28). It is possible, given this initial success, to envision the insertion of other small foreign genes into adenoviruses. However the techniques used in adenoviruses do not teach how to obtain the same result with herpesviruses. In par¬ ticular, these results do not identify the nonessen- tial regions in herpesviruses wherein foreign DNA can be inserted, nor do they teach how to achieve the expression of the foreign genes in herpesviruses, e.g. which promoter signals and termination signals to use. Another group of animal viruses that have been engi¬ neered are the poxviruses. One member of this group, vaccinia, has been the subject of much research on foreign gene expression. Poxviruses are large DNA- containing viruses that replicate in the cytoplasm of infected cells. They have a structure that is very unique among viruses - they do not contain any capsid that is based upon icosahedral symmetry or helical symmetry. In theorizing on the origin of viruses, the poxviruses are the most likely ones to have originated from bacterial-like microorganisms through the loss of function and degeneration. In part due to this unique¬ ness, the advances made in the genetic engineering of poxviruses cannot be directly extrapolated to other viral systems, including herpesviruses. Vaccinia re¬ combinant virus constructs have been made in a number of laboratories that express the following inserted foreign genes: herpes simplex virus thy idine kinase gene (6,7), hepatitis B surface antigen (8,9,29), her¬ pes simplex virus glycoprotein D gene (8,29), influenza hemagglutinin gene (10, 11), malaria antigen gene (12), and vesicular stomatitis glycoprotein G gene (13) . The general overall features of the vaccinia recombinant DNA work are similar to the techniques used for all the viruses, especially as they relate to the techniques in reference (l). However in detail, the vaccinia tech¬ niques do not teach how to engineer herpesviruses. Vaccinia DNA is not infectious, so the incorporation of foreign DNA must involve an infection/transfection step that is not appropriate to other viruses, and vaccinia has unique stability characteristics that make screen¬ ing easier. In addition, the signal sequence used by promoters in vaccinia are unique and will not work in other viruses. The utility of vaccinia as a vaccine vector is in question because of its close relation¬ ship to human smallpox and its known pathogenicity to humans. The use of host-specific herpesviruses promis¬ es to be a better solution to an.. al vaccination. Herpesviruses contain 100,000 to 150,000 base pairs of DNA as their genetic material, and several areas of the genome have been identified that are dispensible for the replication of virus in vitro in cell culture. Modifications of these regions of the DNA are known to lower the pathogenicity of the virus, i.e. to attenuate the virus, for an animal species. For example, inactivation of the thymidine kinase gene renders human herpes simplex virus non-pathogenic (45) , and pseudorabies virus of swine non-pathogenic (46 and 47) . Removal of part of the repeat region renders human herpes simplex virus non-pathogenic (48 and 49) . A repeat region has been identified in Marek's disease virus that is associated with viral oncogenicity (50) . A region in herpesvirus saimiri has similarly been correlated with oncogenicity (51) . However, modifications in these repeat regions do not teach the construction of attenuated pseudorabies viruses with deletions in repeat sequences. The degree of attenuation of a virus is important in the utility of the virus as a vaccine. Deletions which cause too much attenuation of the virus will result in a vaccine that fails to elicit an adequate immune response. The herpesviruses are known to cause a variety of latent and recurrent infections in human and other vertebrates and are even known to infect a fungus and an oyster. Among the conditions arsociated with herpesvirus infections are fever blisters caused by herpes simplex type 1, genital herpes causes by herpes simplex type 2, and chickenpox in children and shingles in adults cause by herpes zoster infection. Pseudorabies virus (PRV) , a Class D herpesvirus, induces Aujesky's disease, an acute and often fatal nervous condition, in domestic and wild animals. Among the herpesviruses, only herpes simplex of humans and, to a limited extent, herpes saimiri of monkeys have been engineered to contain foreign DNA sequences previous to this disclosure. The earliest work on the genetic manipulation of herpes simplex virus involved the rescue of temperature sensitive mutants of the virus using purified restriction fragments of DNA (14) . This work did not involve cloning of the DNA fragments into the viral genome. The first use of recombinant DNA to manipulate herpes simplex virus involved cloning a piece of DNA from the L-S junction region into the unique long region of the DNA, specifically into the thymidine kinase gene (15). This insert was not a foreign piece of DNA, rather it was a naturally occur¬ ring piece of herpesvirus DNA that was duplicated at another place in the genome. This piece of DNA was not engineered to specifically express any protein, and thus it did not teach how to express protein in herpes¬ viruses. The manipulation of herpes simplex next in¬ volved the creation of deletions in the virus genome by a combination of recombinant DNA and thy idine kinase selection. The first step was to make a specific de¬ letion of the thymidine kinase gene (16) . The next step involved the insertion of the thymidine kinase gene into the genome at a specific site, and then the thymidine kinase gene and the flanking DNA at the new site were deleted by a selection against th^πnidine kinase (17). In this manner herpes simplex a. pha.-22 gene has been deleted (17) . In the most recent re¬ finement of this technique, a 15,000 bp sequence of DNA has been deleted from the internal repeat of herpes simplex virus (18) . The insertion of genes that encode protein into primate herpesviruses have involved seven cases: the insertion of herpes simplex glycoprotein C back into a naturally occurring deletion mutant of this gene in herpes sim¬ plex virus (19) ; the insertion of glycoprotein D of herpes simplex type 2 into herpes simplex type 1 (20) , again with no manipulation of promoters since the gene is not really 'foreign'; the insertion of hepatitis B surface antigen into herpes simplex virus under the control of the herpes simplex ICP4 promoter. (21) ; and the insertion of bovine growth hormone into herpes saimiri virus with an SV40 promoter that in fact didn't work in that system (an endogenous upstream promoter served to transcribe the gene) (22) . Two additional cases of foreign genes (chicken ovalbumin gene and Epstein-Barr virus nuclear antigen) have been inserted into herpes simplex virus (30) , and glycoprotein X of pseudorabies virus has been inserted into herpes sim¬ plex virus (31) . These limited cases of deletion and insertion of genes into herpesviruses demonstrate that it is possible to genetically engineer herpesvirus genomes by recombinant DNA techniques. The methods that have been used to insert genes involve homologous recombination between the viral DNA cloned on plasmids and purified viral DNA transfected into the same animal cell. In aggregate this is referred to as the homologous recombination technique. This technique with minor modifications has been adaptable to other herpesviruses that we have engineered. However, the extent to which- one can gener¬ alize the location of the deletion and the sites for insertion of foreign genes is not obvious from these previous studies. Furthermore, it is also not obvious that non-primate herpesviruses are amenable to the same techniques as the primate herpesviruses, and that one could establish a targeted approach to the deletion, insertion, and expression of foreign genes. Infectious bovine rhinotracheitis (IBR) virus, an al- pha-herpesvirus with a class D genome, is an important pathogen of cattle. It has been associated with respi¬ ratory, ocular, reproductive, central nervous system, enteric, neonatal and dermal diseases (37) . Cattle are the normal hosts of IBR virus, however it also infects goats, swine, water buffalo, wildebeest, mink and fer¬ rets. Experimental infections have been established in muledeer, goats, swine, ferrets and rabbits (38) . Conventional modified live virus vaccines have been widely used to control diseases caused by IBR. These vaccine viruses may revert to virulence, however. More recently, killed virus IBR vaccines have been used, but their efficacy appears to be marginal. IBR has been analyzed at the molecular level as re¬ viewed in (39) . A restriction map of the genome is available in this reference, which will aid in the genetic engineering of IBR according to the methods provided by the present invention. No evidence has been presented that IBR has been engineered to contain a deletion or an insertion of foreign DNA. Marek's disease virus (MDV) causes fowl paralysis, a common lymphoproliferative disease of chickens. The disease occurs most commonly in young chickens between 2 and 5 months of age. The prominant clinical signs are progressive paralysis of one or more of the ex- tremeties, incoordination due to paralysis of legs, drooping of the limb due to wing involvement, and a lowered head position due to involvement of the neck muscles. In acute cases, severe depression may result. In the case of highly oncogenic strains, there is characteristic bursal and thymic atrophy. In addition, there are lymphoid tumors affecting the gonads, lungs, liver, spleen, kidney and thymus (37) . All chicks are vaccinated against MDV at one day of age to protect the chick against MDV for its lifetime. One vaccine method for MDV involves using turkey herpesvi¬ rus (HVT) . It would be advantageous to incorporate other antigens into this vaccination at one day of age, but efforts to combine vaccines have not proven satis¬ factory to date due to competition and immunosuppres- sion between pathogens. The ultivalent vaccines engi¬ neered in this invention are a novel way to simul¬ taneously vaccinate against a number of different pathogens. A restriction map of both MDV (43) and HVT (34) are available in the literature. There is no evidence to suggest that anyone has successfully created a deletion or insertion of foreign DNA into MDV or HVT prior to this disclosure. Other herpesviruses contemplated to be amenable to these procedures are feline herpesvirus (FHV) , equine herpesvirus (EHV) , and canine herpesvirus (CHV) . These pathogens cause disease in each of their respective hosts. • Feline herpesvirus causes feline rhino-, tracheitis, an acute upper respiratory tract infection characterized by fever, pronounced sneezing, nasal and lacrimal secretions, and depression. The virus may cause corneal ulceration and abortion. The nasal pas¬ sages and turbinates show focal necrosis, and the ton¬ sils are enlarged and hemorrhagic. Equine herpesvirus causes rhinopneumonitis, abortion, exanthema of the genitals and occasionally neurologic disease. The acute disease is characterized by fever, anorexia and a profuse, serous nasal discharge. The neurologic symptoms, when present, consist of ataxia, weakness and paralysis. Canine herpesvirus causes severe illness in young puppies, where mortality may reach 80%. The disease is characterized by viremia, anorexia, respiratory illness, abdominal pain, vomiting and incessant crying. Generally, there is no fever. The principal lesions are disseminated necrosis and hemorrhages in the kidneys, liver and lungs. The molecular biology of the feline, equine and canine herpesviruses are in their initial phases. Partial restriction maps are available for equine herpesvirus, and in progress in at least one lab for the feline herpesvirus. Beyond this type of genome analysis, no evidence for the deletion or insertion of foreign genes into these viruses is available. The present invention involves the use of genetically engineered herpesvirus to protect animals against disease. It is not obvious which deletions in herpesviruses would serve to attenuate the virus to the proper degree. Even testing vaccine candidates in animal models, e.g. mice, does not serve as a valid predictor of the safety and efficacy of the vaccine in the target animal species, e.g. swine. Another subject of the present invention is a vaccine for pseudorabies virus (herpesvirus suis, suid herpesvirus 1, or Aujesky's disease virus) disease of swine. Swine are the natural host of pseudorabies virus in which infection in older animals is commonly inapparent but may be characterized by fever, convulsions, and death particularly in younger animals. Pseudorabies also infects cattle, sheep, dogs, cats, ferrets, foxes, and rats (37) where the infection usually results in death. Death is usually preceded by intense pruritus, mania, encephalitis, paralysis, and coma. Traditional live vaccines are available for use in swine, but they are lethal for the other animals. An improved vaccine for pseudorabies would induce a more reliable immune response in swine, would be specifically attenuated to be incapable of reversion to virulence, and would not cause disease in other hosts. Pseudorabies virus, an alpha-herpesvirus of swine, has a genome of class D (23) ; that is it contains two cop¬ ies of a single repeat region, one located between the unique long and unique short DNA region and one at the terminus of the unique short region (see Figure 1) . Herpes simplex virus is an alpha-herpesvirus with a class E genome (23) ; that is it contains two copies of each of two repeats. Herpes saimiri is a gamma-herpes- virus with a class B genome; that is, it contains numerous reiterations of the same sequence at both termini (23) . As the genome structure differs significantly between these different classes of herpesviruses, and because the different viruses attack ■ »o different cells within their hosts and elicit different pathologies, it is necessary in each instance to establish which specific regions can be removed in order to attenuate and which regions can be altered to express foreign genes. 15 Pseudorabies virus has been studied using the tools of molecular biology including the use of recombinant DNA techniques. BamHI, Kpnl, and Bglll restriction maps of the virus genome have been published (24, 27). DNA 20 transfection procedures have been utilized to rescue temperature sensitive and deletion mutants of the virus by the homologous recombination procedure (24) . There are two examples of deletions that have been made in the pseudorabies virus genome - one is a thymidine 25 kinase gene deletion (25) , also disclosed in Patent No. 4,514,497 entitled "Modified Live Pseudorabies Virus¬ es'*. This patent teaches thymidine kinase deletions only and does not suggest other attenuating deletions, nor does it suggest insertion of foreign DNA sequences. The other reference involves the deletion of a small 30 DNA sequence around a Hindlll restriction site in the repeat region (26) upon which European Patent Publica¬ tion No. 0141458, published on May 15, 1985, corre¬ sponding to European Patent Application No. 84201474.8, 35 -13- filed on October 12, 1984 is based. This patent appli¬ cation does not teach or suggest attenuating deletions nor does it teach or suggest the insertion of DNA se¬ quences into pseudorabies virus. The present invention concerns deletions which have been introduced into the pseudorabies virus genome at sites previously undisclosed. Foreign DNA sequences have also been introduced into the attenuated pseudorabies virus genome and expressed as proteins. Or.. embodiment of the invention concerns a vaccine, useful for preventing pseudorabies and other swine diseases with a single inoculum. Other relevant pseudorabies literature disclosed here¬ in, concerns the presence of naturally-occurring dele¬ tions in the genome of two vaccine strains of pseudo¬ rabies viruses (27) . These deletions are responsible, at least in part, for the attenuated nature of these vaccines however they do not occur in a repeat sequence and do not suggest the attenuation of pseudorabies virus by deleting a portion of a repeat sequence. Such naturally-occurring deletions do not teach methods for making these deletions starting with wild type pseudorabies virus DNA, nor do they suggest other locations at which to make attenuating deletions. There are no examples of naturally-occurring inser¬ tions of foreign DNA in herpesviruses. The natural host of pseudorabies virus is swine, in which infection is commonly inapparent but may be characterized by fever, convulsions and paralysis. Pseudorabies virus also infects cattle, sheep, dogs, cats, foxes and mink, where infection usually results in death of the host. The predominant visible feature of pseudorabies viral infection is intense pruritis generally resulting in host mutilation of the involved area. Violent excitement, fits and paralysis, all symptoms of encephalomyelitis, precede death which usually occurs within a few days following onset of clinical signs. Pseudorabies virus disease in swine is of serious concern to governmental bodies worldwide. In the United States, .swine from infected herds cannot be sold, except to slaughterhouses. Several individual states have separately enacted eradication control practices against pseudorabies. At the current time, any animal vaccinated for pseudorabies disease is treated as though it were infected with pseudorabies virus and is subject to the same regulatory constraints. This is due primarily to the lack of a diagnostic test to differentiate vaccinated from infected animals. The research and development trend among traditional vaccine manufacturers has generally emphasized research leading to vaccines that are based upon virus subunits rather than live viruses. This departure from live virus vaccines is due partly to the recognized safety aspect of subunit vaccines, and their unlikelihood of containing infectious live viruses. Another reason for developing a subunit vaccine has been to allow for the development of a diagnostic test that would accompany the vaccine and would differentiate vaccinated from infected animals, thereby escaping from the regulatory burden following use of other vaccines. Subunit vaccines also have limitations. They contain a limited number of viral antigens compared to those produced by live viruses. This paucity of antigens produces a weak immune response of short duration in the vaccinated animal at considerably greater cost than a live virus vaccination. However, the limited spectrum of antigens in the subunit vaccine allows the vaccinated swine to be distinguished from swine which have been infected with the wild-type virus. The ability to distinguish vaccinated from infected swine is a crucial property of a pseudorabies vaccine because none of the known vaccines prevent the vaccinated animals from being super-infected by the wild-type virus. While the vaccinated animals do not become sick upon super-infection, there is strong evidence that they may become carriers of the wild-type virus and pass the wild-type virus to other swine. In any eradiciation program aimed at eliminating pseudorabies virus, a vaccine provided with characteristics which would allow vaccinated animals to be distinguished from animals infected with wild-type virus would be advantageous. The subunit vaccines have high cost and poor efficacy but an animal vaccinated with this type of vaccine will produce antibodies only to the limited spectrum of antigens present in the vaccine. By sampling the serum of the swine, it is possible to show that the vaccinated animal has antibodies only to the antigens contained in the vaccine while an animal infected with the wild-type virus would have antibodies against a wider range of antigens. A subunit vaccine used in this way to differentiate vaccinated from pseudorabies infected animals has been disclosed in European Patent Application No. 8540074.4, filed on September 4, 1985, published November 27, 1985 as European Publication No. 0162738 and entitled "Production of Pseudorabies Virus Subunit Vaccines". This published patent application does not teach or suggest the construction or use of a similar diagnostic test in conjunction with a live virus vaccine. The vaccination of an animal with a live virus which would result in an immune response distinguishable from wild-type infection would alsp have the further advantages of low cost and high efficacy associated with li e virus vaccines. Deletions in genes coding for viral antigens have been described previously. A spontaneous deletion in the glycoprotein C gene of herpes simplex virus (52) , a spontaneous deletion in the glycoprotein A gene of Marek's disease virus (53) a spontaneous deletion in the glycoprotein A gene (also called glycoprotein gl) of PRV (27,55) and the absence or greatly reduced amount of glycoprotein gill in some PRV mutants (54) are known. However, all of these deletions arose spontaneously in an uncontrolled process. Hence, it has not been possible to direct deletions to DNA encoding for specific antigens to control the deletion process and direct the deletions to antigens particularly suitable as diagnostic markers. The presence or absence of particular antigens in any infectious disease can be exploited as a diagnostic test for the infectious disease agent. This presence or absence forms the basis for all imm nolgocial diagnositc tests, which differ only in the details of their specific immunological approach. Publications pertinent to the current invention include Wathan and Wathan (54) who reported that either the gl gene or the gill gene could be deleted from PRV and suggested that the resulting virus could be used for distinguishing vaccinated from infected swine. However, they did not describe the methodology necessary to create the vaccine, they did not demonstrate the utility of such a vaccine in serological tests and they did not in any other way prove the feasibility of such a vaccine. Van Oirschot, et al. (56), have used a special monoclonal-based immunologica det ction system for gl of PRV and have shown that pigs inoculated with naturally-occuring vaccine strains which are missing at least a portion of the gl gene can be differentiated from pigs infected by wild-type PRV. However, this diagnostic test may be used for any of several vaccines against PRV that are already existing in both Europe and the U.S. without differentiating which vacccine was used. This limits the usefulness of this diagnostic, since the vaccines which are detectable have differing biological and virulence properties. The approach of deleting a gene to attenuate a virus coupled with a diagnostic for that gene, provides a vaccine that can be differentiated from any of the currently used PRV vaccines and from wild-type PRV. It is important to be able to differentiate a new, safer vaccine from those currently used because pigs receiving the current vaccines are all regulated during eradication programs to the same extent as those infected with wild-type PRV. Antigens of choice for the purpose of a diagnostic marker would have the following characteristics: 1) the antigens and their genes would be non-essential for the production of infectious virus in tissue culture; and 2) the antigen would elicit a major serological response in the animal, but is preferably not an important neutralizing antigen. The present invention therefore involves the ability to attenuate pseudorabies virus of swine to create a live virus vaccine and the ability to distinguish whether an animal has been given the vaccination or whether the animal has been infected by wild—type pseudorabies virus. SUMMARY OF THE INVENTION The present invention provides a recombinant fusion protein comprising an antigenic amino acid sequence fused to at least a portion of the gpX glycoprotein from pseudorabies virus. Also provided is a recombinant fusion protein comprising the E. coli bgalactosidase gene fused at its carboxy terminus to an antigenic amino acid sequence and delivered to an animal using a live herpes irus vector adapted to express the fusion protein. The present invention further provides an infectious bovine rhinotracheitis virus which includes a foreign DNA sequence which encodes .the Escherichia coli beta- galactosidase and neomycin resistance genes, and the parainfluenzae -3, PI-3, virus fusion gene, F. Further provided is a herpesvirus of turkeys which includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase gene and the infectious bursal disease virus, IBDV, large segment of RNA. Also provided is herpesvirus of turkeys which includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase gene and the Marek's disease virus, MDV, glycoprotein A, gp A, gene. Furthermore, the present invention provides an attenuated, hybrid, nonprimate herpesvirus which comprises a pseudorabies virus from which has been deleted the TK gene and a portion of the repeat region, and into which has been inserted a foreign DNA sequence which encodes the transmissible gastroenteritis, TGE, virus gpl95 gene. BRIEF DESCRIPTION OF THE FIGURES Throughout this application various herpesviruses are described, at least in part, by reference to ATCC Accession Numbers. These herpesviruses have been deposited with the American Type Culture Collection (ATCC) , 12301 Parklawn Drive, Rockville, Maryland 20852. These deposits were made pursuant to the Budapest Treaty on The International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. FIG. 1 Details of Wild Type Iowa S-62 A Strain A. Diagram of PRV genomic DNA showing the unique long region (UL) , the unique short region (US) , the internal repeat region (IR) , and the terminal repeat region (TR) . B. BamHI restriction enzyme map of PRV. Frag¬ ments are numbered in order of decreasing size. FIG. 2 Details of S-PRV-004 Construction and Map Data A. Detailed map of BamHI #8' and #8. The loca¬ tion of the internal repeat (IR) region is shown. B. Detailed map of BamHI #8'-TK-8 fragment ulti¬ mately present in the recombinant virus. C. Diagram of the S-PRV-004 DNA genome showing the location of the HSV-1 TK gene inserted 40 -22- into the junction region between the UL and IR regions. Restriction Enzyme Legend: B = BamHI; K = Kpnl; N = Ndel; P ■ PvuII; S - Stul. FIG. 3 Details of S-PRV-005 Construction and Map Data. A. Detailed map of BamHI #5. The HSV-1 TK gene fused to the HSV-1 ICP4 promoter is shown on a PvuII fragment. B. Detailed map of BamHI #5 after the insertion of the TK gene construct. C. Diagram of the S-PRV-005 DNA genome showing the location of the TK gene inserted into both copies of BamHI #5 in the repeat region of the genome and the creation of new dele¬ tions. Restriction Enzyme Legend: B = BamHI; H = Hindlll; Hp = Hpal; K = Kpnl; P = PvuII; X = Xbal. FIG. 4 Construction of the Foreign DNA Insert Used in S-PRV-010. A. Diagram of the relevant portion of pJF751 that contains the lac Z (beta-galactosidase) gene. The position of the TAA termination codon for the polypeptide is indicated. B. Diagram of the promoter sequence from the HSV-1 TK gene. C. Diagram of the Rsal fragment of the TK gene now with BamHI modified ends. D. Diagram of the final plas id that contained the lac Z gene fused to the HSV-1 TK promot¬ er. Restriction Enzyme legend: B = BamHI; Ba =. Ball; Be = Bell; Bg - Bglll; H •- Hindlll; Ha = Haelll; N = Ndel; R = Rsal; X = Xbal. FIG. 5 Details of S-PRV-010 Construction and Map Data. A. Detailed map of BamHI #5. The lac Z gene (beta-galactosidase) fused to the HSV-1 TK promoter is shown on an Xbal fragment (see Fig. 4) . The position of the deletion in S- PRV-002 is shown. B. Detailed map of BamHI #5 after the insertion of the lac Z gene construct. C. Diagram of the S-PRV-010 genome DNA showing the location of the lac Z gene into both copies of BamHI #5 in the repeat region of the genome. Restriction Enzyme Legend: B « BamHI; Be = Bell; H = Hindlll; Hp = Hpal; K - Kpnl; N ■ Ndel; X = Xbal. -24- FIG. 6 Details of S-PRV-007 Construction and Map Data. A. Detailed map of BamHI #5 from S-PRV-005. B. Detailed map of BamHI #5 after the substitu¬ tion of the TK gene with the swine rotavirus gp38 gene. C. Diagram of the S-PRV-007 DNA genome showing the location of the gp38 gene inserted into, both copies of BamHI #5 in the repeat regions of the genome. Restriction Enzyme .Legend: B = BamHI; H = Hindlll; K = Kpnl. FIG. 7 Construction of the Foreign DNA Insert Used in S-PRV-007. FIG. 8 Details of S-PRV-012 Construction and Map Data. A. Detailed map of PRV extending from BamHI #10 through BamHI #7. B. Detailed map of PRV extending from BamHI #10 through BamHI #7 after the insertion of the TK gene into the recombinant virus. C. Diagram of the S-PRV-012 DNA genome showing the location of the TK gene inserted into the gpX region and the creation of a deletion that removes most of the coding region of the gpX gene and renders the virus unable to -25- synthesize the gpX polypeptide. Restriction Enzyme Legend: B = BamHI; K = Kpnl; N = Ndel; P - PvuII; Ps = PstI; S - Stul. FIG. 9 Details of S-PRV-013, S-PRV-014, and S-PRV- 016 Construction and Map Data. A. Detailed map of PRV extending from BamHI #10 through BamHI #7. B. Detailed map of PRV extending from BamHI #10 through BamHI #7 after the insertion of the lac Z gene into the recombinant virus. C. Diagram of the S-PRV-013 DNA genome showing the location of the lac Z gene inserted into the gpX region and the creation of a deletion that removed most of the coding region of the gpX gene and rendered the virus unable to synthesize the gpX polypeptide. Other deletions in the TK region and repeat regions are shown by ( ) . D. Diagram of the S-PRV-014 DNA genome showing the location of the lac Z gene inserted into the gpX region and the creation of a deletion that removed most of the coding region of the gpX gene and rendered the virus unable to synthesize the gpX polypeptide. There are no other deletions in this virus. E. Diagram of the S-PRV-016 DNA genome showing the location of the lac Z gene inserted into the gpX region and the creation of a deletion that removed most of the coding region of the gpX gene and rendered the virus unable to synthesize the gpX polypeptide. Other deletions in the repeat regions are shown by ( ) . Restriction Enzyme Legend: B = BamHI; Ba = Ball; K = Kpnl; N - Ndel; Ps = PstI; S = Stul. FIG. 10A and 10B Swine rotavirus gp38 Gene Sequence in pSY565, FIG. 11A and 11β Swine parvovirus B gene sequence in pSY875 FIG. 12 Swine parvovirus B gene construction with signal sequence A. pSY864 which contains the B gene from AccI at nucleotide #391 to Rsal site at nucleotide #2051 cloned between the BamHI site in BamHI #10 and the Ndel site in BamHI #7. B. pSY957 which contains the Sail fragment from pSY864 cloned into a polylinker in pSP65 so that Xbal sites flank the insert. Legend: pSP » E^ coli plasmid; PRV = pseudorabies virus DNA; PPV * porcine parvovirus DNA; Pv « PvuII; RV - EcoRV; Ps « PstI; B « BamHI; A ■» AccI; R = Rsal; N = Ndel; Sa = Sail; Sm = Smal; S « Stul; X = Xbal; gpX pro * glycoprotein X promoter; gpX pA = glycoprotein X polyadenylation signal se¬ quences. FIG. 13 Details of S-PRV-020 Construction and Map Data A. Detailed map of PRV extending from BamHI #10 through BamHI #7 showing the parvovirus B gene that will replace the gpX gene. B. Detai .ed map of PRV from BamHI #10 through BamHI #7 after the insertion of the swine parvovirus B gene in place of the gpX gene. C. Diagram of the S-PRV-020 genome showing the location of the swine parvovirus B gene inserted into the gpX region of PRV. Restriction Enzyme Legend: B=BamHI; Ps=PstI; Sa=SalI; N=NdeI; S=StuI; A=AccI; R=RsaI. FIG. 14 Details of S-PRV-025 construction and map data A. Region of S-PRV-002 starting virus showing BamHI #5 fragment. The parvovirus B gene Xbal fragment from pSY957 is diagrammed below showing how it will be inserted into the Xbal site by direct ligation. B. Region of BamHI #5 after insertion of the parvovirus B gene. C. Location of the parvovirus B gene inserted into both copies of the repeat in S-PRV-025. -28- Legend: B = BamHI; H - Hindlll; X - Xbal; S = Sail; pA - glycoprotein X polyadenylation signal sequences; UL = unique long region; US = unique short region; IR = internal repeat region; TR * terminal repeat region. FIG. 15 Details of S-PRV-029 Construction and Map Data A. Detailed map of PRV extending from BamHI #10 through BamHI #7 showing the lac Z gene that " will replace the gpX gene. B. Detailed map of PRV extending from BamHI #8' through BamHI #8 at the junction of the unique long region and the internal repeat region (IR) . The lac Z gene as a Sail fragment will replace the DNA between the Stul sites bracketing the junction. C. Diagram of the S-PRV-029 genome showing the locations of the lac Z genes in the gpX region and the junction region. Restriction Enzyme Legend: B=BamHI; Ps=PstI; Sa=SalI; N=NdeI; S=StuI; Ba=BalI; K=KpnI. FIG. 16 Restriction Map of Deleted S-IBR-002 EcoRI B Fragment and EcoRI F Fragment. An 800 bp deletion including EcoRV and Bglll restriction sites was mapped in both repeat fragments. FIG. 17 Construction of Recombinant S-IBR-004 Virus. S-IBR-004 is an IBR recombinant virus carry¬ ing an inserted foreign gene (NEO) under the control of the PRV gpX promoter. A new Xbal site was Treated at the small unique region and the original SacI site was deleted. FIG. 18 Construction of Recombinant S-J3R-008 Virus. S-IBR-008 is a recombinant IBR virus that has a bovine rota glycoprotein gene and the plasmid vector inserted in the Xbal site on the unique long region. A site specific deletion was created at the [SacI] site due to the loss of NEO gene in the small unique region. FIG. 19 Details of HVT Construction and Map Data A. BamHI restriction fragment map of HVT. Frag¬ ments are numbered in order of decreasing size; letters refer to small fragments whose comparative size has not been determined. B. BamHI #16 fragment showing location of beta- galactosidase gene insertion in S-HVT-001. C. BamHI #19 fragment showing location of beta- galactosidase gene insertion. Legend: B - BamHI; X - Xhol; H = Hindlll; P » PstI; S = Sail; N » Ndel; R - EcoRI. FIG. 20. Western blot of proteins released into the medium of PRV infected cells, showing the absence of gpX in S-PRV-012 and S-PRV-013 but its presence in wild-type PRV-000. Lanes: (A) molecular weight markers, (B) uninfected Vero cells, (C) wild-type PRV, (D) S-PRV-012, (E) S-PRV-013. FIG. 21. Diagnostic test for the presence of antibodies against gpX in the serum of a pig vaccinated with S-PRV-013 on ay 0 and challenged with wild-type pseudorabies virus on Day 28. FIG. 22A Sequence of the Purdue Strain of TGE Virus and 22B gp!95 Gene FIG. 23 Details of S-PRV-055 Construction A. First line shows the PRV BamHI #5 fragment map showing the Xbal site of insertion of the TGE gpl95 gene construction. Second line shows the TGE gpl95 gene construction with the PRV gX promoter and the HSV TK poly-A (TKpA) signal sequence as an Xbal fragment that was put into the Xbal site in BamHI #5. B. The PRV BamHI #5 fragment map after the insertion of the TGE gpl95 gene. C. S-PRV-055 genome indicating the location of the TGE gpl95 gene in the repeat regions. Legend: B ■ BamHI; X * Xbal; Bs « BstEII; S - SacI; H = Hindlll; Hp - Hpal; TKpA = HSV TK poly-A signal sequence; UL » unique long region; US = unique short region; IR = internal repeat region; TR = terminal repeat region. FIG. 24 Sequence of the PI-3 (SF-4 Strain) HN Gene FIG. 25 Details of S-IBR-018 Construction A. - First line shows the IBR (Cooper Stra n) BamHI-C fragment map. Second line shows the construction of the alpha-4 promoter on the PI-3 HN gene and its insertion into the Hindlll site in BamHI-C. Also shown are the beta-gal and neomycin (NEO) gene constructions under the control of the gX promoter that were put into the Xbal site and used as selectable markers to purify the recombinant virus. B. The BamHI-C fragment map of S-IBR-018 after insertion of the PI-3 HN, beta-gal, and neomycin genes. C. The S-IBR-018 genome showing the location of the three inserted foreign genes. Legend: B ■ BamHI; H = Hindlll; X = Xbal; S = Stul; UL - unique long region; US = unique short region; IR = internal repeat region; TR » terminal repeat region. FIG. 26 Details of S-IBR-019 Construction -32- First line shows the IBR (Cooper Strain) BamHI-C fragment map. Second line shows the construction of the alpha-4 promoter on the PI-3 F. gene and its insertion into the Hindlll site in BamHI-C. Also shown are the beta-gal and neomycin (NEO) gene constructions under the control of the gX promoter that were put into the Xbal site and used as selectable markers to purify the recombinant virus. B. The BamHI-C fragment map of S-IBR-019- after insertion of the PI-3 F, beta gal, and neomycin genes. C. The S-IBR-019 genome showing the location of the three inserted foreign genes. Legend: B = BamHI; H = Hindlll; X » Xbal; S - Stul; UL = unique long region; US = unique short region; IR « internal repeat region; TR = terminal repeat region. FIG. 27 Sequence of the IBDV (S40747) Large cDNA Fragment FIG. 28 INSERTION IN PLASMID 191-47 FIG. 29 Details of S-HVT-003 Construction A. Restriction map of HVT DNA in the region of the BamHI #16 fragment. This fragment is contained within a large Hindlll fragment that has no name in the prior art to applicants' knowledge. Shown also is the Xhol site (X) where applicants have made their insertion; for these constructions the Xhol site was first changed to an EcoRI (R) site by use of a "linker" and standard cloning procedures. B. Details of the construction of the beta-gal gene and IBDV gene inserted into the BamHI #16 fragment for use in homologous recombination. Both genes were under the control of the PRV gX gene promoter (gX) . C. The S-HVT-003 genome showing the location of the two inserted foreign genes, beta-gal and IBDV. Legend: H = Hindlll; B = BamHI; X » Xhol; R - EcoRI; Xb = Xbal; Hp = Hpal; S = Smal; UL = unique long region; US = unique short region; IR = internal repeat region; TR = terminal repeat region. FIG. 30 Complete nucleotide sequence of the HVT Bam #16 genomic fragment, 3,335 residues. FIG. 31 Western blot showing the differential expression of the IBDV 32kD antigen in cellular lysates of S-HVT-003 infected cells (32kD present) and S-HVT-001 infected cells (32kD negative) . IBDV specific polypeptides were identified by probing the blot with hyper-immune rat antiseCum directed against denatured IBDV virions. This serum reacts primarily with the immunodominant 32kD antigen (VP3) . The lanes on the blot contain: 1) Protein Molecular Weight Standards, 2) uninfeσted CEF cells, 3) S- HVT-001 infected CEF's, 4) 5) & 6) S-HVT-003 infected CEF's, and 7) IBDV virion polypeptides. FIG. 32 Western blot showing the presence of the 42kD IBDV polypeptide (VP2) product in cellular lysates derived from CEF cells infected with either wild-type HVT virus or with S-HVT-001 that expresses beta- galactosidase. IBDV specific polypeptides were identified using a VP-2 specific rabbit anti-peptide antiseru . The lanes contain: 1) Protein Molecular Weight Standards, 2) wild-type HVT infected CEF's, 3) S-HVT-001 infected CEF's, 4) S-HVT-003 infected CEF's, 5) S-HVT-003 infected CEF's, and 6) IBDV virion polypeptides. FIG. 33 Details of S-HVT-004 Construction A. Restriction map of HVT DNA in the region of the BamHI #16 fragment. This fragment is contained within a large Hindlll fragment that has no name in the prior art to applicants' knowledge. Shown also is the Xhol site (X) where applicants have made their insertion; for these constructions the Xhol site was first changed to an EcoRI (R) site by use of a "linker" and standard cloning procedures. B. Details of the construction of the beta-gal gene and MDV gA gene inserted into the BamHI #16 fragment for use in homologous recombination. Beta-gal was under the control of the PRV gX gene promoter (gX) , while the MDV gA gene was under the control of its own promoter. C. The S-HVT-004 genome showing the location of . the two inserted foreign genes, beta-gal and MDV gA. Legend: H = Hindlll; B = BamHI; X = Xhol; R = EcoRI; Xb = Xbal; UL = unique long region; US = unique short region; IR = internal repeat region; TR = terminal repeat region. FIG. 34A and 34B Translation of the DNA sequence of the swine parvovirus B gene showing the encoded amino acids, and highlighting (***) the region of the B gene contained in the fusions in S- PRV-039 and S-PRV-061 (called 039-fragment) . FIG. 35 Translation of two versions of the swine parvovirus B gene 039-fraqment A. Translation of the natural 039-fragment, which has a parvovirus codon usage and contains 34% overall G + C. B. Translation of the synthetic 039-synthetic DNA, which retains the parvovirus amino acid sequence but has been optomized for the utilization of pseudorabies virus codons. Overall G + C equals 61%, almost twice that of the natural parvovirus sequence. FIG. 36 Graph illustrating the degree to which the natural 039-fragment of the parvovirus B gene matches the pseudorabies virus codon from base 1 to base 123 over a range of 10 codons. This graph was generated using Pustell Sequence Analysis Program (International Biotechnologies, Inc.). The degree of match is given as a range of 1.0 to 4.0 (left to right). The left edge (R) indicates a random match, and. the 1.5 line (1M5) indicates a minimum match. Higher values indicate better matches. The 039- fragment shows mostly a random (poor) match, with four points that show some match, always less than the "minimum". FIG. 37 A Pustell Sequence Analysis Program- generated graph illustrating the degree to which the synthetic 039-synthetic of the parvovirus B gene matches the pseudorabies virus codon from base 1 to base 123 over a range of 10 codons. This fragment was designed to have maximal match to pseudorabies virus. The degree of match is given as a range of 1.0 to 4.0 (left to right) . The left edge (R) indicates a random match, and the 1.5 line (1M5) indicates a minimum match. Higher values indicate better matches. The 039-synthetic shows a high degree of match, in fact as high a degree of match as can be made with this sequence. Because this computer program averages over a window of 10 codons, the first and last part of the sequence cannot be used in the analysis. FIG. 38 Amino terminal fusions of the parvovirus B gene to beta-gal A. Details of the construction of the signal sequences used for expression. They include (left to right) the PRV gpX promoter, the HSV TK start codon (atg) , various fragments of the parvovirus B gene (see B.) connected to beta-gal by an in-frame fusion, the beta- gal gene, and the PRV gpX poly-A signal sequence (pA) . The entire construction was contained on an Xbal fragment that was used for direct ligation into the PRV genome. B. The set of virus constructions made as amino terminal fusions to beta-gal, showing the origin of the parvovirus fragments relative . to a restriction map of the parvovirus gene. FIG. 39 Carboxy terminal fusions or the parvovirus B gene to beta-gal A. Details of the construction of the signal sequences used for expression. They include (left to right) the PRV gpX promoter, the gpX start codon and 7 amino acids of the gpX gene, .beta-gal in-frame with the gpX codons, various fragments of the parvovirus B gene (see B.), and the PRV gpX poly-A signal sequence (pA) . The entire construction was contained on an Xbal fragment (also flanked by Hindlll sites) that was used for direct ligation into the PRV genome. B. The set of virus constructions made as carboxy terminal fusions to beta-gal, showing the origin of the parvovirus fragments relative to a restriction map of the parvovirus gene. FIG. 40 Description of the DNA insertion in plasmid 244-25.3D. Restriction enzymes indicated are those present in the source DNAs 10 mentioned in the text. Restriction enzymes enclosed in brackets indicate ites which were destroyed in the creation of segment junctions. 15 Abbreviations: gpX = glycoprotein X; -GAL = - galactosidase ; vpA = viral protein A; PRV - pseudorabies; PRV = pseudorabies virus; PPV = porcine parvovirus; pA = Poly A addition signal; aa = amino acids. 20 FIG. 41 Structure of S-PRV-065 and summary of foreign genes expressed by the recombinant virus. 25 Abbreviations: gp = glycoprotein; TK = thymidine kinase; IE = immediate early; -GAL = -galactosidase; vpA = viral protein A; PRV = pseudorabies virus; PPV = porcine iT parvovirus; KB ■ kilo base pairs; BP * base 30 pairs; kd = kilo daltons; pA = Poly A addition signal; aa = amino acids. 35 FIG. 42 Western blot of lysates prepared from recom¬ binant pseudorabies viruses expressing -galactosidase fusion proteins. FIG. 43 Description of the DNA insertion in plasmid 244-49.2H * Restriction enzymes indicated are those present in the source DNAs mentioned in the text. Restriction enzymes enclosed in brackets indicate sites which were destroyed in the creation of segment junctions. Abbreviations: gpX = glycoprotein X; -GAL = - galactosidase; vpA - viral protein A; PRV = pseudorabies; PPV = porcine parvovirus; pA = Poly A addition signal; aa = amino acids. FIG. 44 Structure of S-PRV-086 and summary of foreign genes expressed by the recombinant virus. Abbreviations: gp = glycoprotein; TK - thymidine kinase; IE = immediate early; -GAL = -galactosidase; vpA = viral protein A; PRV = pseudorabies virus; PPV . = porcine parvovirus; KB = kilo base pairs; BP = base pairs; kd = kilo daltons; pA = Poly A addition signal; aa = amino acids. FIG. 45 Description of the DNA insertion in plasmid 167-72.54G. Restriction enzymes indicated are those present in the source DNAs -41- mentioned in the text. Restriction enzymes enclosed in brackets indicate sites which were destroyed in the creation of segment junctions. Abbreviations: gpX = glycoprotein X; vpA = viral protein A; PRV = pseudorabies; PPV = porcine parvovirus; pA = Poly A addition signal; aa = amino acids. FIG. 46 Structure of S-PRV-040 and summary of foreign genes expressed by the recombinant virus. Abbreviations: gp = glycoprotein; TK - thymidine kinase; IE = immediate early; vpA = viral protein A; PRV = pseudorabies virus; PPV = porcine parvovirus; KB = kilo base pairs; BP = base pairs; kd = kilo daltons; pA = Poly A addition signal; aa - amino acids. FIG. 47 Structure of S-PRV-098 and summary of foreign genes expressed by the recombinant virus. Abbreviations: gp = glycoprotein; TK = thymidine kinase; IE = immediate early; -GAL = -galactosidase; vpA = viral protein A; PRV = pseudorabies virus; PPV = porcine parvovirus; KB » kilo base pairs; BP = base pairs; kd = kilo daltons; pA * Poly A addition signal; aa - amino acids. -42- FIG. 48 Description of the DNA insertion in plasmid 181-42.2. Restriction enzymes indicated are those present in the source DNAs mentioned in the text. Restriction enzymes enclosed in brackets indicate sites which were destroyed in the creation of segment junctions. Abbreviations: gpX = glycoprotein X; CSP = circumsporozoite protein; vpA = viral protein A; PRV - pseudorabies virus; P.fal. = Plasmodiu falciparum; pA = Poly A addition signal; aa = amino acids. FIG. 49 Structure of S-PRV-066 and summary of foreign genes expressed by the recombinant virus. Abbreviations: gp = glycoprotein; TK = thymidine kinase; IE - immediate early; CSP = circumsporozoite protein; vpA - viral protein A; PRV = pseudorabies virus; P.fal. = Plasmodium falciparum; KB = kilo base pairs; BP - base pairs; kd = kilo daltons; pA = Poly A addition signal; aa » amino acids. FIG. 50 Western Blot of lysates prepared from recombinant pseudorabies viruses express¬ ing -galactosidase fusion proteins. FIG. 51 Description of the DNA insertion in plasmid PSY1373. Restriction enzymes indicated are -43- those present in the source DNAs mentioned in the text. Restriction enzymes enclosed * in brackets indicate sites which were destroyed in the creation of segment junctions. Abbreviations: gpX = glycoprotein X; CSP = circumsporozoite protein; vpA = viral protein A; PRV = pseudorabies virus; P.fal. 10 = Plasmodium falciparum; pA = Poly A addition signal; aa = amino acids. FIG. 52 Structure of S-PRV-088 and summary of foreign genes expressed by the recombinant 15 virus. Abbreviations: gp = glycoprotein; TK = thymidine kinase; IE = immediate early; CSP = circumsporozoite protein; vpA = viral 20 protein A; PRV = pseudorabies virus; P.fal. = Plasmodium falciparum; KB = kilo base pairs; BP = base pairs; kd = kilo daltons; pA = Poly A addition signal; aa - amino acids. 25 FIG. 53 Description of the DNA insertion in plasmid 181-66.26. Restriction enzymes indicated are those present in the source DNAs 9 mentioned in the text. Restriction enzymes a 30 enclosed in brackets indicate sites which were destroyed in the creation of segment junctions. 35 -44- Abbreviations: gpX * glycoprotein X; CSP = circumsporozoite protein; vpA = viral protein A; PRV * pseudorabies virus; P.fal. * Plasmodium falciparum; pA = Poly A addition signal; aa = amino acids. FIG.- 54 Structure of S-PRV-093 and summary of foreign genes expressed by the recombinant virus. Abbreviations: gp = glycoprotein; TK = thymidine kinase; IE - immediate early; CSP = circumsporozoite protein; vpA = viral protein A; PRV = pseudorabies virus; P.fal. = Plasmodium falciparum; KB = kilo base pairs; BP = base pairs; kd = kilo daltons; pA = Poly A addition signal; aa = amino acids. DETAILED DESCRIPTION OF THE INVENTION The present invention provides a hybrid, nonprimate herpesvirus comprising DNA which includes a sequence essential for viral replication of the hybrid, non¬ primate herpesvirus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring nonprimate herpesvirus and at least one foreign DNA sequence. The sequence essential for viral replication of the hybrid, nonprimate herpesvirus may be derived from a naturally-occurring nonprimate herpesvirus. The foreign DNA sequence may be adapted for expression in a host and encode an amino acid sequence. In one embodiment of the invention, the foreign DNA sequence is adapted for expression by a herpesvirus promoter. The herpesvirus promoter may be an endogenous upstream herpesvirus promoter or an inserted upstream herpesvi¬ rus promoter. Examples of such herpesvirus promoters include, but are not limited to, the herpes simplex type ICP4 protein promoter, the herpes simplex type I thymidine kinase promoter, the pseudorabies thymidine kinase promoter, the pseudorabies immediate early gene promoter, the pseudorabies glycoprotein X promoter or the pseudorabies glycoprotein 92 promoter. The amino acid sequence encoded by the foreign DNA sequence may be a polypeptide. Furthermore, the polypeptide may be a protein. In one embodiment of the invention, the protein, when expressed in the host, is antigenic. In a further embodiment of the invention, the protein is swine rotavirus glycoprotein 38. In yet another embodiment of the invention, the protein is bovine rotavirus glycorprotein 38. In yet a further embodiment of the invention, the protein is swine parvovirus B capsid protein. The hybrid, nonprimate herpesvirus may comprise DNA of which at least a portion is present in a sequence es¬ sential for replication of a naturally-occurring alpha- herpesvirus. The alpha-herpesvirus may be a pseudorabies virus, infectious bovine rhinotracheitis equine herpesvirus I, feline herpesvirus I or canine herpesvirus I. Additionally the alpha- herpesvirus may be a class D herpesvirus. The class D herpesvirus may be pseudorabies virus, infectious bovine rhinotracheitis virus, equine herpesvirus I, feline herpesvirus I or canine herpesvirus I. In one embodiment of the invention, the alpha-herpesvirus is an infectious bovine rhinotracheitis virus and the foreign DNA encodes the Escherichia coli neomycin resistance gene. This foreign DNA sequence may also be under the control of an inserted pseudorabies virus glycoprotein X promoter. Such a virus has been constructed, designated S-IBR-004, and deposited with the ATCC under Accession No. VR 2134. In another embodiment of the invention, the alpha- herpesvirus is an infectious bovine rhinotracheitis virus with a deletion in the unique short sequence- Furthermore, the foreign DNA sequence may encode the bovine rotavirus glycoprotein 38 gene. This virus, designated S-IBR-008, has been constructed and deposited with the ATCC under Accession No. VR 2141. Additionally the hybrid, nonprimate herpesvirus may comprise DNA of which at least a portion is present in a sequence essential for replication of a naturally- occurring gamma-herpesvirus. The gamma-herpesvirus may be Marek's disease virus or herpesvirus of turkeys. Moreover the gamma-herpesvirus may be a class E herpes¬ » virus. The class E herpesvirus may be Marek's disease virus or herpesvirus of turkeys. Also provided is an attenuated, nonprimate herpesvirus comprising DNA which includes a sequence essential for 10 viral replication of the attenuated, nonprimate herpes¬ virus, at least a portion of which is present in . a sequence essential for replication of a naturally-oc¬ curring nonprimate herpesvirus, from which at least a portion of a repeat sequence has been deleted. The 15 sequence essential for viral replication of the attenu¬ ated, nonprimate herpesvirus may be derived from a naturally-occurring nonprimate herpesvirus. The deleted portion of the repeat sequence may include 20 a portion of a repeat sequence other than a junction region or may include a junction region. Additionally, the deleted portion of the repeat sequence may comprise a nonessential sequence of one repeat sequence or both repeat sequences. Furthermore at least a portion of 25 the essential sequence of a repeat may be deleted. In one embodiment of the invention, one entire repeat may be deleted. Moreover, a sequence not located within a • *.«" repeat may additionally be deleted. In one embodiment of the invention the deleted sequence not located with¬ 30 in a repeat is at least a portion of a gene. The attenuated nonprimate herpesvirus may comprise DNA at least a portion of which is present in a sequence essential for replication of a naturally-occurring 35 alpha-herpesvirus. The alpha-herpesvirus may be a pseudorabies virus, infectious bovine rhinotracheitis virus, equine herpesvirus I, feline herpesvirus I or canine herpesvirus I. Additionally, the alpha- herpesvirus may be a class D herpesvirus. The class D herpesvirus may be a pseudorabies virus, infectious bovine rhinotracheitis virus, equine herpesvirus I, feline herpesvirus I or canine herpesvirus I. In one embodiment of the invention, the alpha-herpesvirus is an infectious bovine rhinotracheitis virus. In another embodiment of the invention, the attenuated, nonprimate herpesvirus comp.. ises an infectious bovine rhinotracheitis virus from which has been deleted at least a portion of both repeat sequences. This virus has been constructed, designated S-IBR-002, and deposited under ATCC Accession No. VR 2140. Further provided is an attenuated, hybrid, nonprimate herpesvirus comprising DNA which includes a sequence essential for viral replication of the attenuated, hybrid, nonprimate herpesvirus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring nonprimate, herpesvirus and at least one foreign DNA sequence. The sequence essential for viral replication of the attenuated, hybrid, nonprimate virus may be derived from a naturally-occurring nonprimate herpesvirus. Furthermore, at least a portion of a repeat sequence of the attenuated, hybrid, nonprimate herpesvirus may be deleted. The foreign DNA sequence may be adapted for expression in a host and encode an amino acid sequence. Additionally, the foreign DNA sequence may be adapted for expression by a herpesvirus promoter. The herpesvirus promoter may be an endogenous upstream promoter or an inserted upstream herpesvirus promoter. The herpesvirus promoter may be the herpes simplex type ICP4 protein promoter, the herpes simplex type I thymidine kinase promoter, the pseudorabies immediate early gene promoter, the pseudorabies glycoprotein X tr promoter or the pseudorabies glycoprotein 92 promoter. The amino acid sequence encoded by the foreign DNA sequence may be a polypeptide. Additionally the 10 polypeptide may be a protein. Furthermore the protein, when expressed in a host, may be antigenic. In one embodiment of the invention the protein is swine rota¬ virus glycoprotein 38. In another embodiment, the protein is bovine rotavirus glycoprotein 38. In a further embodiment of the invention, - the protein is 15 swine parvovirus B capsid protein. The attenuated, hybrid, nonprimate herpesvirus may comprise DNA, at least a portion of which is present in 20 a sequence essential for replication of a naturally- occurring alpha-herpesvirus. The alpha-herpesvirus may be a pseudorabies virus, infectious bovine rhinotracheitis virus, equine herpesvirus I, feline herpesvirus I or canine herpesvirus I. Additionally, 25 the alpha-herpesvirus may be a class D herpesvirus. The class D herpesvirus may be pseudorabies virus, infectious bovine rhinotracheitis virus, equine herpesvirus I, feline herpesvirus I or canine herpesvirus I. 30 Furthermore the attenuated, hybrid, nonprimate herpes¬ virus may comprise DNA, at least a portion of which is present in a sequence essential for replication of a naturally-occurring gamma-herpesvirus. The gamma-her¬ pesvirus may be Marek's disease virus or herpesvirus of 35 turkeys. Additionally the gamma-herpesvirus may be a class E herpesvirus. The class E herpesvirus may be Marek's disease virus or herpesvirus of turkeys. The present invention also provides a vaccine useful for immunizing an animal against a herpesvirus disease. This vaccine comprises an effective immunizing amount of a hybrid, nonprimate herpesvirus of the present invention and a suitable carrier. Also provided is a multivalent vaccine useful for immu¬ nizing an animal against at least one pathogen. This vaccine comprises an effective immunizing amount of a hybrid, nonprimate herpesvirus of the present invention which includes a foreign DNA sequence encoding a pro¬ tein which, when expressed in the host, is antigenic and a suitable carrier. Furthermore, the present invention provides a vaccine useful for immunizing an animal against a herpesvirus disease which comprises an effective immunizing amount of an attenuated, nonprimate herpesvirus provided by the invention and a suitable carrier. Another vaccine useful for immunizing an animal against a herpesvirus disease is also provided. This vaccine comprises an effective immunizing amount of an attenuated, hybrid, nonprimate herpesvirus of the present invention and a suitable carrier. Moreover, a multivalent vaccine useful for immunizing an animal against at least one pathogen is provided. This vaccine comprises an effective immunizing amount of an attenuated, hybrid, nonprimate herpesvirus which includes at least one foreign DNA sequence encoding a protein which, when expressed in the host, is antigenic and a suitable carrier. Methods of immunizing animals against herpesvirus dis¬ eases and methods of immunizing an animal against at least one pathogen are provided. These methods com¬ prise administering to the animal a suitable dose of a vaccine of the present invention. The animals which may be immunized include, but are not limited to, bovine animals, sheep and goats. Methods of identifying the hybrid, nonprimate herpes^ viruses are provided. In one embodiment of the inven- ' tion, the foreign DNA sequence in the virus is detect¬ ed. In another embodiment of the invention, the pre¬ sence of the expressed polypeptide in the host animal or host cell is detected. In yet another embodiment of the invention, the presence of the expressed protein in the host animal or host cell is detected. Furthermore, methods of identifying an attenuated, hybrid, nonprimate herpesvirus of the invention are provided. In one embodiment of the invention, the foreign DNA sequence is detected. In another embodi¬ ment of the invention, the presence of the expressed polypeptide in the host animal or host cell is detect¬ ed. In yet a third embodiment of the invention, the presence of the expressd protein in the host animal or host cell is detected. The present invention further provides a method of producing in an animal a gene product for purposes other than immunization. This method comprises admin¬ istering to the animal a suitable quantity of a hybrid, nonprimate herpesvirus of the present invention which includes a foreign DNA sequence adapted for expression in a host, the foreign DNA sequence of which expresses the gene product. Additionally, a gene product may be produced in an animal for purposes other than immuniza¬ tion by administering to the animal a suitable quantity of an attenuated, hybrid, nonprimate herpesvirus which includes a foreign DNA sequence adapted for expression in a host, the foreign DNA sequence of which expresses the gene product. Methods of preparing an attenuated, hybrid, nonprimate herpesvirus of the present invention are also provided.. One method comprises isolating naturally-occurring nonprimate herpesvirus viral DNA and using restriction enzyme digestion to produce DNA restriction fragments. These restriction fragments are purified by agarose gel electrophoresis to obtain specific DNA fragments which are treated with appropriate enzymes, known to those skilled in the art, to produce modified viral DNA frag¬ ments. These modified DNA fragments are capable of binding to bacterial plasmid DNA sequences. Suitable bacterial plasmids are separately treated with appro¬ priate restriction enzymes, Icnown to those skilled in the art, to produce bacterial plasmid DNA sequences capable of binding to modified viral DNA fragments. These bacterial plasmid sequences are then combined with the modified viral DNA fragments under suitable conditions to allow the viral DNA to bind the bacterial DNA and form a viral-bacterial plasmid. The viral-bacterial DNA plasmid is then mapped by re¬ striction enzymes to generate a restriction map of the viral DNA insert. The viral-bacterial DNA plasmid is then treated with a restriction enzyme known in the art to cause at least one deletion in the viral DNA se¬ quence of the viral-bacterial DNA plasmid. This plasmid, containing at least one deletion in the viral DNA sequence, is transfected with naturally-occurring nonprimate herpesviral DNA into animal cells. The animal cells are maintained under suitable conditions to allow the naturally-occurring nonprimate herpesviral DNA to regenerate herpesviruses and a small percent of viruses which have recombined with the viral-foreign DNA sequence of the viral-bacterial-foreign DNA plasmid. Some of these recombined viruses have dele¬ 10 tions in their genome as a result of deletions in the viral DNA insert of the plasmid. The viruses are idenr tified and subsequently plaque purified away from the undesired viruses. In another embodiment of the invention, naturally-oc¬ 15 curring nonprimate herpes viral DNA is isolated and digested with appropriate restriction enzymes to pro¬ duce viral restriction fragments. Separately, foreign DNA is digested with appropriate enzymes to produce foreign DNA restriction fragments. The foreign DNA 20 restriction fragments are mixed with the viral DNA restriction fragments under suitable conditions so as to allow the fragments to join together to produce viral-foreign DNA fragments. Animal cells are trans¬ fected with the viral-foreign DNA fragments and main¬ 25 tained under suitable conditions so as to allow the foreign DNA fragments to regenerate herpesviruses and a *f* small percent of viruses which have included foreign DNA fragments into their genome. Herpesviruses which have included desired foreign DNA fragments into their 30 genome are identified and plaque purified away from undesired herpesviruses. In still another embodiment, this invention provides a recombinant fusion protein comprising an antigenic 35 amino acid sequence, e.g. a foreign antigen or epitope, fused to at least a portion of the gpX protein from pseudorabies virus, such as the amino terminal transmembrane signal sequence from the gpX glycoprotein. Thus, the antigenic amino acid sequence may be inserted into an internal portion of the gpX glycoprotein, such that the gpX/antigenic amino acid sequence boundary is in frame only on the amino terminal side or such that both gpX/antigenic amino acid sequence boundaries are in frame (an embedded fusion) with each other. A recombinant fusion protein in accordance with the teachings of the subject invention may be delivered to an animal using a live herpes vector adapted to express the fusion protein and, for example, may comprise as the antigenic amino acid sequence all or part of swine parvovirus capsid protein or the malaria CSP protein, particularly the malaria CSP repeat region. In a particular embodiment of the invention the recombinant fusion protein comprises the E. coli beta galactosidase gene fused at its carboxy terminus to an antigenic amino acid sequence and is delivered to an animal using a live herpesvirus vector adapted to express the fusion protein. Effective immunizing amounts of the recombinant fusion proteins of this invention may be formulated into vaccines using methods well known to those skilled in the art. In yet another embodiment of the invention, an infectious bovine rhinotracheitis virus includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase and neomycin resistance genes, and the parainfluenzae -3, PI-3, virus hemagglutinin gene, HN. One such virus, designated S-IBR-018, has been constructed and deposited with the ATCC under Accession 5 No. VR 2180. Also provided is an infectious bovine rhinotracheitis virus which includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase and 10 neomycin resistance genes, and the parainfluenzae -3, PI-3, virus fusion gene, F. One such virus which has been constructed is designated S-IBR-019. Further provided is a herpesvirus of turkeys which 1g includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase gene and the infectious bursal disease virus, IBDV, large segment of RNA. One such virus, designated S-HVT-003, has been constructed and deposited with the ATCC under Accession 20 No. VR 2178. In another embodiment of the invention, a herpesvirus of turkeys which includes a foreign DNA sequence encodes the Escherichia coli beta-galactosidase gene 25 and the Marek's disease virus, MDV, glycoprotein A, gp A, gene. One such virus has been designated S-HVT-004. # The attenuated, hybrid, nonprimate herpesvirus may comprise a pseudorabies virus from which has been •> 30 deleted the TK gene and a portion of the repeat region, and into which has been inserted a foreign DNA sequence which encodes the transmissible gastroenteritis, TGE, virus gpl95 gene. This virus, designated S-PRV-055, has been constructed and deposited with the ATCC under 35 Accession No. VR 2179. This invention further provides attenuated pseudorabies viruses designated S-PRV-065 (ATCC No. VR 2215); S-PRV- 086 (ATCC No. VR 2216); S-PRV-040 (ATCC No. VR 2214; S- PRV-098 (ATCC No. VR 2219) ; S-PRV-066; S-PRV-088 (ATCC No. VR 2217); and S-PRV-093 (ATCC No. VR 2218). The present invention discloses that expression of foreign antigens in herpesviruses is in large part determined by the sequence of DNA encoding the foreign antigen. In particular, the "triplet" frequencies of the codons used in the gene itself and the position of these "triplet" frequencies within the intact messenger RNA become the crucial factors in the expression of all foreign antigens within herpesviruses. Some foreign antigens have these sequences naturally and do not need to be changed, but most do not. The actual biological basis for this effect is still largely unknown, but a computer-modelling test has been derived that can be used to predict the expression of a foreign antigen in herpesviruses. The present invention discloses expression of foreign antigens that had low or no expression using only herpesvirus regulatory signals known in the art, but became much improved in expression when the present invention was applied. The present invention may be practiced by one of the following: 1. directly synthesizing the gene for the foreign antigen substituting wherever possible in the coding region nucleotide triplets (codons) that are favored within the herpesvirus genome, then using this synthetic gene to express the foreign protein in the herpesvirus vector; or -57- 2. by making a fusion between a gene that already has the favored herpesvirus triplet nucleotide (codons) followed by a foreign antigen gene that does not have the favored triplet frequencies, and positioning the favored gene so that it is translated first in the fusion (thereby competing successfully for ribosomes) followed by the foreign gene which utilizes these same ribosomes. The present invention discloses the means to determine if a gene is favorable or unfavorable within the herpesvirus context, and then discloses how to synthesize a gene that is more favorable starting with a gene that is unfavorable. Secondly, it discloses a class of genes that are already favorable, and demonstrates how fusions of these genes with unfavorable genes can be used to drive the expression of the unfavorable part of the fusion. Materials and Methods GROWTH OF HERPESVIRUS IN TISSUE CULTURE. All of the herpesviruses under discussion were grown in tissue culture cells. Unless otherwise noted, the cells used were: Vero cells for PRV; MDBK cells for IBR; CEF cells for HVT; ' Crandall feline kidney cells for FHV. Vero cells are suitable for EHV and MDCK cells are suitable for CHV. PREPARATION OF HERPESVIRUS STOCK SAMPLES. Herpesvirus stock samples were prepared by infecting tissue culture cells at a multiplicity of infection of 0.01 PFU/cell in Dulbecco's Modified Eagle Medium (DMEM) containing 2 mM glutamine, 100 units/ml penicillin, 100 units/ml streptomycin (these components were obtained from Irvine Scientific or equivalent supplier, and hereafter are referred to as complete DME medium) plus 1% fetal bovine serum. After cytopathic effect was complete, the medium and cells were harvested and the cells were pelleted at 3000 rpm for 5 minutes in a clinical cen¬ trifuge. For all herpesviruses except HVT, the cells were resuspended in 1/10 the original volume of medium, and an equal volume of 2 times autoclaved skim milk (9% skim milk powder in H,0 wgt/vol) was added. The virus sample was frozen and thawed 2 times, aliquoted, and stored frozen at -70°C. The titer was usually about Q 10 plaque forming units per ml. For HVT, infected cells were resuspended in complete medium containing 20% fetal bovine serum, 10% DMSO and stored frozen at - 70°C. PREPARATION OF HERPESVIRUS DNA. For herpesvirus DNA preparation, a confluent monolayer of tissue culture cells i .n' a 25 cm2 flask or a 60 mm petri dish was in- fected with 100 microliters of virus sample in 1 ml medium. Adsorption proceeded for 1-2 hours at 37°C in a humidified incubator with 5% CO, in air. After ad¬ sorption, 4 is of complete DME medium plus 1% fetal bovine serum were added. After overnight incubation, or when the cells were showing 100% cytopathic effect, the cells were scraped into the medium, with a cell scraper (Costar brand) . ■ The cells and medium were centrifuged at 3000 rpm for 5 minutes in a clinical centrifuge. The medium was decanted, and the cell pellet was gently resuspended in 0.5 ml solution con¬ taining 0.01 M Tris pH 7.5, 1 mM EDTA, and 0.5% No.nidet P-40 (NP40, an ionic detergent comprising an octyl phenol ethylene oxide condensate containing an average of 9 moles ethylene oxide per molecule, purchased from Sigma Chemical Co., St. Louis, MO.). The sample was incubated at room temperature for 10 minutes. Ten microliters of a stock solution of RNase A (Sigma) were added (stock was 10 mg/ml, boiled for 10 minutes to inactivate DNAase) . The sample was centrifuged for 5 minutes at 3000 rpm in a clinical centrifuge to pel¬ let nuclei. The DNA pellet was removed with a pasteur pipette or wooden stick and discarded. The superna¬ tant fluid was decanted into a 1.5 ml Eppendorf tube containing 25 microliters of 20% sodium dodecyl sul- fate (Sigma) and 25 microliters proteinase-K (10 mg/ml; Boehringer Mannheim supplier). The sample was mixed and incubated at 37°C for 30-60 minutes. An equal volume of water-saturated phenol was added and the sample was mixed on a vortex mixer for 1 minute. The sample was centrifuged in an Eppendorf minifuge for 5 minutes at full speed. The upper aqueous phase was removed to a new Eppendorf tube, and two volumes of -20 C absolute ethanol were added and the tube put at -20 C for 30 minutes to precipitate nucleic acid. The sample was centrifuged in an Eppendorf centrifuge at 4oC for 5 minutes. The supernatant was decanted, and the pellet was washed one time with cold 80% ethanol. The pellet was dried in a lyophilizer, and rehydrated in 17 microliters H20. For the preparation of larger amounts of DNA, the procedure was scaled up to start with a 850 cm2 roller bottle of Vero cells. The DNA was stored in H20 or in 0.01 M Tris pH 7.5, 1 mM EDTA at -20oC or +4oC. PREPARATION OF HERPES VIRUS OF TURKEY DNA. All manipulations requiring herpes virus of turkey (HVT) were made using strain FC-126 (ATCC #584-C) . For the preparation of HVT viral DNA from the cytoplasm of infected cells, primary chicken embryo fibroblasts were infected at a MOI sufficient to cause extensive cytopathic effect before the cells overgrew. All incubations were carried out at 39*C in a humidified incubator with 5% CO_ in air. Best DNA yields were obtained by harvesting monolayers which were maximally infected, but showing incomplete cell lysis (typically 5-7 days) . Infected cells were harvested by scraping the cells into the medium using a cell scraper (Costar brand) . The cell suspension was centrifuged at 3000 rpm for 10 minutes at 5*C in a GS-3 rotor (Sorvall Instruments) . The resultant, pellet was resuspended in cold PBS (20 ml/Roller Bottle) and subjected to another centrifugation for 10 minutes at 3000 rpm in the cold. After decanting the PBS, the cellular pellet was resuspended in 4 ml/ roller bottle of RSB buffer (10 mM Tris pH 7.5, 1 mM EDTA, and 1.5 mM MgCl 2 ) . NP40 (Nonidet P-40;Sigma) was added to the sample to a final concentration of 0.5% and allowed to incubate on ice for 15 minutes with occasional mixing. The sample was centrifuged for 10 minutes at 3000 rpm in the cold to pellet the nuclei and remove cellular debris. The supernatant fluid was carefully transferred to a 15 ml Cprex centifuge tube. Both EDTA (0.5M pH 8.0) and SDS (sodium dodecyl sulfate; stock 20%) were added to the sample to final concentrations of 5 mM and 1%, respectively. One hundred microliters of proteinase-K (10 mg/ml; Boehringer Mannheim) was added per 4 illiliters of sample, mixed, and incubated at 45*C for 1-2 hours. After this period, an equal volume of water-saturated phenol was added to the sample and gently mixed by hand. The sample was spun in a clinical centrifuge for 5 minutes at 3000 rpm to separate the phases. NaOAc was added to the upper aqueous phase to a final concentration of 0.3M (stock solution 3M pH 5.2), and the nucleic acid precipitated at -70*C for 30 minutes after the addition of 2.5 volumes of cold absolute ethanol. DNA in the sample was pelleted by spinning for 20 minutes at 8000 rpm in an HB-4 rotor at 5'C. The supernatant was carefully removed and the DNA pellet washed once with 25 ml of 80% ethanol. The DNA pellet was dried briefly by vacuum (2-3 minutes) , and resuspended in 50 microliters/roller bottle of infected cells of T.-E. buffer (10 mM Tris pH 7.5, 1 mM EDTA). Typically, yields of viral DNA ranged between 5-10 icrograms/roller bottle of infected cells. All viral DNA was stored at approximately 10*C. PREPARATION HERPESVIRUS CELLYSATES. For cell lysate preparation, a conflunent monolayer of tissue culture cells in a. 25 cm flask or a 60 mm petri dish was infected with 100 microliters of virus sample in 1 ml of medium. Adsorption proceeded for 1-2 hours at 37 * C in a humidified incubator with 5% CO in air. After adsorption, 4 mis of medium were added. After 40 -62- overnight incubation, or when cells were showing 100% cytopathic effect, the cells were scraped into the medium with a cells scraper (Costar brand) . The cells and medium were centrifuged at 3000 rpm for 5 minutes in a clinical centrifuge. The medium was decanted, and the cell pellet was suspended in 250 microliters of disruption buffer (2% sodium dodecyl sulfate, 2% beta- mercapto-ethanol) . The samples were sonicated for 30 seconds on ice and stored at -20*C. PHENOL EXTRACTION. Phenol extraction was performed on. any convenient volume of DNA sample, typically between 100 microliters to 1 ml. The DNA sample was diluted in 0.01M Tris pH 7.5, 1 mM EDTA and an equal volume of water saturated phenol was added. The sample was mixed briefly on a vortex mixer and placed on ice for 3 min¬ utes. After centrifugation for 3 minutes in a micro- fuge, the aqueous layer was removed to a new tube and was precipitated by ethanol. ETHANOL PRECIPITATION. DNA in a sample was concentrat¬ ed by ethanol precipitation. To the DNA sample were added 1/10 volume of 3M sodium acetate, pH 7.5 and 3 volumes of cold ethanol. The DNA was precipitated for 30 minutes at -70°C or overnight at -20°C and then pelleted by centrifugation in the microfuge for 15 minutes at 4°C. The pellet was washed once with 200 microliters of cold 80% ethanol and pelleted again for 10 minutes at 4°C. After air drying or lyophilization, the pellets were resuspended in. the appropriate buffer or H 2 0. RESTRICTION ENZYME DIGESTION. DNA was cut by restric¬ tion enzymes using the buffer recommended by the manu¬ facturer (International Biotechnologies Inc. , New Ha- -63- ven, CT. (IBI) , Bethesda Research Laboratories, Bethesda, MD. (BRL) , and New England Biolabs, Beverly, MA) . Whenever possible, the concentration of DNA was kept below 1 microgram/50 microliters. Incubation was at 37°C for 1-4 hours. AGAROSE GEL ELECTROPHORESIS OF DNA. To visualize the restriction pattern of the DNA, 5 microliters of load¬ ing buffer (5X electrophoresis buffer, 0.01% bromphenol blue dye, 50 mM EDTA, and 50% glycerol) were added. The sample was loaded into a lane in a horizontal sub¬ marine electrophoresis unit containing a 0.6% agarose gel. The electrophoresis buffer was 40 mM Tris, 10 mM EDTA, adjusted to pH 7.8 with acetic acid, and with or - without 0.5 micrograms/i-.__. ethidium bromide. The gel was run at 40-50V for 18 hours, and the gel was removed and stained with 0.5 micrograms/ml ethidium bromide for 30 minutes. The DNA bands were visualized on a long wavelength UV transilluminator. PHOSPHATASE TREATMENT OF DNA. Phosphatase treatment of DNA was performed by adding 1 microliter (25 units) of calf intestinal phosphatase (Boehringer Mannheim) di¬ rectly to the restriction enzyme digestion reactions and continuing the incubation for 30 minutes at 37°C. The phosphatase was inactivated for 60 minutes at 65 C prior to phenol extraction. POLYMERASE FILL-IN REACTION. DNA was resuspended in buffer containing 50 mM Tris pH 7.4, 50 mM KCl, 5 mM MgCl_, and 400 micromolar each of the four deoxynu- cleotides. Ten units of Klenow DNA polymerase (BRL) were added and the reaction was allowed to proceed for 15 minutes at room temperature. The DNA was then phe¬ nol extracted and ethanol precipitated as above. -64- EXONUCLEASE RESECTION REACTION. DNA was resuspended in 100 microliters of 60 mM Tris pH 8.0, 0.66 mM MgCl., 1 mM beta-mercaptoethanol. ' The sample was warmed to 30 C for 5 minutes, and 10 units of lambda exonuclease III (BRL) were added. At frequent time intervals (e.g. every 2.5 minutes), 10 microliter aliquots were dilut¬ ed into 100 microliters of 30 mM sodium acetate pH 4.5, 250 mM NaCl, 1 mM ZnSO., 4 micrograms/100 microliters yeast tRNA, 30 units/ 100 microliters S nuclease. .After 45 minutes at 30°C, 15 microliters of stop buffer consisting of 625 mM Tris pH 9.0, 150 ' mM EDTA, 1% SDS were added. The samples were then phenol extracted and ethanol precipitated as above. The DNA digestion products were then analyzed and purified by agarose gel electrophoresis. PHENOL EXTRACTION OF DNA FROM AGAROSE. DNA bands cut from low melting point agarose gels were diluted to less than 0.5% agarose to a final concentration of 0.3 M sodium acetate. The samples were heated to 65°C to melt the agarose and then cooled to 37°C for 5 minutes. An equal volume of phenol was added and the sample was phenol extracted three times (see PHENOL EXTRACTION) . The DNA was then ethanol precipitated and the pellet resuspended at a concentration of 3-6 fmole DNA/ microliter. LIGATION. DNA was joined together by the action of the enzyme T4 DNA ligase (BRL) . Ligation reactions con¬ tained 10 fmoles DNA, 20 mM Tris pH 7.5, 10 mM MgCl 2 , 10 mM dithiothreitol (DTT) , 200 micromolar ATP, and 20 units T4 DNA ligase in 10 microliters final reaction volume. The ligation was allowed to proceed for 3-16 hours at 15°C. Typically DNA fragments to be ligated together were added at an equal molar ratio. Typically two different DNA fragments were joined during liga¬ tion, but joining of three or four different DNAs at once was also possible. RESTRICTION MAPPING OF DNA. Restriction mapping of DNA was performed as detailed in Maniatis et al. (1). Once it was cloned, the DNA was digested with a number of different restriction enzymes and the DNAs were ana¬ lyzed on agarose gels and the sizes of the resulting fragments were measured. A double digest with two different restriction enzymes was performed on the same DNA sample to aid in the interpretation of the maps. Another approach used was to cut the DNA with a re- striction enzyme that has a single unique site in the DNA, label the end of the DNA with 32 P using T4 DNA kinase or Klenow DNA polymerase (see POLYMERASE FILL-IN REACTION) and then cut the DNA with other restriction enzymes at low temperature or for short times so that only partial digestion occurred. The subsequent analy¬ sis of the partial digestion fragments on agarose gels served to order the restriction sites on the map. All of these mapping procedures are well understood by those skilled in the art and are detailed in Maniatis et al. (1). The most complete restriction maps can only be composed once the DNA has been sequenced, and the sequence is then analyzed by a computer searching for all the known restriction enzyme sites. Some of our maps have been generated from sequence information. SOUTHERN BLOTTING OF DNA. The general procedure for Southern blotting was taken from Maniatis et al. (1). DNA was blotted to nitrocellulose filters (S&S BA85) in 20X. SSC (IX SSC * 0.15M NaCl, 0.015M sodium citrate, pH 7.0), and prehybridized in hybridization solution 40 -66- consisting of 30% forma ide, IX Denhardt's solution (0.02% polyvinylpyrrolidone (PVP) , 0.02% bovine serum albumin (BSA) , 0.02% Ficoll) , 6X SSC, 50 mM NaH 2 P0 4 , pH 6.8, 200 micrograms/ml salmon sperm DNA for 4-24 hours at 55°C. Labeled probe DNA was added that had been labelled by nick translation using a kit from Bethesda Research Laboratories (BRL) and one 32P-labeled nucleotide. The probe DNA was separated from the unin¬ corporated nucleotides by NACS column (BRL) or on a Sephadex G50 column (Pharmacia) . After overnight hy- bridization at 55°C, the filter was washed once with 2X SSC at room temperature followed by two washes with 0.1X SSC, 0.1% sodium dodecyl sulfate (SDS) for 30 mmiinnuutteess at 55°C. The filter was dried and autoradio- graphed. DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS. The method is based upon the calcium phosphate DNA precipi¬ tation procedure of Graham and Van der Eb (32) with the following modifications. For transfection into animal cells, 0.1-0.2 micrograms of plasmid DNA containing the foreign DNA flanked by appropriate herepesvirus cloned sequences (the homovector) were mixed with 0.3 micrograms of intact DNA. Both DNAs were stored either in H_0 or 0.01 M Tris pH 7.5, 1 mM EDTA and the Λ 2 final volume should be less than 0.25 ml. To the mix¬ ture was added an equal volume of 2X HEPES buffered saline (10g N-2-hydroxyethyl piperazine N'-2-ethane- sulfonic acid (HEPES), 16g NaCl, 0.74g KCl, 0.25g Na 2 HP0..2H 2 0, 2g dextrose per liter H,0 and buffered with NaOH to pH 7.4). The mixture was then diluted to 0.5 ml by the addition of the appropriate volume of IX HEPES buffered saline (prepared by diluting the above solution 1:1 with H_0) . After mixing, 35 microliters of 2.2 M CaCl. were added to the DNA mixture and mixed. 2 The mixture was incubated at room temperature for 30 minutes. Medium was removed from an 80% confluent monolayer of rabbit skin cells, Vero cells, or CEF cells growing in a 25 cm flask, and the DNA mixture was added to the flask and distributed over the cells. After a 30 minute incubation at room temperature, 5 mis of complete DME medium plus 10% fetal bovine serum were added. The cells were incubated for 5 hours at 37°C in a humidified incubator containing 5% C0 2 in air. The medium was changed at 5 hours either with or without a glycerol shock. When used, the glycerol ^ shock consisted of removing the medium, and adding DME containing 20% glycerol for 3 minutes at room temperar ture, followed by a wash with 10% glycerol in DME, and a wash in 5% glycerol in DME, followed by the addition of fresh complete DME medium plus 10% fetal bovine serum. The cells were incubated at 37°C as above for 3-4 days until cytopathic effect from the virus was 50- 100%. Virus was harvested as described above for the preparation of virus stocks. This stock was referred to as a transfection stock and it was subsequently screened for recombinant virus either with or without a selection mechanism to enrich for recombinant plaques as described below. DNA • COTRANSFECTION FOR GENERATING RECOMBINANT HVT VIRUS. The method is based upon the polybrene-DMSO procedure of Kawai and Nishizawa (Mol and Cell bio., vol 4, pages 1172-1174, 1984) with the following modifications. Generation of recombinant HVT virus is dependent upon homologous recombination between HVT viral DNA and the plasmid homology vector containing the desired foreign DNA flanked by the appropriate herpesvirus cloned sequences. Transfections were carried out in 6 cm plates (Corning plastic) of 50% -68- confluent primary chick embryo fibroblast (CEF) cells. The cells were plated out the day before in CEF growth media (IX F10/199, 5% fetal calf serum, 2% glutamine, 1% non-essential amino acids, and 2% penicillin/streptomycin) containing 4 micrograms/milliliter polybrene (stock 4 mg/ml in IX HBSS) . For cotransfeetions into CEF cells, 5 micrograms of the plasmid homology vector was mixed with 5 micrograms of intact HVT DNA, and suspended in 1 ml of CEF media containing 30 micrograms/milliliter polybrene (stock 4 mg/ml in IX HBSS) . The DNA-. polybrene suspension (1 ml) was then added to a 6 cm plate of CEF cells from which the media had been aspirated, and incubated at 39'C for 30 minutes. The plates were rocked periodically during this time to redistribute the inoculum. After this period, 4 ml of CEF growth media was added directly to each plate, and incubated an additional 2.5 hours at 39*C. At this time, the media was removed from each plate, and the cells shocked with 2 ml of 30% DMSO (Dimethyl Sulfoxide, J.T. Baker Chemical Co.) in IX HBSS for 4 minutes at room temperature. The 30% DMSO was carefully removed and the monolayers washed once with IX HBSS at room temperature. The cells were then incubated at 39*C after the addition of 5 mis of CEF growth media. The next day, the media was changed to remove any last traces of DMSO and to stimulate cell growth. Cytopathic effect from the virus becomes apparent within 6 days. Generation of a high titer stock (80%-90% CPE) can usually be made within 1 week from this date. HVT stock samples were prepared by resuspending the infected cells in CEF growth media containing 20% fetal calf serum, 10% DMSO and stored at -70*C. DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUSES. Rather than using homovectors and rely¬ ing upon homologous recombination to generate recombi¬ nant virus, the technique of direct ligation was devel¬ oped to insert foreign genes into herpesviruses. In this instance, the cloned foreign gene did not require flanking herpesvirus DNA sequences but only required that it have restriction sites available to cut out the foreign gene fragment from the plasmid vector. A compatible restriction enzyme was used to cut the herpesvirus DNA. A requirement of the technique was that the restriction enzyme used to cut the herepesvirus DNA must cut at a limited number of sites, preferably less than 3 sites. For PRV DNA, we have used xbal, which cut PRV DNA in two places, and contemplate the use of Hindlll (2 cuts) , EcoRV (2 or 3 cuts) or Ndel (3-5 cuts) . The herpesvirus DNA was mixed with a 30-fold molar excess of plasmid DNA, and the mixture was cut with the appropriate restriction enzyme. The DNA mixture was phenol extracted and ethanol precipi¬ tated to remove restriction enzymes, and ligated to¬ gether according to the ligation procedure detailed above. The ligated DNA mixture was then phenol ex¬ tracted, ethanol precipitated, and resuspended in 298 microliters 0.01M Tris pH 7.5, 1 mM EDTA. Forty- two microliters of 2M CaCl 2 were added, followed by an equal volume of IX HEPES buffered saline (see above) , and the sample was used to transfeet animal cells as described above. The virus in the transfection stock was then screened for foreign DNA inserts as described below. The advan¬ tage of the direct ligation technique was that it re¬ quired less construction of sub-clones in the plasmid state, and that the recombinant virus was present in the transfection stock at a much higher frequency than with homologous recombination. HAT SELECTION OF RECOMBINANT HERPESVIRUS EXPRESSING THYMIDINE KINASE. Deletion mutants of herpesviruses which suffered deletions in the thymidine kinase (TK) gene were constructed. These PRV strains have been designated S-PRV-002 and S-PRV-003 and have been depos¬ ited with the ATCC under Accession No. VR 2107 and VR 2108 respectively. These TK minus (TK-) viruses have been '.ιsed as recipients for the insertion of the for¬ eign herpes simplex type 1 (HSV-1) TK gene. One HSV-1 TK gene that we have used contains the HSV-1 ICP4 pro¬ moter and was from B. Roizman (16) . It was sub-cloned to lie between two flanking regions of PRV DNA, for example by insertion of the TK gene into PRV BamHI #5 fragment between Xbal and Hpal sites. The plasmid construct was then transfected with the PRV TK- DNA to yield recombinant virus. The transfection stock was enriched for TK-containing virus by the HAT selection procedure described in (35) . The transfection stock was used to infect monolayers of 143 TK- cells in 60 mm culture dishes that had been preincubated in HAT medium for 16 hours at 37°C (HAT medium: medium 199 contain¬ ing 2 mM glutamine, 100 units/ml penicillin, 100 units/ml streptomycin, 10% fetal bovine serum, 5 X 10 5 M hypoxanthine, lθ "5 M thymidine, 5 X lθ "6 M aminopterin) . Samples of the transfection stock virus -3 —7 were infected into the 143 TK- cells using 10 to 10 dilutions of virus. After one or two days at 37°C, the dishes inoculated with the highest dilution of virus and still showing virus plaques were harvested for virus stocks, and the selection was repeated a second time. The virus stock harvested from the second HAT selection was used in a plaque assay and individual plaques were picked and tested for foreign DNA inserts as described below. BROMODEOXYURIDINE SELECTION OF RECOMBINANT HERPESVIRUS. In order to insert a foreign gene in place of a TK gene already present in the herpesvirus genome, the foreign gene was cloned in plasmids so that it contained the same flanking homology regions as the TK genes. These flanking regions could be part of the TK gene itself, or parts of the herpesvirus that flank the TK gene. In either case, the plasmid DNA containing the foreign gene was transfected with intact herpesvirus genomic * DNA containing the HSV-1 TK gene. The transfection stock of recombinant virus was grown for two selections in 143 TK- cells in the presence of 40 micrograms/ml bromodeoxyuridine (BUDR, Sigma) in complete DME medium plus 10% fetal bovine serum. The drug BUDR is an ana¬ logue of thymidine that is recognized by the viral enzyme thymidine kinase (TK) and is ultimately incorpo¬ rated into DNA. When incorporated into the DNA, BUDR is mutagenic and lethal and thus selects against virus¬ es that have an active TK gene. By this selection method, viruses that had exchanged their TK gene for a foreign gene by homologous recombination were enriched in the population. Screening for the recombinant vi¬ ruses was then performed by one of the techniques de¬ tailed below. HYBRIDIZATION SCREEN FOR RECOMBINANT HERPESVIRUS. One procedure used is described in (36) . The technique involved doing a plaque assay on PRV under agarose, removing the agarose once plaques had formed, and lift¬ ing the cell monolayer from the dish onto a nitrocellu¬ lose membrane filter. The filter was then processed through the Southern procedure for DNA hybridization as detailed above. The DNA probe used in the procedure was made from the foreign gene that had been inserted into the virus. Thus plagues that contain the foreign gene were identified, and they were picked from the agarose overlay that had been saved. BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS. When the foreign gene encoded the enzyme beta-galactosidase, the plaques that contained the gene were visualized more easily. The chemical Bluogal- (BRL) was incorpo- rated at thfc level of 200-300 micrograms/ml into the agarose overlay during the plaque assay, and the plaques that expressed active beta -galactosidase turned blue. The blue plaques were then picked and. purified by further blue plaque isolations. Other foreign genes were inserted by homologous recombination such that they replaced the beta- galactosidase gene; in this instance non-blue plaques were picked for purification of the recombinant virus. ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS. A third method for screening the recombinant virus stock was to look directly for the expression of the foreign gene with antibodies. Herpesvirus plaques were spotted and picked by inserting a toothpick through the agarose above the plaque and scraping the plaque area on the dish. Viruses were then rinsed from the toothpick by inserting the toothpick into a well of a 96-well micro- titer dish (Falcon Plastics) containing a confluent monolayer of tissue culture cells that had been washed 3 times in DME medium without serum. It was important for the virus to grow without serum at this stage to allow the immunological procedure to work. After cyto- pathic effect was complete, the plates were put at - 70 C to freeze and lyse the cells. The medium was thawed, and the freeze/thaw procedure was repeated a second time. Then 50-100 microliters of medium were removed from each well and filtered under vacuum through a nitrocellulose membrane (S&S BA85) using a DotBlot- apparatus (BRL) . The filter blots were soaked in a blocking solution of 0.01 M Tris pH 7.5, 0.1 M NaCl, 3% bovine serum albumin at room temperature for two hours with shaking. The filter blots were then placed in a sealable bag (Sears Seal-A-Meal^ or equiva¬ lent) , and 10 mis of the blocking., solution that con¬ tained 10 microlit«rs of a tibody specific for the foreign protein were added. After overnight incubation at room temperature with shaking, the blot was washed 3 times with 100 mis 0.01 M Tris, pH 7.5, 0.1 M NaCl, 0.05% Tween 2C detergent (Sigma). The blot was put in another sealable bag and 10 is blocking solution 6 1 _ __ containing 10 counts per minute of I-protein A (New England Nuclear) were added. After allowing the pro¬ tein A to bind to the antibody for 2 hours at room temperature with shaking, the blot was washed as above, dried, and overlayed with an x-ray film and an intensi¬ fying screen (Dupont) and autoradiographed for 1-3 days at -70°C. The film was developed by standard proce¬ dures. Virus from the positive wells which contained the recominant virus was further purified. WESTERN BLOTTING PROCEDURE. Samples of cell lysates, positive controls and protein standards were run on a polyacrylamide gel according to the procedure of Laemmli (42). After electrophoresis, the gel was soaked in a transfer buffer (0.025 M Tris base, 0.192 M glycine, 20% methanol) plus 0.1% SDS for 20 minutes. The stacking gel portion was removed and the separation gel was placed onto Whatman 3 mm paper. A matching- sized piece of nitrocellulose filter was prewet in the transfer buffer and placed onto the polyacrylamide gel to cover the gel completely and make intimate contact. A prewet piece of Whatman 3 mm paper was placed on top of the nitrocellulose filter to create a "sandwich", and the sandwich was placed into an electrophoretic transfer device (Biorad) . The sandwich wa-i completely submersed in transfer buffer. The electrophoretic transfer was carried out for 3 hours at 250 milliamps. After transfer, the nitrocellulose filter was removed from the assembly and placed in a dish containing 50 mis of blocking buffer (50 _ιg/ml bovine serum albumin, 10 mM magnesium chloride, 100 mM potassium chloride, 1 mM calcium chloride, 10 mM imidazole pH 7.0, 0.3% Tween-20, 0.02% sodium azide) . The nitrocellulose blot was incubated for 1-2 hours in the blocking buffer at room temperature on a shaker. The blot was then placed in a sealable bag containing 15 mis of the blocking buffer plus the specific antiserum as a probe and incubated overnight at 37°C on a shaker. The blot was then removed from the probe solution and rinsed with 5- 6 changes of phosphate buffered saline over a period of 1 hour. The phosphate buffered saline was removed and 50 mis of blocking buffer containing 5 x 105 cpm of 125 I labeled protein A (Amersham) were added. The blot was incubated for 1 hour with the labeled protein A solution, the labeled protein A solution was removed and the blot was rinsed with 5-6 changes of phosphate buffered saline solution containing 0.3% Tween-20. The blot was air dried and autoradiographed overnight with an intensifying screen. METHOD FOR cDNA CLONING SWINE ROTAVIRUS gp38 GENE VIRUS GROWTH. The OSU strain of porcine rotavirus (ATCC VR-892) was propagated on MA-104 cells (Rhesus monkey kidney cells from MA Bioproducts) . Confluent monolayers were infected at a multiplicity of infection of greater than 10 in DMEM containing 5 micrograms/ml trypsin. Cells were incubated with the virus for 48 hours or until a cytopathic effect was obtained. Media and cell debris were collected and centrifuged at 10,000 x g for 20 minutes at 4°C. The supernatant containing the rotavirus was then centrifuged at 10,000 x g in a preparative Beckman Ti45 rotor at 4°C. Virus pellets were resuspended in SM medium (50 mM Tris-HCl pH 7.5, 100 mM KCL, 10 mM MgCl 2 ) and homogenized light¬ ly in a Dounce-type homogenizer. The resuspended virus was centrifuged at 10,000 x g for 10 minutes then load¬ ed onto 25-50% CsCl gradients in SM buffer. Gradients were centrifuged at 100,000 x g for 4 hours at 20°C. The two blue-white bands representing intact virions and cores of rotavirus were collected, diluted, and the CsCl gradient procedure was repeated a second time. Virus obtained from the second gradient was dialyzed overnight against SM buffer at 4°C. VIRAL RNA ISOLATION. Dialyzed swine rotavirus was twice extracted with an equal volume of SDS/phenol then twice more with chloroform: isoamylalcohol (24:1). The double stranded RNA was precipitated with ethanol in the presence of 0.2 M sodium acetate, centrifuged and resuspended in water. The yield was typically 100 micrograms from 1,000 cm of infected cells. SYNTHESIS AND CLONING OF gp38 cDNA. 160 micrograms of double-stranded swine rotavirus RNA obtained from the above procedure was mixed with one microgram each of two synthetic oligo nucleotide primers in a volume of 160 microliters (sequences of primers were: 5'-GGGAATTCTGCAGGTCACATCATACAATTCTAATCTAAG-3' and 5'-GGGAATTCTGCAGGCπTTAAAAGAGAGAATTTCCGTTTGGCTA-3') derived from the published sequence of bovine rotavirus (24) . The RNA-priϋ≤r mixture was boiled for 3 minutes in a water bath then chilled on ice. Additions of 25 microliters of 1 M Tris-HCl pH 8.3, 35 micro-li¬ ters of 1 M KCl, 10 microliters of 0.25 M MgCl 2 , 7 microliters of 0.7 M 2-mercaptoethanol, 7 micro¬ liters of 20 mM dNTP's and 6 microliters of reverse transcriptase (100 units) were made sequentially. The reaction was incubated at 42°C for 1.5 hours then 10 microliters of 0.5 M EDTA pH 8.0 was added and t__e solution was extracted once with chloroform: phenol (1:1). The aqueous layer was removed and to it 250 microliters of 4 M ammonium acetate and 1.0 ml of 95% ethanol was added, the mixture was frozen in dry ice and centrifuged in the cold. The resulting pellet was resuspended in 100 microliters of 10 mM Tris-HCl pH 7.5 and the ammonium acetate precipitation .procedure was repeated. The pellet was resuspended in 100 microliters of 0.3 M KOH and incubated at room temperature overnight then at 37°C for 2 hours. The solution was brought to neutral pH by addition of 10 microliters of 3.0 M HC1 and 25 microliters of 1.0 M Tris-HCl pH 7.5. The resulting single-stranded cDNA was then precipitated two times by the above described ammonium acetate-ethanol procedure. The pellet ob¬ tained was resuspended in 50 microliters of 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, boiled in a water bath for 2 minutes then incubated at 59°C for 16 hours. The solution was lyophilized to a volume of 15 microliters and the resulting double-stranded cDNA was run on a 1.0% agarose gel (Sigma agarose Type II). The ethidium bromide stained DNA migrating at 1,000- 1,100 base pair length was excised from the gel and electroeluted in a CBS electroeluter device. The solu- tion was lyophilized, and the cDNA was resuspended in 25 microliters of water. To this solution was added 2 microliters of 1.0 M Tris-HCl pH 7.5, 2 microliters of 1 M KCl, 1 microliter of 0.25 M MgCl 2 , 1 micro¬ liter of 20 mM dNTP's and 5 units of E^ coli DNA polymerase I. The reaction was incubated at room tem¬ perature for 15 minutes, then chloroform/phenol ex¬ tracted and ammonium acetate-ethanol precipitated as described above. The resulting cDNA was tailed with dCTP using terminal deoxynucleotide transferase (BRL buffer and enzyme used) . The reaction was stopped wi-th 2 microliters of 0.5 M EDTA, chloroform/phenol ex¬ tracted and precipitated with sodium acetate in the presence of 10 micrograms of carrier tRNA. The resus¬ pended cDNA was mixed with 200 ng of dGMP-tailed Pst I cut pBR322 (BRL catalog #5355SA) in 200 microliters of 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, heated to 65 C for 5 minutes then 57 C for 2 hours. The an¬ nealed cDNA-vector pBR322 was transformed onto E. coli DH-1 cells prepared for high efficiency transformation. Colonies that showed sensitivity to ampicillin and tetracycline resistance were grown and DNA was prepared and cut with Pst I to determine the size of the cDNA insert. Several clones having Pst I inserts of 1,050- 1,100 base pairs were analyzed and found to have iden¬ tical restric n enzyme digest patterns. The largest clone was designated pSY565 and has been deposited with the ATCC under accession number 53,340. For one of these clones, the 1,100 base pair Pst I insert was subcloned into a M13 phage sequencing vector. The entire DNA sequence of this clone was determined and is shown in Fig. 10A and 10B. The location of the gp38 open reading frame was determined from the amino acid homology to human and bovine sequences already published (44) . -78- METHOD FOR cDNA CLONING BOVINE ROTAVIRUS gp38 GENE VIRUS GROWTH. The Calf Nebraska strain of bovine rotavirus (USDA) was propagated on MA-104 cells (Rhesus monkey kidney cells from MA Bioproducts) . Confluent monolayers were infected at a multiplicity of infection of greater than 10 in DMEM containing 5 micrograms/ml trypsin. Cells were incubated with virus for 48 hours or until a cytopathic effect was obtained. Media and 10 cell debris were collected and centrifuged at 10,000 x g for 20 minutes at 4°C. The supernatant containing the rotavirus was then centrifuged at 10,000 x g in a preparative Beckman Ti45 rotor at 4°C. Virus pellets were resuspended in SM medium (50 mM Tris-HCl pH 7.5, , 10_ 100 mM KCL, 10 mM MgCl_-_) and homogenized lightly in a Dounce-type homogenizer. The resuspended virus was centrifuged at 10,000 x g for 10 minutes then loaded onto 25-50% CsCl gradients in SM buffer. Gradients were centrifuged at 100,000 x g for 4 hours at 20°C. 20 The two blue-white bands representing intact virions and cores of rotavirus were collected, diluted, and the CsCl gradient procedure was repeated a second time. Virus obtained from the second gradient was dialyzed overnight against SM buffer at 4°C. 25 VIRAL RNA ISOLATION. Dialyzed bovine rotavirus was twice extracted with an equal volume of SDS/phenol then twice more with chloroform: isoamylalcohol (24:1). The double stranded RNA was precipitated with ethanol 30 in the presence of 0.2 M sodium acetate, centrifuged and resuspended in water. The yield was typically 100 micrograms from 1,000 cm of infected cells. SYTHESIS AND CLONING OF gp38 cDNA. 160 micrograms of 35 double-stranded bovine rotavirus RNA obtained from the above procedure was mixed with one microgra each of two synthetic oligo nucleotide primers in a volume of 160 microliters (sequences of primers were: 5'-GGGAATTCTGCAGGTCACATCATACAATTCTAATCTAAG-3' and 5'-GGGAATTCTGC^GGCTTTAAAAGAGAGAATTTCCGTTTGGCTA-3') derived from the published sequence of bovine rotavirus (24). The RNA-primer mixture was boiled for 3 minutes in a water bath then chilled on ice. Additions of 25 microliters of 1 M Tris-HCl pH 8.3, 35 microliters of 1 M KCl, 10 microliters of 0.25 M MgCl 2 , 7 micro¬ liters of 0.7 M 2-mercaptoethanol, 7 microliters of 20. mM dNTP's, and 6 microliters of reverse transcriptase (100 units) were made sequentially. The reaction was incubated at 42°C for 1.5 hours then 10 microliters of 0.5 M EDTA pH 8.0 was added and the solution was extracted once with chloroform: phenol (1:1). The aqueous layer was removed and to it 250 microliters of 4 M ammonium acetate and 1.0 ml of 95% ethanol was added, the mixture was frozen in dry ice and centri¬ fuged in the cold. The resulting pellet was resuspen¬ ded in 100 microliters of. 10 mM Tris-HCl pH 7.5 and the ammonium acetate precipitation procedure was re¬ peated. The pellet was resuspended in 100 microliters of 0.3 M KOH and incubated at room temperature over¬ night then at 37°C for 2 hours. The solution was brought to neutral pH by addition of 10 microliters of 3.0 M HC1 and 25 microliters of 1.0 M Tris-HCl pH 7.5. The resulting single-stranded cDNA was then precipi¬ tated two times by the above described ammonium ace- tate-ethanol procedure. The pellet obtained was resus¬ pended in 50 microliters of 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, boiled in a water bath for 2 min¬ utes then incubated at 59°C for 16 hours. The solution was lyophilized to a volume of 15 microliters and the resulting double-stranded cDNA was run on a 1.0% aga- rose gel (Sigma agarose Type II) . The ethidium bromide stained DNA migrating at 1,000-1,100 base pair length was excised from the gel and electroeluted in a CBS electroeluter device. The solution was lyophilized, and the cDNA was resuspended in 25 microliters of water. To this solution was added 2 microliters of 1.0 M Tris-HCl pH 7.5, 2 microliters of 1 M KCl, 1 microliter of 0.25 M MgCl 2 , 1 microliter of 20 mM dNTP's, and 5 units of E. coli DNA polymerase I. The reaction was incubated at room temperature for 15 " min¬ utes, then chloroform/phenol extracted and ammonium acetate-ethanol precipitated as described above. The resulting cDNA was tailed with dCTP using terminal deoxynucleotide transferase (BRL buffer and enzyme used) . The reaction was stopped with 2 microliters of 0.5 M EDTA, chloroform/phenol extracted and precipi¬ tated with sodium acetate in the presence of 10 micro¬ grams of carrier tRNA. The resuspended cDNA was mixed with 200 ng of dGMP-tailed Pst I cut pBR322 (BRL cata¬ log #5355SA) in 200 microliters of 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, heated to 65°C for 5 min¬ utes then 57°C for 2 hours. The annealed cDNA-vector pBR322 was transformed onto E. coli DH-1 cells prepared for high efficiency transformation. Colonies that showed sensitivity to ampicillin and tetracycline re¬ sistance were grown and DNA was prepared and cut with Pst I to determine the size of the cDNA insert. Sever¬ al clones having Pst I inserts of 1,050-1,100 base pairs were analyzed and found to have identical re¬ striction enzyme digest patterns. For one of these clones, the.1,100 base pair Pst I insert was subcloned into a M13 phage sequencing vector. Part of the DNA sequence of this clone was determined and was found to be identical to the published sequence (24) . SELECTION OF G418 RESISTANT HERPESVIRUS. The antibiot¬ ic G418 (GIBCO) has a wide range of inhibitory activity on protein synthesis. The recombinant virus, however, expressed the aminoglycoside 3'-phosphotransferase, encoded by the NEO gene, upon acquiring the foreign gene and became resistant to G418. The transfection stocks of recombinant viruses were grown on MDBK (for IBR virus) , Vero (for PRV) or QT35 (for HVT) cells in the presence of 500 micrograms/ml G418 in complete DME medium plus 1% fetal bovine serum. After one or two days at 37°C, plaques from the dishes inoculated with the highest dilution of virus were picked for virus stocks. The selection was repeated a second or third time. The virus stocks generated from the G418 selection were tested for NEO gene insertion by the SOUTHERN BLOTTING OF DNA hybridization procedure described above. PURIFICATION OF gpX. gpX was purified from the tissue culture medium of infected Vero cells grown in complete DME plus 1% fetal bovine serum. Confluent Vero cells were infected at a multiplicaity of infection equal to 5, with wild-type, Iowa S-62 strain pseudorabies virus. The viral proteins were radiolabelled with 14C glucosamme and/or 35S methionine by adding the appropirate label to the flask eight hours after infection. The cells and media were harvested at twenty hours post infection, when the cells showed considerable σytopathic effect and the fluids were centrifuged. The supernatant fluid was concentrated 10X and dialyzed against 0.02M sodium sulfate/0.01M sodium phosphate buffer, pH 7.2 (16 hours, 0°C) , then against two changes of 0.01M sodium phosphate buffer, pH 7.2 (24 0 ' -82- hours, 0°C) . The dialysate was treated for 30 minutes at 0°C with 70% perchloric acid to a final concentration of 0.2M perchloric acid, then centrifuged at 10,000 rpm for 25 minutes. The supernatant fluid was then dialyzed against 0.02M Tris, pH 8.5. Purification was carried out by high performance liquid chromatography on a Beckman Model 334 HPCL. The acid-soluble proteins were separated on a Biogel TSK D AE 5-PW column (75 x 75mm) * using a 60 minute linear gradient, flow rate 0.8 ml/minute. Starting buffer was 0.02M Tris, pH 8.5, limit buffer was 0.02M Tris, pH 7.0 containing 0.75M NaCl. The gpX eluted as a major radioactive peak at 64% of the limit buffer. The recovered material represented 25% of the applied radioactivity. ELISA ASSAY. A standard enzyme-linked immunosorbent assay (ELISA) protocol was used to determine the immune status of swine following vaccination and challenge. A purified gpX antigen solution (40 microliters) was allowed to a. orb to the wells of polycarbonate microtiter dishes for 2 hours at room temperature. The antigen was in a (0.015M) carbonate-(0.04M) bicarbonate buffer, pH 9.6. The coated wells were rinsed 3 times with ELISA wash solution (0.05% Tween 20 non-ionic detergent in phosphate buffered saline, pH 7.5). Forty microliters of serum containing gpX antibody (diluted 1 to 10 in Tris buffer containing 1% bovine serum albumin and 0.05% Tween 20) were added to the wells and incubated 1 hour at 37°C. The anti-serum was removed and the wells were washed 3 times with ELISA wash solution. A solution containing Staphylococcal protein A coupled to horseradsih peroxidase (Bio-Rad) (diluted 1:10,000 in the Tris/BSA/Tween buffer described above) was added (50 microliters) to visualize the wells containing antibody against the specific antigen. The solution was incubated 1 hour at 37°C, then removed and the wells were washed 3 times with ELISA wash solution. 100 microliters of substrate solution (equal volumes of hydrogen peroxide and ATBS buffer (Bio-Rad) were added to each well and color as allowed to develop for 20 minutes. The reaction was terminated by addition of 50 microliters of 0.01M oxalic acid. The color was read at absorbance (A) 410nm on a automatic plate reader. VACCINATION STUDIES IN SWINE. Weaned pigs (4-6 weeks old) and pregnant sows were obtained from swine herds known to be free of pseudorabies disease. Susceptibility of the test animals to pseudorabies was further verified by testing the pig serum for absence of neutralizing antibodies to pseudorabies virus (PRV) . The. weaned pigs and 3-to-4 day old piglets were inoculated intramuscularly with 1 ml of virus fluid containing about 10 4 to 10 6 infectious units (TCID 5Q ) . Animals were observed each day after vaccination for adverse reactions (clinical signs of PRV disease) and body temperatures were recorded. Samples of tonsillar secretions were obtained and cultured to determined if the vaccine virus was capable of shedding and spreading to other animals. Immunity was determined by measuring PRV serum antibody levels at weekly intervals and in -84- some cases, by challenging the vaccinated pigs with virulent virus. In the latter case, the vaccinated animals and a group of non-vaccinated pigs were inoculated with virulent, Iowa S-62 strain PRV, using an amount of virus that caused PRV disease in at least 80% of the unvaccinated group of pigs. This was done about 28 days after vaccination. The challenged animals were observed daily for signs of disease and for increased body temperatures. A necropsy was conducted on animals that died and selected tissues were examined and cultured for PRV. cDNA CLONING. cDNA cloning refers to the methods used to convert RNA molecules into DNA molecules following state of the art procedures. Applicants' methods are described in (57) . Bethesda Research Laboratories (Gai- thersburg, MD) have designed a cDNA Cloning Kit that is very similar to the procedures used by applicants, and contains the best set of reagents and protocols to duplicate our results. PREPARATION OF RNA. For cloning virus mRNA species, a host cell line sensitive to infection by the virus was infected at 5-10 plaque forming units per cell. When cytopathic effect was evident, but before total de¬ struction, the medium was removed and the cells were lysed in 10 mis lysis buffer (4 M guanidine thiocya- nate, 0.1% antifoam A, 25 mM sodium citrate pH 7.0, 0.5% N-lauroyl sarcosine, 0.1 M beta-mercaptoethanol) . The cell lysate was poured into a sterilized Dounce homogenizer and homogenized on ice 8-10 times until the solution was homogenous. For RNA purification, 8 ls of cell lysate were gently layered over 3.5 mis of CsCl solution (5.7 M CsCl, 25 mM sodium citrate pH 7.0) in a Beckman SW41 centrifuge tube. The samples were centrifuged for 18 hrs at 20° C at 36000 rpm in a Beckman SW41 rotor. The tubes were put on ice and the supernatants from the tubes were carefully removed by aspiration to leave the RNA pellet undisturbed. The pellet was resuspended in 400 microliters glass dis¬ tilled water, and 2.6 mis of guanidine solution (7.5 M guanidine-HCl, 25 mM sodium citrate pH 7.0, 5 mM di- thiothreitol) were added. Then 0.37 volumes of 1 M 10 acetic acid were added, followed by 0.75 volumes of cold ethanol and the sample was put at -20° C for 18 " hrs to precipitate RNA. The precipitate was collected by centrifugation in a Sorvall centrifuge for 10 min at 4° C at 10000 rpm in an SS34 rotor. The pellet was 15 dissolved in 1.0 ml distilled water, recentrifuged at 13000 rpm, and the supernatant saved. RNA was re- extracted from the pellet 2 more times .as above with 0.5 ml distilled water, and the supernatants were pooled. A 0.1 volume of 2 M potassium acetate solution 20 was added to the sample followed by 2 volumes of cold ethanol and the sample was put at -20° C for 18 hrs. The precipitated RNA was collected by centrifugation in the SS34 rotor at 4° C for 10 min at 10000 rpm. The pellet was dissolved in 1 ml distilled water and the 25 concentration taken by adsorption at A260/280. The RNA was stored at -70° C. POLY A SELECTION. mRNA containing polyadenylate tails (poly-A) was selected using oligo-dT cellulose « 30 (Pharmacia #27 5543-0) . Three milligrams of total RNA 35 was boiled and chilled and applied to a 100 mg oligo-dT cellulose column in binding buffer (0.1 M Tris pH 7.5, 0.5 M LiCl, 5 mM EDTA pH 8.0, 0.1% lithium dodecyl sulfate) . The retained poly-A RNA was eluted from the column with elution buffer (5 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 0.1% sodium dodecyl sulfate). This mRNA was reapplied to an oligo-dT column in binding buffer and eluted again in elution buffer. The sample was precip¬ itated with 200 mM sodium acetate and 2 volumes cold ethanol at -20° C for 18 hrs. The RNA was resuspended in 50 microliters distilled water. FIRST STRAND REACTION.. Ten micrograms poly-A + RNA was * denatured in 20 mM methyl mercury hydroxide for 6 min at 22 C. Beta-mercaptoethanol was added to 75 mM and the sample was i; abated for 5 min at 22° C. The reac¬ tion mixture for first strand cDNA synthesis in 0.25 ml contained 1 microgram oligo-dT primer (P-L Bio- chemicals) or 1 microgram synthetic primer, 28 units placental ribonuclease inhibitor (Bethesda Research Labs #5518SA) , 100 mM Tris pH 8.3, 140 mM KCl, 10 mM MgCl- , 0.8 mM dATP, dCTP, dGTP, and dTTP (Pharmacia), 32 100 microcuries P-labelled dCTP (New England Nuclear #NEG-013H) , and 180 units AMV reverse transcriptase (Molecular Genetics Resources #MG 101) . The reaction was incubated at 42° C for 90 min, and then was termi¬ nated with 20 mM EDTA pH 8.0. The sample was extracted with an equal volume of phenol/chloroform (1:1) and precipitated with 2 M ammonium acetate and 2 volumes of cold ethanol -20° C for 3 hrs. After precipitation and centrifugation, the pellet was dissolved in 100 micro¬ liters distilled water. The sample was loaded onto a 15 ml G-100 Sephadex column (Pharmacia) in buffer (100 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 100 mM NaCl). The leading edge of the eluted DNA fractions were pooled, and DNA was concentrated by lyophilization until the volume was about 100 microliters, then the DNA was precipitated with ammonium acetate plus ethanol as above. SECOND STRAND REACTION. The entire first strand sample was used for second strand reaction which followed the Gubler and Hoffman (57) method except that 50 micro- grams/ml dNTP's, 5.4 units DNA polyme.τase I (Boerhinger Mannheim #642-711), and 100 units/ml E. coli DNA ligase * (New England Biolabs #205) in a total volume of 50 microliters were used. After second strand synthesis, the cDNA was phenol/chloroform extracted and precipi¬ tated. The DNA was resuspended in 10 microliters dis¬ tilled water, treated with 1 microgram RNase A for 10 min at 22 C, and electrophoresed through a 1% agarose gel (Sigma Type II agarose) in 40 mM Tris-acetate buff¬ er pH 6.85. The gel was stained with ethidium bromide, and DNA in the expected size range was excised from the gel and electroeluted in 8 mM Tris-acetate pH 6.85. Electroeluted DNA was lyophilized to about 100 micro¬ liters, and precipitated with ammonium acetate and ethanol as above. The DNA was resuspended in 20 micro¬ liters water. TAILING THE DNA. Oligo-dC tails were added to the DNA to facilitate cloning. The reaction contained the DNA, 100 mM potassium cacodylate pH 7.2, 0.2 mM di- thiotreitol, 2 mM CoCl 2 , 80 micromoles dCTP, and 25 units terminal deoxynucleotidyl transferase (Molecular Genetic Resources #S1001) in 50 microliters. After 30 min at 37° C, the reaction was terminated with 10 mM EDTA, and the sample was phenol/chloroform extracted and precipitated as above. CLONING THE cDNA. The dC-tailed DNA sample was an¬ nealed to 200 ng plasmid vector pBR322 that contained oligo-dG tails (Bethesda Research Labs #5355 SA/SB) in 200 microliters of 0.01 M Tris pH 7.5, 0.1 M NaCl, 1 mM EDTA pH 8.0 at 65° G for 2 min and then 5" Q C for 2 hrs. Fresh competent E. coli DH-1 cells were prepared and transformed as described by Hanahan (58) using half the annealed cDNA sample in twenty 200 microliter aliquots of cells. Transformed cells were plated on L- broth agar plates plus 10 micrograms/ml tetracycline. Colonies were screened for the presence of inserts into the ampicillin gene using Ampscreen\ (Bethesda Research Labs #5537 UA) , and the positive colonies were picked for analysis. MEANS TO DETERMINE THE SUITABILITY OF GENES FOR EXPRESSION IN HERPESVIRUSES. The first step in the analysis is to determine the overall G + C content of the gene in question. For good expression of a foreign antigen in herpesviruses, the G + C content of the foreign DNA must be equal to or higher than the G + C content of competing mRNAs. Said another way, the higher the G + C content of the foreign gene, the better will be the expression. The second step is to construct a "codon bias" table for known genes of the herpesvirus using a computer program such as the IBI DNA analysis system discussed in Example 24. The resulting table of "triplet frequencies" will form the final basis for comparison of the sequence. The IBI DNA analysis package provides a way to plot the similarity of any gene to a codon bias table. One can get from this plot a relative fit of the foreign gene to a herpesvirus gene (see Example 24) . The analysis can then be used to make a prediction — will the gene be expressed well within the context of a herpesvirus genome? The higher the G + C content, and the better the fit with herpesvirus codon usage, the higher will be the expression of the gene in the herpesvirus genome and the less need to practice tire methods of this invention. From this analysis, the deficiencies in the foreign gene become apparent. If the G + C content is low, then the G + C content must be raised — this is one way to practice the invention. If raising the G + C content is to be practiced by DNA synthesis, then the method of choice in the practice of the invention is to consult the codon usage bias of the herpesvirus to utilize codons in the synthesis that best fit the herpesvirus codon usage. FOREIGN GENES ALREADY FAVORABLE FOR HERPESVIRUS EXPRESSION. The applicants have found some genes already exist that are favorable for expression in herpesviruses. The trivial cases are those genes that are already present in the herpesvirus genome — i.e., herpesvirus genes themselves. However not all herpesvirus genes work in all other herpesviruses. For example, the herpesvirus of turkeys (HVT) glycoprotein A gene is not well expressed in pseudorabies virus (applicants' unpublished work) . This result is predicted by the above analysis - the HVT gA gene has 47% G + C content and PRV has 70% G + C and their codon usage is very different. Applicants have used several genes that are well expressed in pseudorabies virus, and some have been tested in IBR and HVT as well. These genes include the E. coli beta-galactosidase gene, the neomycin resistance gene, and the HSV-1 thymidine kinase' gene. These genes have a higher than average G + C content (55-60%) and by chance match the pseudorabies codon usage better than the average. A second method to practice the invention is to use one of these genes to drive the expression of the foreign gene in herpesvirus by linking the two genes together in a fusion. Most of the other genes that code for the -antigenic proteins of animal viruses have a relatively low G + C content and do not match the herpesvirus codon usage, and their expression in herpesviruses can be improved by practicing this invention. Some examples of these viruses are swine parvovirus (37.8% G + C), swine and bovine rotavirus (34% G + C) , swine transmissible gastroenteritis virus (37% G +C) , parainfluenza type 3 (35% G + C) , bovine viral diarrhea, Newcastles disease virus (46% G + C) , infectious bronchitis virus (36% G + C) , to a lesser extent, and infectious bursal disease virus (53% G + C) . BETA-GALACTOSIDASE ONPG ASSAY METHOD (67) . The assay meth___ followed these steps: 1. Infect Vero or other cells at high multiplicity of infection and wait for total cytopathic effect (usually next day) . 2. Add detergent NP40 to the medium in each dish to a final concentration of 1% (use 20% NP40 stock in water) . Pipet to lyse cells, and pellet to clarify supernatant. Save supernatant for assay. 3. Make up Z buffer as below. Make up a stock of ONPG (o-nitrophenyl-B, D-galactopyranoside from Sigma) at a concentration of 4 mg/ml in Z buffer. Store both Z buffer and ONPG solution at 4*C in the dark. 4. For the reaction, mix 0.7 ml Z buffer, 0.2 ml ONPG solution, and 0.1 ml supernatant sample in tube. Let reaction proceed at room temperature until yellow color forms. Intensity of yellow indicates beta-gal activity. 5. For quantitative measurement, spectrophotometer readings must be taken at A420. The first reading must be taken at +10-15 minutes of reaction as a starting point. The second reading should occur when a good yellow color is present subject to the following constraints - less than 20 hours duration of reaction, and the A420 reading must be less than 0.9 on the spectrophotometer. Within these constraints, the reaction is linear. The calculations applicants use are: rate = [(A420 at T2)-(A420 at T1)]/(T2-T1 in minutes) units - rate/0.0045 (1 nmole NP=0.0045) total units. = units x totals mis in supernatant x 10 1 unit = 1 nmole ONPG converted to NP per minute Applicants do most of their comparisons in terms of total units. For information purposes, applicants have determined that 267 units of beta-galactosidase activity is equal to 1 microgram of active protein. Z Buffer per Liter 16.1 g Na 2 HP0 4 .7H20 (0.06M) 5.5 g NaH 2 PO 4 .H 2 0 (0.04M) 0.75 g KCl (0.01M) 0.246 g MgSO 4 .7H 2 0 (0.001M) 2.7 ml beta-mercaptoethanol (0.05M) Adjust pH to 7.3-7.6 (original reference says pH 7.0) Do not autoclave PROTECTION OF VACCINATED PIGS AGAINST PARVOVIRUS VIREMIA. Weaned pigs, four to six weeks of age, were obtained from a swine herd known to be free of porcine parvovirus. Susceptibility of the pigs was verified by demonstrating the absence of serum neutralizing antibodies against parvovirus at the time of vaccination. Pigs were given two doses of vaccine containing 10 PFU of virus, 21 to 28 days apart. One vaccine group was given a commercially available, inactivated parvovirus vaccine as the second dose. Serum samples were obtained weekly for evaluation of serum antibodies to pseudorabies virus and to porcine parvovirus. Twenty-one to 28 days after the second vaccination, vaccinated pigs and two, non-vaccinated, age-matched pigs were challenged oronasally with virulent parvovirus. Parvovirus viremia was the criterion used for measuring vaccine efficacy. Parvovirus viremia was measured as follows: whole blood was collected and the cells were separated from plasma. Lymphocytes were separated by passage over a Ficoll gradient and their DNA was recovered following treatment of the cells with protease and phenol. The isolated DNA was reacted, in a slot blot assay (Schleicher & Schuell) , with 12P-labelled parvovirus RNA. The slot blots were exposed to Kronex X-ray film (Kodak) and developed. Parvovirus serum neutralizing antibody was determined by infecting swine testis cell cultures with parvovirus that had been incubated with varying dilutions of vaccinated swine serum. Three days after infection, the cell culture monolayers were fixed in Q acetone/methanol and incubated with a polyclonal rabbit anti-PPV serum. The fluorescent tag was goat anti- . rabbit IgG (Kirkegaard & Perry) . The serum antibody titer was determined to be that dilution which resulted in a 50% or greater reduction of fluorescent foci. 5 0 5 0 5 EXAMPLES EXAMPLE 1 S-PRV-004 We have created a virus that has a deletion in the junction region between the unique long DNA and the internal repeat of PRV, and a deletion in the endo¬ genous PRV thymidine kinase gene in the unique long region. Into the junction deletion we have cloned the herpes simplex type 1 (HSV-1) thymidine kinase (TK) gene under the control of the ICP4 promoter. This virus is designated S-PRV-004. To create this virus, we first cloned the Sail #1 frag¬ ment of PRV. PRV DNA was prepared and then cut with Sail restriction enzyme. The cut DNA was electropho¬ resed on an agarose gel and the largest Sail band (15 kb) was purified from the gel (see PHENOL EXTRACTION OF DNA FROM AGAROSE) . The purified DNA was ligated into the plasmid pSP64 (see LIGATION) and the DNA mixture was used to transform E. coli HB101 according to Maniatis et al. (1). The Sail #1 clone was mapped for restriction sites. The homologous recombination procedure was used to cre¬ ate S-PRV-004 (see Fig. 2) . The exact position of the junction region was determined by sequencing the DNA from Sail #1 fragment. It was found that the junction region was positioned between two Stul sites (Fig. 2A) . Two fragments of DNA from the Sail clone were used to create the homology vector for recombination. One was a fragment from BamHI #8' from Stul to BamHI and the other was from BamHI #8 from BamHI to Stul (see Figs. IB and 2A) . These fragments were cloned into the BamHI _■ site of pSP64. This plasmid was cut with Stul, and a * 3.8 kb PvuII fragment, obtained from B. Roizman (16), The University of Chicago, and containing the ICP4 promoter on the BamHI-N fragment and the HSV-1 TK gene on the BamHI-Q fragment, fused at the BamHI/Bglll sites, was ligated into the Stul site. The net result from this, series of clonings was a plasmid which had suffered a deletion of 3kb from between the Stul sites, 10 and into which 3.8kb of the foreign TK gene had aeen incorporated (see Fig. 2B) . The TK gene was thus flanked by PRV DNA sequences to allow for insertion of the foreign gene into the PRV genome by homologous recombination. The plasmid DNA was tranfected into 15 rabbit skin cells along with the intact PRV DNA from S- PRV-003, which is a pseudorabies virus that has a dele¬ tion in the endogenous TK gene.. The transfection stock of virus was selected in HAT medium and the virus was identified and selected by analysis of the restriction 20 pattern of DNA isolated from the infected cells. S-PRV-004 contained the HSV-1 TK gene and was express¬ ing this gene as demonstrated by the incorporation of 14C-thymidine in a plaque assay described in Tenser et 25 al. (40) and by direct analysis of TK activity in in¬ fected cell extracts, following the procedure of Cheng et al. (41). The location of this gene in the genome of PRV is shown in Figure 2C. 30 35 Six weaning age pigs were vaccinated with 105"0 infectious units of S-PRV-004 and challenged with virulent PRV 28 days later, according to the VACCINATION STUDIES IN SWINE procedure. The vaccinated pigs remained healthy following vaccination and developed serum neutralizing antibody against PRV (see Table I below) . Vaccine virus was not recovered from nasal or tonsillar secretions. After exposure to virulent PRV, 83% of the vaccinated swine were protected against PRV disease. TffiLE I RESPONSES OF WEΛΪ∑D PIGS VACCINATED WISH S-PHV-004 AND CHALLENGED WITH VIPULUNT PS*/ Sabs * T " ey to clinical signs: OQiS, F-Febrilβ EXAMPLE 2 S-PRV-005 S-PRV-005 is a pseudorabies virus that has a deletion in the repeat region and in the endogenous PRV TK gene in the long unique region, and has an insertion of the HSV-1 TK gene under the control of the ICP4 promoter incorporated into both copies of the repeat region between the Xbal site and the Hpal site in the BamHI #5 fragment (See Fig. 3) . ' To create this virus, we first obtained a clone of BamHI #5 fragment from PRV (Fig. IB) . The BamHI #5 fragment was cloned into the plasmid pACYC184 at the BamHI site (see LIGATION above) . A map of the BamHI #5 fragment is shown in Fig. 3A. The plasmid containing the BamHI #5 fragment was cut with Xbal and Hpal and the linearized plasmid was puri¬ fied (see PHENOL EXTRACTION OF DNA FROM AGAROSE) . The 3.8kb PvuII fragment described in Example 1 and con¬ taining the TK gene and ICP4 promoter was likewise purified. The Xbal site was filled to yield a blunt end (see POLYMERASE FILL-IN REACTION) , and the two DNAs were mixed and ligated together. The resulting plasmid that had incorporated the TK gene in the Xbal-Hpal deletion was selected and analyzed by restriction map¬ ping (Fig. 3B) . The plasmid containing the TK gene flanked by PRV Bam HI #5 seguences was used to transfect rabbit skin cells along with purified DNA from S-PRV-003, a pseudorabies virus that had a deletion in the endogenous TK gene. The resulting recombinant PRV that had incorporated the HSV-1 TK gene into the deletion in the repeats was screened and purified from the transfection stock by the HYBRIDIZATION SCREEN FOR RECOMBINANT HERPESVIRUS procedure without any prior selection. S-PRV-005 recombinant PRV was shown to express the HSV-1 TK gene by incorporation of 14C-thymidme in a plaque assay (40) , by analysis of the TK activity in infected cell lysates (41) , and by immunodetection of the HSV-1 TK protein according to the ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS procedure outlined above. The location of this gene in the genome of PRV is shown in Fig. 3C. EXAMPLE 3 S-PRV-010 S-PRV-010 is a pseudorabies virus that has a deletion in the PRV TK gene in the long unique region, a dele¬ tion in the repeat region, and the insertion of the E. coli beta-galactosidase gene (lacZ gene) incorporated into both copies of the repeats at the Xbal site in BamHI #5 fragment (see Fig. 5A) . The beta- galactosidase gene was constructed ho be expressed using the HSV-1 TK gene promoter which we have shown in this construct to be active in PRV. The method used to insert the beta-galactosidase gene into S-PRV-010 was direct ligation (see DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS) . The beta-galactosidase gene was on plasmid pJF751, obtained from Jim Hoch, Scripps Clinic and Research Foundation. This gene is truncated at the 5' end with a BamHI site that has removed the AGT initiation codon, and the Aval site in pBR322 was used at the other end (see Fig. 4A) . The HSV-1 TK promoter (Fig. 4B) was taken from the McKnight TK gene as an Rsal fragment, gel purified, and ligated to a synthetic piece of DNA which contained a BamHI site within the sequence CGGATCCG (Fig. 4C) . After digestion with BamHI, the fragment was cloned into the BamHI site at the start of the beta-galactosidase gene (Fig. 4D) . The plasmid was constructed with the E^ coli plasmids pSP64 and pSP65 such that Xbal sites from the polylinkers could be used to excise the entire construct from the plasmid. The ligation mixture was used to transfect E. coli HB101 according to published procedures (Maniatis et al. (l)).This construct was planned such that the first three amino acids of the protein were from the HSV-1 TK gene, the next three were from the synthetic linker, and the rest were from the beta-galactosidase gene. The gene contained the following sequence at the fusion between TK and lacZ: CGT ATG GCT TCG TCG GAT CCC GTC GTT TTA 3' MET ala ser ser asp pro val val leu TK gene lac Z BamHI linker A pseudorabies virus construct designated S-PRV-002 which has a deletion in the PRV TK gene in the unique long region and a deletion in the repeat region was used as the recipient for the beta-galactosidase gene. Intact S-PRV-002 DNA was mixed with a 30-fold molar excess of plasmid DNA containing the beta- galactosidase gene under the control of the HSV-1 TK promoter, and this mixture was digested with Xbal re¬ striction enzyme. The ligated DNA was used to trans¬ fect animal cells, and the transfection stock was ana¬ lyzed for recombinant PRV. First, PRV DNA was prepared from cells infected with the transfection stock virus and this DNA was cut with restriction enzymes and analyzed on an agarose gel. This analysis showed that the recombinant virus was present as the major species in the transfection stock, and it was subsequently purified from other virus species by plaque assay coupled with the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS. Because beta-galactosidase reacted with the drug Bluogal- to yield a product with blue color, it was possible to plaque purify the recombinant by picking blue plaques. The final result of the purification was the recombi¬ nant PRV designated S-PRV-010. It was shown to express the enzyme beta-galactosidase by the formation of blue plaques as noted above, and by the detection of the enzyme in infected cell extracts using the substrate O- nitrophenyl-beta-D-galactopyranoside (Sigma) following t ^e procedure of Norton and Coffin (33) . The location, of this gene in the genome of PRV is shown in Fig. 5C. Previous studies demonstrated that swine vaccinated with S-PRV-002 developed antibody to- PRV and were fully protected against clinical disease following exposure to virulent PRV virus. Animal studies were conducted with S-PRV-010 to determine the utility of a recombi¬ nant pseudorabies virus as a vaccine against pseudo¬ rabies disease. A group of weaned pigs and a litter of four-day-old piglets were vaccinated with S-PRV-010 and challenged three to four weeks later, according to VACCINATION STUDIES IN SWINE. Responses of weaned pigs vaccinated with S-PRV-010 are shown in Table II. Administration of this virus did not cause adverse reactions in the pigs. The vaccinated animals developed PRV neutralizing anti¬ body. Two, non-vaccinated control animals (#75 and #91) placed in contact with the vaccinates did not develop PRV antibody prior to challenge, indicating the vaccine virus was not shed from vaccinates. After challenge, all ten vaccinated animals remained clini- cally normal and free of PRV disease. In contrast, the two in-contact control animals and three of five non- vaccinated control animals developed PRV disease and one of these pigs died of PRV. To test further the utility of S-PRV-010 as a vaccine, the virus was inoculated into 4-day old piglets. The results, presented in Table III, demonstrated that the virus elicited an antibody response in vaccinated pig¬ lets and did not cause adverse reactions. The virus apparently was shed from vaccinates, since one (#67) two non-vaccinated, in-contact control piglets had developed PRV antibody by Day 24. After challenge, all vaccinated animals and the sero-positive in-contact control animal remained free of PRV disease. By com¬ parison, the three non-vaccinated control pigs and the second in-contact control pig developed clinical signs of PRV and died. The conclusion from that study is that S-PRV-010 given 4 0 6 0 at a dosage of 10 * or 10 , elicits a protective response in vaccinated piglets or weaned pigs capable of preventing infection by virulent virus. ** TABLE III SERCLOGIC AND CLINICAL RESPONSES OF 4-DAY-OLD PIGLETS FOLLOWING VACCINATION WITH S-PRV-010 AND CHALLENGE WZIH WILD-TYEE IKV a Determined ty RIEEA b Died 8 Days Post Vaccination Fran Ruptured Stanach c Died on or Prior to Day 7 Bast-Challenge d CNS Signs include Ataxia, Incoordination, Circling Lateral Recumbency NT: Not Tested -105- EXAMPLE 4 S-PRV-007 S-PRV-007 is a pseudorabies virus that has a deletion in the PRV TK gene in the unique long region, a dele¬ tion in the repeat region, and the swine rotavirus glycoprotein 38 gene under the control of the HSV-l ICP4 promoter inserted into the repeat region. S-PRV-005 virus described in Example 2 above was fur-<- ther engineered to contain the rotavirus antigen (see Fig. 6) as follows. The swine rotavirus gp38 gene was cloned into plasmid pBR322 at the PstI site by proce¬ dures previously described herein. The resulting plasmid was called pSY565 (see Fig. 7) . The 1090 bp PstI fragment containing the gp38 gene was cloned into vector pϋC4K at the PstI site such that it became flanked by BamHI sites in a plasmid called pSY762. Plasmid pSY590 has had a complex origin as inferred from the flow chart. These clonings were routine in nature and are of historical interest but are not strictly required to practice the invention. Briefly this history is: (1) The McKnight TK gene was the HSV-l BamHI Q frag¬ ment from Haelll at -178 relative to CAP site to BamHI at +2700 which was cloned between Hindlll and BamHI in PBR327. (2) pSY491..The entire TK coding region from the Bglll site at +55 (relative to CAP site) to the BamHI site at +2700 was cloned into the BamHI site in pSP65 and called pSY491. -106- (3) pSY481..The polyA signal sequence (pA) on an 800 bp Smal fragment from TK was subcloned into the Smal site in pSP65 and was called pSY481. (4) pSY583..The pA 800 bp Smal fragment from pSY481 was cloned into the Hindi site in pSP65 and called PSY583. (5) pSY429..The HSV-l BamHI N fragment was obtained from Dr. B. Roizman cloned into the BamHI site of pBR322 and was called pSY429. (6) pSY584..The 2.2kb fragment of BamHI N from PvuII to BamHI (Ref. 16) in pSY420 was subcloned into pSP65 between Hindi and BamHI in the polylinker and was called pSY584. (7) pSY479..A plasmid was constructed from pSP64 and pSP65 that contained a fused polylinker sequence. Both plasmids were cut with PstI in the polylinker and Pvul in the plasmid body. The net effect of this construct was to create a fusion plasmid called pSP66 which has a symmetrical polylinker sequence centered on the PstI site. pSY479 is the name of this plasmid and it also contained a PstI fragment cloned into the PstI site that is irrelevant for the manipulations that follow. Plasmid pSY590 was created from pSY583, pSY584, and pSY479 in a three fragment ligation of the following elements: the 3kb plasmid sequences from pSY479 (pSP66) cut with PstI, the 800 bp Smal pA fragment cut from the polylinker in pSY583 with PstI and BamHI, and the 2200 bp BamHI N fragment cut from pSY583 with PstI and BamHI. Fig. 7 shows the final configuration of all of these DNA fragments in pSY590. There is a single BamHI site in the plasmid between the promoter in BamHI N and the TK pA signal that was used to insert the coding region of the gp38 gene. For the creation of the homology vector used in the formation of S-PRV-007, the plasmid pSY590 was opened with BamHI, and the 1090 bp gp38 gene was removed from pSY762 by cutting with BamHI, and these two fragments were ligated together to form pSY596. The correct orientation of the gp38 gene was confirmed by diagnos¬ tic restriction enzyme digestion utilizing sites with gp38 (see Fig. 10A and 10B) . In pSY596 described above, the gp38 gene resided be¬ tween two flanking HSV-l DNA fragments. These two regions were thus homologous to similar regions on the HSV-l TK gene in S-PRV-005, and these regions were used for the homologous recombination to create S-PRV-007 (Fig. 6A) . The plasmid and S-PRV-005 DNAs were mixed and used in the DNA TRANSFECTION PROCEDURE FOR GENERAT¬ ING RECOMBINANT VIRUS. A virus that had incorporated the rotavirus antigen in place of the TK gene was selected with BUDR. Recombinants from the selected virus stock that had incorporated the rotavirus DNA were screened by the HYBRIDIZATION SCREEN FOR RECOMBINANT HERPESVIRUS and by analyzing restriction digests of DNA by the SOUTHERN BLOTTING OF DNA procedure using the rotavirus cloned gp38 gene as probe. The final result of this screening was a recombinant PRV called s-PRV-007 which had the rotavirus gp38 gene incorporated into the repeat region between the Xbal and Hpal sites in PRV BamHI #5 fragment shown in Figure 6C. The. presence in a host of gp38 expressed by S-PRV- has not yet been detected, EXAMPLE 5 S-PRV-012 S-PRV-0 2 is a pseudorabies virus that has a deletion in the PRV TK region in the unique long region, a dele¬ tion in the repeat region, and a deletion in the unique short region encoding the PRV glycoprotein X, called gpX and identified and mapped by Rea et al. (23). The HSV-l TK gene under the control of the ICP4 promoter was inserted in place of the gpX gene. The following procedure was used to make the deletion of gpX and the simultaneous insertion of the HSV-l TK gene. The flanking regions for homology to PRV were from cloned fragments of BamHI #10 fragment and BamHI #7 fragment extending from Ndel to BamHI (Fig. 8) . The BamHI and Ndel sites were filled in according to the POLYMERASE FILL-IN REACTION, and the PvuII fragment of HSV-l DNA was inserted by LIGATION. This plasmid was transfected with intact S-PRV-002 DNA according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure. The recombinant virus was selected by HAT SELECTION OF RECOMBINANT HERPESVIRUS procedure, and screened by the ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS procedure using antibodies specific for the HSV-l protein. The recombinant virus selected by this procedure was designated S-PRV-012 and has been deposited with the ATCC under Accession No. VR-2119 and was shown by RE¬ STRICTION MAPPING OF DNA and SOUTHERN BLOTTING OF DNA to contain the HSV-l TK gene inserted in place of the gpX gene (Fig. 8B) . The ANTIBODY SCREEN FOR RECOM¬ BINANT HERPESVIRUS procedure showed that the virus was expressing the inserted HSV-l TK gene. The structure of this virus is shown in Figure 8C. EXAMPLE 6 S-PRV-013 S-PRV-013 is a pseduorabies virus that has a deletion in the TK gene in the long unique region, a deletion in the repeat region and a deletion in the gpX coding region. The gene for E. coli beta-galactosidase (lacZ gene) was inserted in place of the gpX gene and is under the control of the endogenous gpX gene promoter. The following procedures were used to construct S-PRV- 013 by homologous recombination. The flanking PRV homology regions were from the cloned BamHI #10 frag¬ ment which contained the gpX promoter, and from the cloned BamHI- #7 fragment extending from the Ndel site to the BamHI site (Figure 9A) . The Ndel site was filled in according to the POLYMERASE FILL-IN REACTION, and the beta-galactosidase gene was inserted between the BamHI #10 and BamHI #7 fragments. This construct positioned the beta-galactosidase gene between the gpX promoter and the gpX poly A signal sequences with a deletion of almost all of the coding regions of gpX. The plasmid DNA and DNA from S-PRV-002, a PRV strain with a deletion in both repeat sequences and a deletion in the thymidine kinase gene, were mixed and transfected according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure. The recombinant virus was screened and purified from the transfection stock by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure. The resulting virus from this screen was designated S- PRV-013 and has been deposited with the ATCC under Accession No. VR 2120. It contained the beta- galactosidase gene in place of the gpX coding regions (Figures 9B and 9C) as determined by PREPARATION OF HERPESVIRUS DNA followed by SOUTHERN BLOTTING OF DNA. The expression of the beta-galactosidase gene was confirmed by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS test, and by the o-nitrophenyl- galactopyranoside substrate assay (33) . To confirm that the coding region for gpX had been removed from S-PRV-013, DNA extracted from a stock of purified S-PRV-013 was digested with BamHI and the fragments were separated on agarose gel electrophoresis * and analyzed by SOUTHERN BLOT HYBRIDIZATION. The hy¬ bridization probe was the BamHI-NDE fragment of pseudorabies BamHI #7 fragment from the unique short region. This probe fragment included 90% of the coding sequences of gpX. In this analysis, the gpX region was shown to be missing from S-PRV-013. To confirm these results, cells were infected with either wild-type pseudorabies, S-PRV-012 or S-PRV-013, and samples of media from the infected cultures were subjected to SDS-polyacrylamide gel electrophoresis. The cell was blotted and analyzed using the WESTERN BLOTTING PROCEDURE. The anti-serum used was a rabbit hyper-immune serum raised against a chemically- synthesized gpX antigenic peptide linked to bovine serum albumin. As shown in Figure 4, gpX is prominent in the media of cells infected with wild-type virus (PRV 000) , but is not detected in the media of cells infected with S-RPV-012 or S-PRV-013. These results demonstrate that the pgX gene is missing from both S- RPV-012 and S-PRV-013 and the protein, gpX, is not produced in cells infected by either S-PRV-012 or S- PRV-013. The following experiments indicate that S-PRV-013 may be used as a vaccine to protect swine against psuedorabies disease and that it produces an immune response which can readily be distinguished from wild- type infection. In the first study, susceptible weaned pigs and four- day old piglets were vaccinated intramuscularly with S- PRV-013 as follows: 4 of each group were inoculcated with 10 6 TCID 50 and 4 were inoculated with 10 4 TCID 5Q oi virus. The animals were observed, then challenged as described in VACCINATION STUDIES WITH SWINE (see Table IV below) . TffiLE IV RESPONSES OF 4-DAY-OLD PIGLETS VACCINATED WITH S-PRV-013 AND CHALLENGED WIIH VIHJLENT PR- Following vaccination, all animals were free of adverse reactions and all but 2 (weaned pigs) developed serum neutralizing antibody titers of 1:2 to 1:64. Virus was not recovered from tonsillar swabs of any pig or from tissues taken from the piglet (#11) sacrificed on Day 4. One of 2 contact control piglets (#19) was sacri¬ ficed 7 days into the experiment because it was a runt and doing poorly. Tissues from this piglet were nega¬ tive when cultured for PRV. The other contact control 10 remained healthy ; nά did not develop PRV antibody prior to challenge. After challenge, all vaccinated animals remained clini¬ cally normal and developed secondary antibody respons¬ 15 es. The contact control piglet and the three challenge control pigs all developed typical central nervous system signs of PRV and one control died following challenge. 20 In a second study with S-PRV-013 using larger numbers of animals, 2 litters of susceptible 3-day-old piglets and a group of 15 susceptible weaned pigs were vacci- nated with 10 TCID..- of virus, then challenged as described in VACCINATION STUDIES WITH SWINE (see Tables 25 V and VI below) . * 30 3c -116- TflBLE V RESPONSES OF 3-ΩAY-CLD PIGLETS VACCINATED WITH S-PRV-013 MD CHALLENGED WIIH VIHILEWT EH7 A IT * increase in temperature was observed in day 1 in these vaccinates TSBLE VI RESPONSE OF WE2NED PIGS VACCINATED WHH S-PRV-013 2 D OULLEICED WITH VIHJLENT PR7 finical signs: NH-r*Negative, OQϊSr B*Death, F-Febrile, I*«Respiratory « t tested In this experiment, all of the vaccinated animals re¬ mained healthy following vaccination, developed seru neutralizing antibody to PRV and did not shed vaccine virus in tonsillar secretions. After challenge with virulent virus, vaccinates of both age groups remained free of PRV disease, whereas the 3 non-vaccinated con¬ tact controls and 10 of 11 of the challenge controls developed severe pseudorabies disease. The serum samples collected from the vaccinated and -challenged swine were assayed by the gpX ELISA assay. Because the gene for gpX was deleted from S-PRV-013, it is expected that swine vaccinated with S-PRV-013 would be sero-negative in the ELISA test for this antigen. The challenge virus carrier the gpX gene. The vaccinated animals were protected by the vaccination from pseudorabies disease when challenged with the wild-type virus. However, vaccinated animals were asymptomatically super-infected by the challenge strain and would, therefore, be expected to produce antibodies to gpX upon challenge. As shown in Figure 5, serum from an animal vaccinated with S-PRV-013 remained negative for gpX until after challenge with the wild-type virus. These results indicate that S-PRV-013 is an effective vaccine strain which permits vaccinates to be distinguished from animals infected with wild-type virus by a sample serum diagnostic assay. EXAMPLE 7 S-PRV-014 S-PRV-014 is a pseudorabies virus that has a deletion in the gpX coding region. ' The gene for E. coli beta- galactosidase was inserted in place of the gpX gene and is under the control of the endogenous gpX promoter. The following procedures were used to create S-PRV-014 by homologous recombination. The flanking PRV homology regions were from the cloned BamHI #1.0 fragment which contains the gpX promoter, and from the cloned BamHI #7 fragment extending from the Ndel site to the BamHI site (Figure 9) . The Ndel site was filled in according to the POLYMERASE FILL-IN REACTION, and the beta- galactosidase gene was inserted between the BamHI #10 and BamHI #7 fragments. This construct positioned the beta-galactosidase gene behind the gpX promoter and the gpX poly A signal seguence with a deletion of almost all of the coding region of gpX. The plasmid DNA and DNA from wild-type PRV were mixed and transfected according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure. The recombinant virus was screened and purified from the transfection stock by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure. The resulting virus from this screen was designated S- PRV-014 and has been deposited with the ATCC under Accession No. VR 2135. It contains the beta- galactosidase gene in place of the gpX coding region as determined by PREPARATION OF HERPESVIRUS DNA followed by SOUTHERN BLOTTING DNA. The expression of the beta- galactosidase gene was confirmed by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS test, and by the o-nitro- phenylgalactopyranoside substrate assay (33) . The structure of this virus is shown in Figure 9D. EXAMPLE 8 S-PRV-016 S-PRV-016 is a pseudorabies virus that has a deletion in both repeat sequences, and a deletion in the gpX coding region. The gene for E. coli beta-galactosidase was inserted in place of the gpX gene and is under the control of the endogenous gpX gene promoter. Th following procedures were used to coi _rtruct S-PRV- 016 by homologous recombination. The flanking PRV homology regions were from the cloned BamHI #10 fragment which contains the gpX promoter, and from the cloned BamHI #7 fragment extending from the Ndel site to the BamHI site (Figure 9) . The Ndel site was filled in according to the POLYMERASE FILL-IN REACTION, and the beta-galactosidase gene was inserted between the BamHI #10 and BamHI #7 fragments. The construct positioned the beta-galactosidase gene behind the gpX promoter and the gpX poly A signal sequence with a deletion of almost all of the coding region of gpX. The plasmid DNA and DNA from S-PRV-001 were mixed and transfected according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure. The recombinant virus was screened and purified from the transfection stock by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure. The resulting virus from this screen was designated S- PRV-016 and has been deposited with the ATCC Accession No. VR 2136. It contains the beta-galactosidase gene in place of the gpX coding region as determined by PREPARATION OF HERPESVIRUS DNA followed by SOUTHERN BLOTTING OF DNA. The expression of the beta- galactosidase gene was confirmed by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS test, and by the o- nitrophenylgalactopyranoside substrate assay (33). The structure of this virus is shown in Figure 9E. EXAMPLE 9 S-PRV-020 S-PRV-020 is a pseudorabies virus that contains a deletion in the TK gene, a deletion in the repeat regions, and a deletion of the gpX gene, with an insertion of the swine parvovirus B capsid protein gene into the gpX region. 10 For cloning the s ?ine parvovirus B gene, the NADL-8 strain double-stranded replicative-form DNA was purified from swine parvovirus infected cells and was supplied by Dr. T. Molitor, University of Minnesota. The parvovirus NADL-8 DNA was cloned into the E^ coli 15 plasmid pSP64 by methods detailed in (15) . The DNA was partially sequenced to allow the determination of the start and the end of the major caspid protein gene, the B gene. Identification was confirmed by comparison of related sequences in the rat HI parvovirus capsid gene 20 (28,29). The sequence of the swine parvovirus B gene is shown in Fig. 11A and 11B. The PRV glycoprotein X (gpX) gene promoter was used to express the B gene and the gpX poly A signal sequence 25 was used to terminate transcription. The parvovirus B gene from the AccI site at nucleotide #391 to the Rsal site at nucleotide #2051 was cloned between the BamHI «J> and Ndel site of gpX (see Figure 7A and B) . Plasmid pSY864 contained this fragment of the parvovirus B gene 30 flanked by the gpX signal sequence as shown in Figure 13. It was used as the homologous DNA to promote homologous recombination between S-PRV-013 DNA and the plasmid DNA to facilitate the incorporation of the B gene into the PRV genome. The plasmid DNA and S-PRV- 35 013 DNA were mixed and transfected together according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure. The recombinant virus was screened and purified for the transfection stock by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure with the following modification. Because the parental S-PRV-013 contained the beta-galactosidase gene, it generated blue plaques in the screening procedure. Since the parvovirus B gene would replace the beta-galactosidase gene in the virus, the plaques with this insert would appear colorless. Therefi re, colorless plaques were picked and analyzed during this screening. A virus that contained the B gene was isolated from this screening and was designated S-PRV-020. S-PRV-020 has been deposited with the ATCC under Accession No. VR 2137. DNA from S-PRV-020 was isolated by the PREPARATION OF HERPESVIRUS DNA procedure and used to confirm the insertion of the parvovirus B gene according to the SOUTHERN BLOTTING OF DNA procedure using the B gene as a probe. The test showed that the parvovirus B gene has been incorporated into the PRV genome as expected. The structure of S-PRV-020 is shown in Figure 13C. EXAMPLE 10 S-PRV-025 The cloning of the B gene and construction of these signal sequences onto the B gene are described in Exam¬ ple 9 and are shown in Figure 12. The DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBI¬ NANT HERPESVIRUS was used to insert the parvovirus B 10 gene into PRV. The plasmid pSY9S7 containing the B gene was mixed with S-PRV-002 DNA and they were cut with restriction enzyme Xbal. The DNA mixture was ligated as described in the method and the DNA was transfected into Vero cells. A virus that contained 15 the B gene was isolated from the transfection stock of virus and was designated S-PRV-025. S-PRV-025 has been deposited with the ATCC under Accession No. VR 2138. DNA from S-PRV-025 was isolated by the PREPARATION OF 20 HERPESVIRUS DNA procedure and used to confirm the insertion of the parvovirus B gene according to the SOUTHERN BLOTTING OF DNA procedure using the B gene a probe. The test showed that the parvovirus B gene has been incorporated into the PRV genome as expected. The 25 structure of S-PRV-025 is shown in Figure 14. ? 30 35 -126- EXAMPLE 11 S-PRV-029 S-PRV-029 is a pseudorabies virus that has a deletion in the junction region between the unique long region and the internal repeat of PRV, and a deletion in the gpX gene in the unique short region. The E. coli beta- galactosidase gene under the control of the gpX promoter and polyadenylation signals has been inserted into both deletions in S-PRV-029. To- construct this virus, the Sail #1 fragment of PRV was first cloned. PRV DNA was prepared and then cut with Sail restriction enzyme. The cut DNA was electrophoresed on an agarose gel and the largest Sail band (15 kb) was purified from the gel (see PHENOL EXTRACTION OF DNA FROM AGAROSE) . The purified DNA was ligated into the plasmid pSP64 (see LIGATION) and the DNA mixture was used to transform E. coli HB101 according to Maniatis et al. (1). The Sail #1 clone was mapped for restriction sites. The homologous recombination procedure was used to create S-PRV-029. The exact position of the junction region was determined by sequencing the DNA from the Sail #1 fragment. It was found that the junction region was positioned between two Stul sites (see Figure 15B) . Two fragments of DNA from the Sail clone were used to create the homology vector for. recombination. One was a fragment from BamHI #8' from Stul to BamHI and the other was from BamHI to Stul (Figure 15B) . The E. coli beta-galactosidase gene was previously engineered to contain the gpX promoter and polyadenylation signals as described for S-PRV-013. To put this B-galactosidase gene into the junction region clone, a Hindlll linker was first inserted into the Stul site between the BamHI #8 and BamHI #8', and into this Hindlll site was cloned a Hindlll fragment containing the beta-galactosidase gene with the gpX signals. The resulting plasmid plus wild-type PRV DNA wer transfected into Vero cells by the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure. A virus was isolated from the transfection stock that contained the beta-galactosidase gene inserted into both the junction deletion (Fig. 15B) and the gpX deletion (Fig. 15A) due to the presence of homology to both of these regions in the plasmid. This virus was purified by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure and was designated S-PRV-029. S-PRV-029 has been deposited with the ATCC under Accession No. VR 2139. S-PRV-029 was shown to be expressing beta-galactosidase by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure and the o-nitrophenylgalactopyranoside assay (33). The structure of this virus is shown in Figure 15C. EXAMPLE 12 S-IBR-002 S-IBR-0O2 is an IBR virus that has a deletion of ap¬ proximately 800 bp in the repeat region of the genome. This deletion removes the only two EcoRV restriction sites on the virus genome and an adjacent Bglll site (Figure 16) . To-construct this virus, the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUSES was performed. Purified IBR DNA (Cooper strain) digested with EcoRV restriction enzyme was mixed with Dral-restriction enzyme-digested plasmid DNA containing the beta- galactosidase gene under the control of the HSV-l TK promoter. After ligation the mixture was used to transfect animal cells and the transfection stock was screened for recombinant IBR virus by the HYBRIDIZATION SCREEN FOR RECOMBINANT HERPESVIRUSES procedure. The final result of the purification was the recombinant IBR designated S-IBR-002. It was shown by Southern hybridization that this virus does not carry any foreign genes. Restriction enzyme analysis also showed that the insertion sites (EcoRV) at both repeats were deleted. Figure 16 shows the restriction map of the EcoRI B fragment which contains the EcoRV restriction sites and the map of S-IBR-002 which lacks the EcoRV sites. S-IBR-002 has been deposited with the ATCC under Accession No. VR 2140. EXAMPLE 13 S-IBR-004 S-IBR-004 is an IBR recombinant virus carrying an in¬ serted foreign gene, Tn5 NEO (aminoglycoside 3'- phosphotransferase) gene, under the control of the pseudorabies virus (PRV) glycoprotein X promoter. To construct this virus, the Hindlll K DNA fragment from wild type IBR virus was cloned into the plasmid pSP64 at the Hindlll site. This plasmid was designated pSY524. A map of the Hindlll K fragment is shown in Figure 17. The DNA from the Xhol site to the Hindlll site and containing the Ndel site from pSY524 was cloned into plasmid pSP65 and called pSY846. The Ndel to EcoRI fragment was removed from pSY846 by digestion with Ndel and EcoRI restriction enzymes, followed by POLYMERASE FILL-IN REACTION and LIGATION. The resulting plasmid was called pSY862. The plasmid pNEO (P.L. Biochemicals, Inc.) contains the aminoglycoside 3 # -phosphotransferase (NEO) gene and confers resistance to ampicillin and neomycin on E. coli hosts. The coding region of this gene (Bglll-BamHI fragment) was isolated and cloned between the PRV gpX promoter and the HSV-Tk poly A sequence in a plasmid called pSY845. The NEO gene construct in pSY845 was excised with Hindlll, made blunt ended by the POLYMERASE FILL-IN REACTION, and cloned into the SacI site of plasmid pSY862. The final product was called pSY868. Wild type IBR DNA was mixed with pSY868 DNA and the mixture was transfected into rabbit skin cells to gen- erate recombinant IBR. The recombinant IBR virus car¬ rying a functional NEO gene was then isolated and puri¬ fied according to the SELECTION OF G418 RESISTANT VIRUS method. S-IBR-004 recombinant IBR was shown to express the NEO gene by the fact that cells infected with this virus were resistant to the toxicity of G418. A detailed map of the plasmid construction is shown in Figure 17. The structure of S-IBR-004 is also shown in Figure 17. S- IBR-004 has bee . deposited with the ATCC under Accession No. VR 2134. EXAMPLE 14 S-IBR-008 S-IBR-008 is an IBR virus that has a deletion in the short unique region, and an insertion of the bovine rotavirus glycoprotein 38 (gp38) gene in the Xbal site in the long unique region. First the bovine rotavirus gp38 gene was engineered to contain herpesvirus regulatory signals as shown in Figure 18. This was accomplished by cloning the gp ' 38 gene BamHI fragment contained in pSY1053 between the BamHI and Bglll sites in pSY1052. The resulting plasmid, pSY1023, contained the PRV gpX promoter in front of the gp38 gene, and the HSV-l TK polyadenyl- ation signal behind the gp38 gene. The entire con¬ struct was flanked by Xbal sites to allow for the in¬ sertion of the Xbal fragment into IBR by direct liga¬ tion. S-IBR-004 was the starting virus for the generation of S-IBR-008. S-IBR-004 DNA and pSY1023 DNA were mixed together, cut with Xbal, and transfected into rabbit skin cells according to the DIRECT LIGATION FOR GENER¬ ATING RECOMBINANT HERPESVIRUS. procedure. The transfec¬ tion stock was screened for recombinant virus by the ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS procedure using antibodies prepared against the rotavirus gp38 protein. One of the viruses purified by this screen was S-IBR- 008, which has the following characteristics. It con¬ tains the rotavirus gp38 gene plus the plasmid DNA inserted into the Xbal site in the long unique region of the virus genome, but no longer contains the NEO gene of parent S-IBR-004 in the unique short region. In fact, a small deletion was created in the unique short region at the location of the NEO gene, as evi¬ denced by the absence of an Xbal site at this location in S-IBR-008. S-IBR-008 was shown to be expressing the rotavirus gp38 gene by analysis of RNA transcription in infected cells, and by the ANTIBODY SCREEN FOR RECOMBINANT HER¬ PESVIRUS procedure using antibodits specific for the gp38 gene. S-IBR-008 has been deposited with the ATCC under Accession No. VR 2141, and its structure is shown in Figure 18. EXAMPLE 15 Herpes Virus of Turkeys Herpes virus of turkeys (HVT) is another herpesvirus that is similar in organization and structure to the other animal herpesvirus examples described above. The restriction enzyme map of HVT has been published (34). This information was used as a starting point to engi¬ neer the insertion of foreign genes into HVT. The Ban I restriction map of HVT is shown in Figure 19A. From this data, several different regions of HVT DNA into which insertions of foreign genes could be made were targeted. The foreign gene chosen for insertion was the E^ coli beta-galactosidase gene (beta-gal) , which we have used in PRV. The promoter was the PRV gpX promoter. The beta-gal gene was inserted into the unique long region of HVT, specifically into the Xhol site in the BamHI #16 (3300bp) fragment, and has been shown to be expressed in an HVT recombinant by the formation of blue plaques using the substrate Bluogal. Similarly, the beta-gal gene has been inserted into the Sail site in the repeat region contained within the BamHI #19 (900bp) fragment. These experiments show that HVT is amenable to the procedures described within this application for the insertion and expression of foreign genes in herpesvi¬ ruses. In particular, two sites for insertion of for¬ eign DNA have been identified (Figs. 19B and 19C) . EXAMPLE 16 Methods for Constructing; An Attenuated Herpesvirus Containing A Foreign DNA Insert Applicants contemplate that the procedures disclosed herein which have been utilized to attenuate and insert foreign DNA sequences into PRV, IBR and HVT may be suitable for constructing other herpesviruses which are attenuated or contain inserted foreign DNA seguences which are ranslated into amino acid sequences in a host or both. Equine herpesvirus-1 (EHV) , canine her- pesvirus-1 (CHV) , feline herpesvirus-1 (FHV) or any animal herpesvirus whose genomic structure is related to these viruses are contemplated to be amenable to these methods. More specifically, the following proce¬ dures may be followed to construct such viruses. GROW ANIMAL HERPESVIRUS IN CELL CULTURE. Established cell lines or primary cells may be used. The methodol¬ ogy for the growth of these viruses exists in the lit¬ erature and does not require new art. EHV grows in Vero cells, CHV grows in Madin Darby canine kidney cells and FHV grows in Crandell feline kidney cells. PURIFY HERPESVIRUS DNA. The procedure disclosed herein for purifying herpesvirus DNA was successful for all herpesviruses tested, including PRV, IBR, HVT and cyto- megalovirus, and is a general method applicable to all herpesviruses. CLONE RESTRICTION FRAGMENTS. The cloning of herpesvi¬ rus restriction fragments is a. state of the art recom¬ binant DNA procedure and is described in Maniatis et al. (l). MAP RESTRICTION FRAGMENTS TO GENOME. It is useful to have a restriction enzyme map of the virus genome to * * identify and select regions for deletion and insertion. 5 Such maps arr available for PRV and IBR, and partially for HVT. A map exists for EHV, but not for CHV or FHV. The creation of this map does not require any new tech¬ nology and is detailed in Maniatis et al. (1). 10 IDENTIFY RESTRICTION FRAGMENTS THAT CORRESPOND TO THE REPEAT REGION. The identification of repeat regions requires the SOUTHERN BLOTTING PROCEDURE as detailed in the methods section. Clones of the repeat region hy¬ bridize to multiple bands in a restriction enzyme di¬ gest due to the fact that they are repeated in the 15 virus genome. This feature, coupled with their loca¬ tion in the genome, are diagnostic of repeat regions. MAKE DELETION IN REPEAT REGION CLONE. Genetic informa¬ tion in the. repeat region is duplicated in the other 20 copy of the repeat in the genome. Therefore one copy of the repeat region is nonessential for replication of the virus. Hence the repeat region is suitable for deletions and insertions of foreign DNA. After the repeat region is cloned and mapped by restriction en¬ 25 zymes, enzymes may be chosen to engineer the repeat deletion and to insert foreign DNA. It is obvious to one skilled in the art that enzyme sites will exist in a given stretch of DNA and that they can be found by analysis. The methodology involves RESTRICTION DIGES¬ 30 TION OF DNA, AGAROSE GEL ELECTROPHORESIS OF DNA, LIGA¬ TION and cloning in bacterial cells as detailed in the methods section and in Maniatis et al. (l) . 35 MAKE INSERTION OF MARKER GENE INTO DELETION IN REPEAT REGION CLONE. The methodology of this insertion is that described in Maniatis et al. (1) for the cloning of genes into bacteria. What is not obvious prior to the present disclosure is which marker genes to use that will be active in a herpesvirus-, nor which signal seguences to use for the expression of foreign genes in these herpesviruses. The E^ Coli beta-galactosidase gene and neomycin resistance gene under the control of the HSV-l ICP4 promoter, the PRV gpX promoter or the HSV-l TK promoter have been :sed. The gpX promoter, in particular, works in PRV, IBR, and HVT. The other promoters have also worked in more limited testing. TRANSFECTION WITH MARKER GENE CLONE + HERPESVIRUS DNA. The intent of this procedure is to put into the same cell the intact herpesvirus DNA and the repeat region clone with the deletion and containing the marker gene. Once these two DNAs are present in the same cell, nor¬ mal mechanisms of homologous recombination ensure that a recombination will occur between the homologous re¬ gions in the clone and the same region in the herpesvi¬ rus DNA, thus substituting the marker gene for the deleted regions in the virus, with frequency of about 1%. The technique involves the TRANSFECTION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUSES as detailed in the methods section. PURIFY HERPESVIRUS DNA. Herpesvirus DNA may be puri¬ fied according to the methods described above. SELECT RECOMBINANT PLAQUE. All the herpesviruses con¬ templated by this invention form plaques (foci of in¬ fection in cell culture) that enable their purifica¬ tion. A plaque results from infection by a single virus particle. Thus picking a single plaque selects for the progeny of a single recombinational event. This technical feat requires a method to identify which plaque to pick. The methods used herein include SOUTHERN BLOTTING OF DNA to pick the plaque based upon the presence of the inserted gene, ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS to pick the plaque based upon the presence of protein made from the gene, BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUSES to pick a plaque that expresses the marker gene beta-galactosidase or G- 418 SELECTION TO PURIFY RECOMBINA HERPESVIRUSES to pick the plaque by its ability to form in the presence of the antibiotic G-418. The first two methods are applicable to any gene; the latter two are specific for the beta-galactosidase gene and neomycin resistance gene respectively. The biology of these screening and selection systems is such that they are applicable to any herpesvirus, including EHV, CHV, FHV, and any animal herpesvirus related to them. PURIFY RECOMBINANT VIRUS. This procedure involves multiple plaque purifications in succession to com¬ pletely purify the recombinant virus away from the parental virus. The screening is applied at each, step to choose the plaque with which to continue. The pro¬ cedures are known to those skilled in the art of vi¬ rology. Multivalent vaccines for animals may be constructed by inserting a foreign antigen gene into a herpesvirus. The procedures and methodology are very analogous to those ised for the initial insertion of the marker gene into the virus and may be performed as follows. SUBSTITUTE FOREIGN ANTIGEN GENE FOR MARKER GENE IN REPEAT CLONE. This is a cloning experiment that in¬ volves putting the antigen gene behind the same herpes¬ virus promoter used with the marker gene and inserting this construction into the same identical deletion in the repeat clone. The methods for this cloning are described in Maniatis et al. (1) . TRANSFECTION WITH ANTIGEN CLONE + RECOMBINANT HERPES DNA CONTAINING MARKER. The marker gene that is already present in the herpesvirus genome may be use to aid in the selection of the new recombinant. For example, it has proven useful to select white plaques instead of blue ones to test for the absence of beta-galactosidase in this step. One reason for the present of a white plaque is the replacement of the beta-galactosidase gene with the foreign antigen gene by homologous recombination (the desired outcome) . Continued screening for this new recombinant by the SOUTHERN BLOT PROCEDURE or by the ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS becomes more focused, less time-consuming and specifically identifies the recombinant of interest. ISOLATE RECOMBINANT HERPES DNA. The transfection pro¬ cedure requires intact infectious herpesvirus DNA. Recombinant herpesviruses which include an inserted marker gene may be used. The isolation of herpesvirus DNA procedure is equally applicable to these recombi¬ nant viruses. SCREEN TRANSFECTION STOCK FOR FOREIGN GENE INSERTION. Screening methods have been described above. They are a combination of indirect methods (screening for the absence of the marker) as well as direct methods (SOUTHERN BLOT for the antigen gene, and ANTIBODY SCREEN for the expressed protein) . The methods may be applied sequentially during the purification of the virus. PURIFY RECOMBINANT VIRUSES CONTAINING FOREIGN ANTIGEN GENE. The recombinant virus containing the foreign antigen gene may be purified according to the proce¬ dures described above. This sequence of steps, along with the methods And examples described herein, enable anyone skilled in the art to successfully practice this invention with any animal herpesvirus. EXAMPLE 17 The present invention involves the use of genetically engineered herpesviruses to protect animals against disease. It was not apparent at the outset of research which deletions in herpesviruses would serve to attenu¬ ate the viruses to the proper degree so as to render them useful as vaccines. Even testing vaccine candi¬ dates in animal models, e.g. mouse, does not serve as a valid indicator of the safety and efficacy of the vac¬ cine in the target animal species, e.g. swine. To illustrate this point more clearly, Table VII shows summary data of the safety and efficacy of various pseudorabies viruses which were constructed and tested in swine according to the VACCINATION STUDIES IN SWINE procedure. T3BLE VII SUMMARY OF SIUDIES CONDUCTED IN PIGS WITH VARIOUS ESEDEORABIES VIRUS CDNSTFDCTS A-Repeats; B-TK; C-Junction; D-gpX; E-beta-galactosidase insert The eight constructs that have been tested have the following deletions and insertions in the genome of the virulent Shope strain of PRV: S-PRV-001 has a deletion in both repeat regions; S-PRV-002 has a deletion in both repeat regions and in the thymidine kinase gene; S-PRV-003 has a deletion in the thymidine kinase gene; S-PRV-004, S-PRV-010, S-PRV-013, S-PRV-014 and S-PRV- 016 are described in Example #'s 1, 3, 6, 7 and 8 re¬ spectively. A superior vaccine .product must not produce clinical signs in 3-4 day old piglets (the more sensitive age) ' , " and give 100% protection in pigs of all ages. From Table VII, it is apparent that each vaccine candidate provided some degree of attenuation and protection in swine, but each vaccine provided a unique response. The best vaccine candidate from this list to date is S- PRV-013, which contains three deletions; one in the repeat region; one in the TK gene, and one in the gpX gene. The utility of this combination of deletions was unexpected. These results are novel, unpredicted, and useful in the selections of a superior pseudorabies vaccine product. EXAMP3LE 18 S-PRV-055 S-PRV-055 is a pseudorabies virus that has a deletion in the TK gene, a deletion in the repeat region, and an insertion of the transmissible gastroenteritis virus (TGE) gpl95 gene in the Xbal site in the repeat region. For cloning the TGE gpl95 gene, the Purdue strain of TGE was grown in swine testes cells in culture and RNA was extracted from infected cells. The RNA was used 10 in a reverse transcription protocol as outlined in the cDNA CLONING procedure using poly-dT as primer for reverse transcriptase. From this procedure, a series of clones was obtained that comprised parts of the genome of the TGE virus. The location of the gene 15 encoding the TGE gpl95 gene has been published (59) and this information was used to locate the gene in our clones. The entire open reading frame of the gpl95 gene was sequenced by applicants and is given in Figure 22. 20 The PRV gpX promoter was used to express the TGE gpl95 gene and the HSV TK poly-A signal was used to terminate transcription. The engineering of this construct was done as shown in Figure 23 A and B. The construct 25 contained (5' to 3') the gX promoter, the gX TATA box, the gX cap site, the gX 5' untranslated region, the gX start codon, 28 codons of the gX gene, an in-frame fusion to the TGE gpl95 gene at the BstEII site, the r TGE structural gene, the TGE stop codon, a fusion with¬ 30 in the TGE 3' untranslated region to the HSV TK 3' un- 35 translated region, and the HSV TK poly-A signal se¬ quence. The TGE construction was used in the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUSES. Restriction enzyme Xbal was used to cut the PRV DNA and the plasmid DNA prior to ligation. After the trans¬ fection step in the procedure, the resulting recombi¬ nant virus from the transfection stock was plague puri¬ fied by analysis of the DNA at each step. The virus that resulted from this screening was designated S-PRV- 055. S-PRV-055 contained the TGE gpl95 gene inserted at the Xbal site in the repeat region as shown by the SOUTHERN BLOTTING OF DNA procedure using the TGE coding region as probe. The expression of the gpl95 protein was Shown by the ANTIBODY SCREEN FOR RECOMBINANT HERPESVI¬ RUS procedure. The structure of S-PRV-055 is shown in Figure 23 C. EXAMPLE 19 S-IBR-018 S-IBR-018 is an IBR virus that has three foreign genes inserted: the E. coli beta-galactosidase gene and the neomycin resistance gene in the Xbal site in the unique long region, and the parainfluenza-3 (PI-3) virus hem- agglutinin gene (HN) in the Hindlll site in the unique long region immediately adjacent to the Xbal site. For cloning the PI-3 HN gene, the SF-4 strain of PI-3 was grown in MADIN-DARBY bovine kidney (MDBK) cells in culture and RNA was extracted from infected cells. The RNA was used in a reverse transcription protocol as outlined in the cDNA CLONING procedure using poly-dT as. primer for reverse transcriptase. From this procedure, a series of clones was obtained that comprised parts of the genome of the PI-3 virus. The location of the gene for the human PI-3 HN gene has been published (60,61) and this information was used to locate the gene in applicants' bovine PI-3 clones. The entire open reading frame of the bovine PI-3 HN gene was sequenced by applicants and is given in Figure 24. The HSV ICP4 promoter was used to express the PI-3 HN gene and the HSV TK poly-A signal was used to terminate transcription. The engineering of this construct was done as shown in Figure 25 A and B. The construct con¬ tained (5' to 3') the HSV ICP4 promoter, the ICP4 TATA box, the ICP4 cap site, a fusion within the ICP4 5' untranslated region to the PI-3 HN gene at the Hhal site, the HN gene start codon, the HN structural gene, the HN stop codon, a fusion within the HN 3' untrans¬ lated region to the HSV TK untranslated 3' region, and the HSV TK poly-A signal sequence. This plasmid also contained the beta-galactosidase gene under the control of the PRV gpX promoter with the gpX poly-A termination signal, as well as the neomycin resistance gene under the control of the gpX promoter with the TK poly-A termination signal. These latter two genes were cloned in tandem at the Xbal site in BamHI-C fra ment (Figure 25 A and B) . This BamHI-C fragment contained the homology regions for- use in the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS pro¬ cedure. After the transfection step in the procedure, the resulting recombinant virus from the transfection stock was selected for by the SELECTION OF G418 RESIS¬ TANT HERPESVIRUS procedure, followed by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure, and sub¬ sequently analyzed for the insertion of the PI-3 HN gene by SOUTHERN BLOTTING OF DNA procedure. The virus that resulted from this screening was designated S-IBR- 01S. The structure of S-IBR-018 is shown in Figure 25 C. EXAMPLE 20 S-IBR-019 S-IBR-019 is an IBR virus that has three foreign genes inserted: the E. coli beta-galactosidase gene and the neomycin resistance gene in the Xbal site in the unique long region, and the parainfluenza-3 (PI-3) virus fusion gene (F) in the Hindlll site in the long unique region adjacent to the Xbal site. 10 For cloning the PI-3 F gene, the SF-4 strain of PI-3 was grown in MADIN-DARBY bovine kidney (MDBK) cells in culture and RNA was extracted from infected cells. The RNA was used in a reverse transcription protocol as outlined in the cDNA CLONING procedure using poly-dT as 15 primer for reverse transcriptase. From this procedure, a series of clones was obtained that comprised parts of the genome of the PI-3 virus. The location of the gene for the Sendai virus F gene has been published (62) and this comparative sequence information was used to 20 locate the homologous gene in applicants' bovine PI-3 clones. The HSV ICP4 promoter was used to express the PI-3 F gene and the HSV TK poly-A signal was used to terminate 25 transcription. The construct contained (5' to 3') the HSV ICP4 promoter, the ICP4 TATA box, the ICP4 cap site, a fusion in the ICP4 5' untranslated region to the PI-3 F gene, the F start codon, the F structural If, gene, the F stop codon, a fusion in the F 3' untrans¬ 30 lated region to the HSV TK 3' untranslated region, and the TK poly-A signal sequence. 35 This plasmid also contained the beta-galactosidase gene under the control of the PRV gpX promoter with the gpX poly-A termination signal, as well as the neomycin resistance gene under the control of the gpX promoter with the TK poly-A termination signal. These latter two genes were cloned in tandem at the Xbal site in BamHI-C fragment (Figure 26 A and B) . This BamHI-C fragment contained the homology regions for use in the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS pro¬ cedure. After the transfection step in the procedure, the resulting recombinant virus from the transfection stock was selected for by the SELECTION OF G418 RESIS¬ TANT HERPESVIRUS procedure, followed by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure, and sub¬ sequently analyzed for the insertion of the PI-3 F gene by SOUTHERN BLOTTING OF DNA procedure. The virus that resulted from this screening was designated S-IBR-019. The structure of S-IBR-019 is shown in Figure 26 C. EXAMPLE 21 S-HVT-003 S-HVT-003 is a herpesvirus of turkeys (HVT) that contains the E.coli beta-galactosidase gene plus the infectious bursal disease virus (IBDV) strain S40747 large segment of RNA (as a cDNA copy) inserted into the unique long region of the HVT genome. This IBDV DNA contains one open reading frame that encodes three proteins (5 , VP2-VP4-VP3 3'), two of which are antigens to provide protection against IE f infections of chickens. Expression of the genes for both beta- galactosidase and the IBDV polyprotein are under the control of the pseudorabies virus (PRV) gpX gene promoter. S-HVT-003, deposited under ATCC Accession No. VR 2178, was made by homologous recombination. The IBDV genes were cloned by the cDNA CLONING PROCEDURE. Clones representing the genome of IBDV were screened by SOUTHERN BLOTTING OF DNA procedure against blots containing authentic IBDV RNA. Positive clones were then characterized by restriction mapping to identify groups of clones. Two such clones were identified, that together were found to represent the entire coding region of the IBDV large segment of RNA (3.3 kb dsRNA) . One cDNA clone (2-84) contained an approximately 2500 base pair fragment representing the first half of the IBDV gene. The second clone (2-40) contained an approximately 2000 base pair fragment representing the distal half of the IBDV gene. Plasmid 2-84/2-40, representing the entire IBDV gene, was constructed by joining clone 2-84 and 2-40 at a unique Pvu II site present in the overlapping seguences. The IBDV genome can be obtained from plasmid 2-84/2-40 as ah approximately 3400 base pair S a I to Hpa I fragment. Confirmation of the nature of the proteins encoded by the IBDV gene was obtained by expressing the clone (2-84/2-40) in E.coli and detecting VP3 antigen using antiserum made against purified ' IBDV capsid proteins on Western blots. Applicants' sequence of the large DNA segment that encodes the IBDV antigens is given in Figure 27. This sequence shows one open reading frame that will henceforth be referred to as the IBDV gene. Recently, the sequence of an Australian IBDV strain has been published which bears close homology to applicants' sequence (63) . Comparison of the amino acid differences between the two -iruses revealed 29 amino acid changes within the 1012 amino acid coding region. There were only 3 amino acid differences deduced for VP4 and only 8 in VP3. In contrast, VP2 contained 18 amino acid changes, 14 of which were clustered between amino acids 139 to 332. For insertion into the genome of HVT, the coding region for the IBDV gene was cloned between the PRV gpX promoter and the HSV TK poly-A signal sequence, creating plasmid 191-23. To aid in the identification of HVT recombinants made by homologus recombination, containing the IBDV gene, the gpX promoted IBDV fragment from plasmid 191-23 was inserted behind (in tandem to) a beta-galactosidase gene controlled by a gpX promoter. The resultant plasmid, 191-47, contains the E.coli beta-galactosidase gene and the IBDV gene under the control of individual PRV gpX promoters. In constructing plasmid 191-47, various DNA fragments were joined by recombinant DNA techniques using either naturally occurring restriction sites or synthetic linker DNA. Details concerning the construction of these genes contained in plasmid 191-47 can be seen in figure 28. The first segment of DNA (segment 1, figure 28) contains the gpX promoter region including the residues encoding the first seven amino acids of the gpX gene, and was derived from a subclone of the PRV Bam HI number 10 fragment as an approximately 800 base pair Sal I to Bam HI fragment. The second segment of DNA (segment 2, figure 28) contains the E.coli beta- galactosidase coding region from amino acid 10 to am. ΛQ acid 1024 and was derived from the plasmid p F75Ϊ (obtained from Jim Hoch, Scripps Clinic and Research Foundation) as an approximately 3300 base pair Bam HI to Bal I fragment followed by an approximately 40 base pair Ava I to Sma I fragment. The third segment of DNA (segment 3, figure 28) contains the gpX poly A signal sequence and was derived from a subclone of the PRV Bam HI number 7 fragment as an approximately 700 base pair Nde I to Stu I fragment. Segment three was joined to segment two by ligating the Nde I end which had been filled in according to the POLYMERASE FILL-IN REACTION, to the Sma I site. The fourth segment of DNA (segment 4, figure 28) contains the gpX promoter (TATA box and cap site) and was derived from a subclone of the PRV Bam HI number 10 fragment as an approximately 330 base pair Nae I to Alu I fragment. Additionally, segment four contains approximately 36 base pairs of HSV TK 5* ntranslated leader sequence as a Pst I to Bgl II fragment in which the Pst I site has been joined to the Alu I site through the use of a synthetic DNA linker (64) . DNA segments four through six were inserted as a unit into the unique Kpn I site of segment three which is located 3' of the gpX poly A signal sequence. The fifth segment of DNA (segment 5, figure 28) contains the entire coding region of the IBDV large segment of RNA (cDNA clone) as an approximately 3400 base pair Sma I to Hpa I fragment. The Sma I site of segment five was fused to the Bgl II site of segment four which h-d been filled in according to the POLYMERASE FILL IN REACTION. Expression of the IBDV gene (5'VP2-VP4-VP3 3') is under the control of the gpX promoter (segment 4) , but utilizes its own natural start and stop codons. The sixth segment of DNA (segment 6, figure 28) contains the HSV TK poly-A signal sequence as an approximately 800 base pair Sma I fragment (obtained from Bernard Roizman, Univ. of Chicago) . The Hpa ϊ site of segment five was fused to the Sma I site of segment six through the use of a synthetic DNA liner. In summary, the construct used to create S-HVT-003 (plasmid 191-47) contains (5' to 3') the PRV promoter, the gpX TATA box, the gpX cap site, the first seven amino acids of gpx, the E.coli beta-galactosidase gene, the PRV poly-A signal sequence, the PRV gpX promoter, the gpX TATA box, the gpX cap site, a fusion within the gpX untranslated 5' leader to the IBDV gene, IBDV start codon, a fusion within the IBDV untranslated 3' end to HSV TK untranslated 3' end, and the TK poly-A signal sequence. The cassette containing these genes was engineered such that it was flanked by two Eco RI. restriction endonuclease sites. As a result, an approx; -.ately 9100 base pair fragment containing both beta-galactosidase and the IBDV gene can be obtained by digestion with Eco RI. Henceforth, the 9161 base pair Eco RI fragment will be referred to as the IBDV/b-gal cassette. The following procedures were used to construct S-HVT- 003 by homologous recombination. The IBDV/b-gal cassette was inserted into the unique Xho I site present within a subclone of the HVT Bam HI number 16 fragment. To achieve this, the Xho I jite was first changed to an Eco RI site through the use of an Eco RI linker. This site had previously been shown to be nonessential in HVT by the insertion of beta- galactosidase (S-HVT-001) . It was also shown that the flanking homology regions in Bam HI number 16 were efficient in homologous recombination. Shown in Figure 29, the genomic location of the Bam HI number 16 fragment maps within the unique long region of HVT. The complete nucleotide sequence of the approximately 3329 base pair Bam HI number 16 fragment is presented in figure 30. HVT DNA was prepared by the PREPARATION OF HERPES VIRUS OF TURKEY DNA procedure. Cotransfeetions of HVT DNA and plasmid DNA into primary chick embryo fibroblast (CEF) cells were done according to the DNA COTRANSFECTION FOR GENERATING RECOMBINANT HVT VIRUS procedure. The recombinant virus resulting from the cotransfeetion stock was purified by three successive rounds of plaque purification using the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure. When 100% of the plaques were blue, the DNA was analyzed for the presence of the IBDV gene by the SOUTHERN BLOTTING OF DNA procedure. Southern blots, probing Eco RI digested S-HVT-U03 DNA with an IBDV specific nick translated probe (plasmid 2-84/2-40) , confirmed the presence of the 9100 base pair Eco RI fragment. This result confirmed that S-HVT-003 contained both the beta-galactosidase gene and the IBDV gene incorporated into its genome. Additional Southern blots, using a probe specific for Bam HI #16, confirmed that the homologous recombination occurred at the appropriate position in Bam 16 and that ho deletions were created. No differences in the growth of S-HVT- 003 compared to wild type virus (S-HVT-000) were observed .in vitro. Expression of IBDV specific proteins from S-HVT-003 were assayed vitro using the WESTERN BLOTTING PROCEDURE. Cellular lysates were prepared as described in PREPARATION OF HERPESVIRUS CELL LYSATES. Briefly, the proteins contained in the cellular lysates of S- HVT-003 were separated by polyacrylamide gel electrophoresis, transferred to nitrocellulose, and probed with either an antiserum made against denatured purified IBDV capsid proteins or antiserum made against a synthetic peptide corresponding to a predicted imuno dominant region of the IBDV 40 kd (VP2) capsid protein. The filters were washed and treated with [ 125I] protein A to detect the position of the bound antibodies. Figure 31 shows the results obtained using the antiserum made against denatured purified IBDV capsid proteins, which have been shown by the applicants to primarily react with VP3 (32 kd protein) . As seen, S- HVT-003 produces a protein which is immunologically indistinguishable from the authentic VP3 protein from intact IBDV virions. Moreover, the polyprotein appears to be processed correctly, producing a VP3 species that comigrates with the authentic VP3 protein. Recent evidence using an Australian IBDV strain indicates that VP4 is involved in the processing of the precursor polyprotein into mature VP2 and VP3 protein species (65). Figure 32 shows the results obtained using a rabbit antiserum raised against a synthetic peptide that is homologous to a 14 amino acid region of the IBDV VP2 (40 kd) capsid protein. As seen, S-HVT-003 produces a protein that is immunologically indistinguishable from the authentic viral VP2 protein. In addition, the VP2 protein produced from S-HVT-003 comigrates with the 40 kd species of VP2 isolated from intact IBDV virions. This species represents a major component of infectious (complete) viral particles. In summary, analysis of the expression of IBDV specific proteins from S-HVT-003 has shown that the polyprotein is processed in CEF cell culture, producing proteins of the appropriate size that react to immunological reagents specific for either VP2 or VP3 proteins on Western blots. The following set of experiments was carried out in chickens to analyze the _in vivo expression of the IBDV genes contained within S-HVT-003 as determined by sero- conversion data, serum neutralization results, and protection from IBDV challenge. The first experiment was designed to show the seroconversion of chickens to IBDV upon being vaccinated with S-HVT-003. Eleven 11-week-old chickens, seronegative to HVT and IBDV were obtained from SPAFAS Inc. Six birds were vaccinated subcutaneously in the abdominal region with one-half milliliter of a cellular suspension of CEF cells containing S-HVT-003 (40,000 PFU per milliliter). Serum samples were obtained every seven days for eight weeks for all birds in this study. On day 28 (4th week) , three of these birds received a boost of S-HVT- 003, while the other three birds received one-half milliliter of an inactivated IBDV vaccine inoculated subcutaneously in the cervical region. Three additional birds were given only the inactivated vaccine on day 28. Two birds served as contact controls and received no vaccinations. On day 56, all birds were sacrificed and necropsied. Table VIII shows the results of the serum neutralization assay against IBDV. No detectable SN activity was observed in the birds given only S-HVT-003. Additionally, only one of the three birds that were given only the inactivated vaccine demonstrated low but detectable SN activity. SN titers were also detected in one of the three birds that received the S-HVT-003 followed by the inactivated IBDV vaccine boost; these titers were at a much higher level than with the inactivated IBDV vaccine alone. These results suggest that S-HYT-003 is priming the chicken for. a secondary response against IBDV. In vitro analysis of the serum samples by WESTERN BLOTTING confirmed the seroconversion of the chickens to IBDV upon vaccination with S-HVT-003 both prior to and after boosts administered on day 28. 56. ND In the second experiment, twenty five 1-day old SPF chicks were vaccinated with S-HVT-003 (20 with 0.2 ml subcutaneously and 5 by bilateral eyedrop) . Twenty chicks were kept as controls. On days four and seven postinfection, five vaccinates and two control birds were bled, sacrificed and their spleens removed for virus isolation. Spleen cell suspensions were made by standard method, and -1x10 cells in 3 ml of chick embryo fibroblast (CEF) growth media were inoculated directly onto secondary cells. Cultures were incubated for 6-7 days and then scored for cytopathic effects (CPE) as determined by observing cell morphology. The cultures were passed a second time, and again scored for CPE. The results are shown in table IX. All nonvaccinated coαtrol birds remained negative for HVT for both day 4 and 7 spleen cell isolations. Four out of the five birds vaccinated with S-HVT-003 were positive for HVT at day 4 for both the first and second passages. One bird did not produce virus, this may represent a vaccination failure. Five out of five birds were positive for HVT on day 7 at both passage one and two. Overall, the vector recovery experiment demonstrates that S-HVT-003 replicates as well as wild type HVT virus ji vivo and that insertion of the IBDV/beta-galactosidase cassette into the Xho I site of Bam HI #16 does not result in detectable attenuation of virus. Subsequent experiments examining the recovered virus by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure confirmed the in vivo stability of S-HVT-003, by demonstrating beta-galactosidase expression in 100% of the viruses. -158- TABLE IX N = control, T = vaccinated. CPE ranged from negative (-) to 5+ At days 0, 4, 7, 14, 21, and 27 postinfection, blood samples were obtained from the rest of the chickens for determining serum ELISA titers against IBDV and HVT antigens as well as for virus neutralizing tests against IBDV. Additionally, at 21-days postinfection five control and fourteen vaccinated chicks were challenged with virulent IBDV by bi-lateral eyedrop (10 3 * 8EID 5Q ) . All birds were sacrificed 6-days post challenge and bursa to body weight ratios were calculated. A summary of the results is shown in tables X and XI, respectively. As presented in table X, no antibodies were detected against HVT antigens by ELISA . rior to 21-27 days post vaccination. In chickens, the immune response during the first two weeks post hatch is both immature and parentally suppressed, and therefore these results are not totally unexpected. In contrast, IBDV ELISA's were negative up to day 21 postvaccination, and were only detectable after challenge on day 27. The ELISA levels seen on day 27 postvaccination indicate a primary response to IBDV. Table XI comparing the Bursa-to-Body weight ratios for challenged controls and vaccinated/challenged groups show no significant differences. Vaccination with S-HVT-003 under these conditions did not prevent infection of the vaccinated birds by IBDV challenge, as indicated by the death of four vaccinated birds following challenge VN IBDV <100 nd nd <100 <100 nd <100 nd <100 nd nd nd C=control, T=vaccinated, CC=challenged control, CT=Challenged & vaccinated, ELISA titers are GMTs and they range from 0-9. Values are mean values. Body weights are different in control group because challenged birds did not feed well. Four challenged-treated birds died. A third experiment was conducted repeating Experiment 2 but using immunologically responsive chicks (3 weeks of age) . Six three week old SPF leghorn chickens were vaccinated intraperitoneally with 0.2ml of S-HVT-003 (one drop in each eye) . Serum samples were obtained every seven days for six-weeks and the birds were challenged with the virulent USDA standard challenge IBDV virus on day 43 postvaccination. Six days post challenge, the control, vaccinated-challenged, and challenged groups were sacrificed and bursas were harvested for probing with anti-IBDV monoclonal antibodies (MAB) (provided by Dr. David Snyder, Virginia-Maryland Regional College of Veterinary Medicine) . Bursal homogenates were prepared by mixing 1 ml of 0.5% NP40 with one bursa. Bursa were then ground and briefly sonicated. Supernatants from the homogenates were reacted with the R63 MAB which had been affixed to 96-well Elisa plates via a protein A linkage. After incubation, a biotin labeled preparation of the R63 MAB was added. After washing, an avidin-horse radish peroxidase conjugate was added and incubated. Tests were developed with Tris-malcate buffer (TMB) + H 2 0 2 substrate. The test results are presented in table XII. The data show the presence of high levels of IBDV antigen in all bursa in the vaccinated-challenged group and in the challenged group. No IBDV antigen was detected in the controls. IBDV specific antigen could be detected at dilutions of over 1/1000, and there does not appear to be differences between vaccinated and non-vaccinated challenged groups. HVT titers as determined by ELISA were first detectable at day 7 in four out of the six birds vaccinated. By day 14, six out of six vaccinated birds showed titers to HVT. All six birds continued to show HVT titers throughout the experiment. No IBDV SN titers were seen prior to the challenge. In contrast, analysis of these same serum samples by the WESTERN BLOTTING procedure demonstrated the seroconversion of chickens vaccinated with S-HVT-003 tp IBDV prior to administration of the virus challenge. The level of response, however, remains small unless boosted by challenge. Comparison between the vaccinated/challenged and challenged only groups clearly demonstrates that the level of reactivity by Western blots is much higher in the vaccinated/challenged group. These results show that S-HVT-003 is seroconverting vaccinated birds to IBDV, and suggest that the level of IBDV specific expression are not high enough to induce a neutralizing response in the birds. S-HVT-003 shows the merit of the vaccine approach the applicants have invented. HVT has been engineered to simultaneously express the foreign antigens (b- galactosidase and IBDV antigens) that are recognized in the host by an immune response directed to these proteins. Applicants' invention will enable progression towards a product based on this technology. TABLE XII Maximum titer level is 9 EXAMPLE 22 S-HVT-004 S-HVT-004 is a recombinant herpesvirus of turkeys that contains the Marek's disease virus (MDV) glycoprotein A (gpA) gene inserted into the long unique region, and the beta-galactosidase gene also inserted in the long unique region. The MDV antigen is more likely to elic¬ it the proper antigenic response than the HVT equiva¬ lent antigen. The MDV gpA gene was cloned by standard DNA cloning gpA procedures. An EcoRI restriction fragment had been reported to contain the MDV gpA gene (66) and this fragment was identified by size in the DNA clones. The region of the DNA reported to contain the gpA gene was sequenced by applicants and found to contain a glycoprotein gene as expected. The DNA from this gene was used to find the corresponding gene in HVT by the SOUTHERN BLOTTING OF DNA procedure, and a gene in HVT was identified that contained a very similar sequence. This gene is the same gene previously called gpA (66) . For insertion into the genome of HVT, the MDV gpA gene was used intact because it would have good herpesvirus signal sequences already. The beta-galactosidase gene was inserted into the Xhol fragment in BamHI fragment #16, and the MDV gpA gene was inserted behind beta-gal as shown in Figure 33 A and B. Flanking regions in BamHI #16 were used for the homologous recombination. HVT DNA and plasmid DNA were co-transfected according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure into primary chick embryo fibroblast (CEF) cells. The virus from the transfection stock was purified by successive plaque purifications using the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS proce¬ dure. At the end of this procedure, when 100% of the plaques were blue, the DNA was analyzed for the pres¬ ence of the MDV gpA gene. S-HVT-004 • is a recombinant virus that contains both the beta-galactosidase gene and the MDV gpA gene incorporated into the genome. Figure 33 C shows the structure of S-HVT-004 EXAMPLE 23 BOVINE CORONAVIRUS Bovine coronavirus (BCV) is closely related to TGE virus in overall structure. We have cloned the major neutralizing antigens from BCV for use in a herpesvi¬ rus delivery system ' (Infectious bovine rhinotracheitis virus, IBR) . The procedures that we have utilised for the construc¬ tion of herpesvirus signal sequences for expression are being applied to BCV. It is contemplated that the procedures that have been used to express TGE in PRV and PI-3 in IBR and are disclosed herein are also ap¬ plicable to BCV. NEWCASTLE'S DISEASE VIRUS Newcastle's disease virus (NDV) is closely related to PI-3 in overall structure. We have cloned the hemag- glutinin (HN) and fusion (F) genes from NDV for use in the herpesvirus delivery system (Herpesvirus of turkeys, HVT) . The procedures that we have utilized for the construc¬ tion of herpesvirus signal seguences for expression are being applied to NDV. It is contemplated that the procedures that have been used to express IBDV in HVT and PI-3 in IBR and are disclosed herein are also ap- plicable to NDV. INFECTIOUS BRONCHITIS VIRUS Infectious bronchitis virus (IBV) is a virus of chick¬ ens closely related in overall structure to TGE. We have cloned the major neutralizing antigens from three strains of IBV: Massachusetts, Connecticut, and Arkan- sas-99 for use in a herpesvirus delivery system (HVT) . The procedures that we have utilized for the construc¬ tion of herpesvirus signal seguences for expression are being applied to IBV. It is contemplated that the procedures thar have been used to express IBDV in HVT and TGE in PRV and are .disclosed herein are also ap¬ plicable to IBV. BOVINE VIRAL DIARRHEA Bovine viral diarrnea (BVD) is a virus of cattle. We have cloned the major neutralizing antigen of BVD for use in a herpesvirus delivery system (IBR) . The procedures that we have utilized for the construc¬ tion of herpesvirus signal sequences for expression are being applied to BVD. It is contemplated that the procedures that have been used to express TGE in PRV and PI-3 in IBR and are disclosed herein are also ap¬ plicable to BVD. EXAMPLE 24 Synthetic sequences of DNA may be used to provide the favored triplet frequencies for expression within the herpesvirus genome. The herpesvirus is pseudorabies virus of swine (PRV) and the foreign gene is a fragment of DNA from the swine parvovirus B gene. This fragment of parvovirus DNA is small, but it illustrates dramatically the effect even such a short unfavorable sequence has on expression, and it is small enough that a synthetic DNA sequence can be readily synthesized for it. Larger unfavorat e sequences have an even more dramatic effect on expression, and they too can be made synthetically at some cost of materials and manpower. Figure 34 shows the sequence of the entire parvovirus B gene, with the sequence of the fragment (hereinafter called 039-fragment) overlined. Figure 35A shows the amino acids that are coded for by the 039-fragment in the parvovirus B protein. The design of the synthetic DNA fragment starts with the amino acid sequence of the authentic gene. This amino acid sequence is "reverse translated" back to DNA using a computer program. One such program is sold by International Biotechnologies, Inc., New Haven, Connecticut, and is called the IBI DNA/protein Sequence Analysis System. In constructing a new gene, changes can be incorporated into the synthetic DNA at any point using alternative codons for any amino acid. The next level of analysis is to approximate a new synthetic DNA based upon G + C content. The 039-fragment has a G + C content of 34%, while the herpesvirus PRV has a G + c content of about 70%. Therefore codons that are richer in G + C need to be substituted wherever possible into the synthetic DNA. The next step is to compare potential synthetic DNA pieces for the 039-fragment with actual coding regions from PRV to assign the best new sequence. This is accomplished by another program in the same computer package, which first creates a "codon bias" table for known PRV genes. Using this table, the synthetic DNA which best fits the PRV codon usage can be determined. This is the synthetic DNA of choice since it "looks most like" a PRV gene. Figure 35B shows the synthetic DNA fragment (called 039-synthetic) that was made to match the 039-fragment in amino acid sequence. It is a requirement of the invention that the amino acids encoded by both the natural and the synthetic DNA remain substantially the same. In practice some amino acids may be changed in order to create convenient restriction sites for the subsequent use of the synthetic DNA in constructions. Usually these changes can be limited to the addition of extra amino acids at the ends of the sequence of interest. Other changes within the body of the synthetic DNA are contemplated as well and are included within the scope of this invention, but they are in the main unnecessary in the practice of this invention. Figures 36 and 37 illustrate the degree to which the natural 039-fragment and the synthesized 039-synthetic match the codon bias of a PRV gene. These figures dramatically show that the synthetic DNA has been optimized for PRV codon usage and G + C content. EXAMPLE 25 A fusion protein may be used to provide the foreign antigen with the necessary triplet nucleotide frequencies to get expression in the herpesvirus genome. In this case, the fusion protein was the E. coli beta-galactosidase (beta-gal) ene which is efficiently expressed in the pseudorabies virus genome and which has a high G + C content and a triplet nucleotide frequency that is sufficiently similar to a real herpesvj.rus gene. To demonstrate the improvement aspects of the present invention, the applicants have made both amino terminal fusions of the parvovirus B-gene to beta-gal (which are not the invention) and carboxy terminal fusions to beta-gal (which are the invention) and have compared their expression in pseudorabies virus. Figure 38 shows the construction details of the amino termir^l fusions made to beta-gal, and Figure 39 shows tne construction details of the carboxy terminal fusions made to beta-gal. Representative examples of these fusions were tested for the expression level of beta- gal made from the fusion. The method of testing the expression was the BETA-GALACTOSIDASE ONPG ASSAY METHOD given in the Methods section. In addition, the WESTERN BLOTTING METHOD was used to measure the amount of beta- gal present in the infected lysate, which did not rely upon active beta-gal expression. In all cases the amount of beta-gal determined enzymatically and the amount determined immunologically were the same. The size of the beta-gal fusion protein on Western blots showed that the protein contained the parvovirus amino acid sequence attached to the beta-gal. Table XIII shows the results of analysis of the expression of beta-gal in representative examples of the fusions. The results are normalized to a control for beta-gal expression, S-PRV-043, which contains no parvovirus sequences. Clearly, putting the parvovirus B-gene sequences in front of beta-gal (at the amino terminus) drastically reduced expression of beta-gal. Conversely, putting the parvovirus sequence behind beta-gal (at the carboxy terminus) resulted in significantly better expression of both the beta-gal part of the fusion (Table XIII) and the parvovirus part of the fusion) as determined by the size and amount of the fusion protein on Western blots) . The best direct comparison to see this effect is to compare S-PRV-039 (6% expression) with S-PRV-061 (72% expression) , where the same 44 amino acids of parvovirus are involved (Table XIII) . This example provides a demonstration of the second method of expressing a gene in herpesvirus. To practice the invention, a fusion should be made by putting at the amino terminus a gene that is well expressed, and putting at the carboxy terminus a gene that is less well expr e ssed. The order of these two genes must not be altered to benefit from the invention. TABLE XIII. EXPRESSION OF BETA-GAL IN FUSIONS WITH PARVOVIRUS B-GENE VIRUS INSERT EXPRESSION OF B-GAL control S-PRV-043 β-GAL ALONE 100% amino fusions S-PRV-039 44aaPPV/β-gal 6% S-PRV-049 212aaPPV/β-gal 0 . 2% carboxy fusions S-PRV-061 β-gal/4 aaPPV 72% . S-PRV-060 ø-gal/260aaPPV 68% S-PRV-065 ø-gal/666aaPPV 58% Example 26 S-PRV-065 S-PRV-065 is a pseudorabies virus that has a deletion in the TK gene in the long unique region, and a deletion in the repeat region. A gene coding for a fusion protein between E.coli beta-galactosidase (lacZ gene) and the swine parvovirus A capsid was inserted into the repeat regions. This virus is an example of a unique method for expressirT foreign antigens from a herpesvirus vector. This method involves the construction of herpesvirus containing a gene which codes for the foreign antigen as a carboxyl-terminal fusion to E.coli beta- galactosidase. This method has several advantages over previously known approaches. First and foremost this method often results in a dramatic increase in the absolute amount of antigen produced from the recombinant virus. Second the method as performed here results in an enzymatically active fusion protein, which allows the recombinant virus to be purified by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS procedure. Third the resulting fusion protein can easily be characterized by the WESTERN BLOTTING procedure using commercially available antibody to E.coli beta-galactosidase. The DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was used to construct PRV-065. This procedure requires a parental virus DNA, a -173- parental plasmid DNA, and a specific restriction enzyme. The parental virus DNA was from PRV-002 deposited under ATCC Accession No. VR2107 and described in parent application U.S. Serial No. 773,403, filed September 6, 1985. The parental plasmid DNA was from 244-25.3D (see fig. 40) and the restriction enzyme used was Xba I. The plasmid 244-25.3D contains an E. coli beta-galactosidase-swine parvovirus fusion gene as an Xba I fragment in the plasmid vector pSP65. Several segments of DNA were linked together utilizing either 10 naturally occurring restriction sites or s? • nthatic linker DNA. The detailed structure of this gene is shown in fig. 40. The first segment of DNA (segment 1 in fig. 40) contains the gpX promoter including the first seven amino acids of the gpX coding region and 15 was derived from a subclone of the PRV Bam HI number 10 fragment as an approximately 400 base pair Sal I to Bam HI fragment. The second segment of DNA (segment 2 in fig. 40) contains the E.coli beta-galactosidase coding region from amino acid 10 to amino acid 1024 and was 20 derived from the plasmid pJF751 (obtained from Jim Hoch, Scripps Clinic and Research Foundation) as two fragments of DNA, an approximately 3000 base pair Bam HI to Nde I fragment followed by an approximately 55 base pair Nde I to Pvu II fragment. The third segment 25 of DNA (segment 3 in fig. 40). contains the swine parvovirus capsid A coding region from amino acid 64 to amino acid 729 and can be derived from swine parvovirus * * replicative form DNA (68) as two fragments of DNA, an approximately 1600 base pair Pvu II to Nde I fragment 30 followed by an approximately 450 base pair Nde I to Rsa I fragment. These segments were assembled as indicated in fig. 40. The recombinant virus resulting from this construction was purified by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS and confirmed by restriction 35 analysis of viral DNA prepared from the purified virus. This virus was designated S-PRV-065 and has been deposited with the ATCC under Accession No. VR 2216. The structure of PRV-065 is shown in fig. 41. Expression of the parvovirus antigen was assayed in vitro utilizing the WESTERN BLOTTING PROCEDURE. Cell lysates were prepared as described in PREPARATION OF HERPESVIRUS CELL LYSATES. Fig. 42 shows that a band of the expected size (185 kilodaltons) for a beta- galactosidase-swine parvovirus capsid A fusion pro ir reacts specifically with an antibody directed against beta-galactosidase. Based on comparisons to known amounts of purified beta-galactosidase protein it is estimated that -30 ng of parvovirus capsid A are produced from an infection of a 60 mm petri dish of vero cells with S-PRV-065. Expression of the parvovirus antigen was also assayed in vitro using the ELISA ASSAY FOR PARVOVIRUS ANTIGEN. Table XIV shows that S-PRV-065 expresses antigen which reacts specifically with antibody directed against parvovirus protein. Results of an experiment in which weaned pigs were vaccinated with S-PRV-065 as shown in Table XV, indicate that S-PRV-065 may be used as a vaccine to protect swine against parvovirus infection. Following vaccination all animals were free of adverse reactions and five out of five pigs developed serum neutralizing antibodies to swine parvovirus. After challenge vaccinated animals exhibited a significant reduction in viremia relative to non vaccinated control animals. TAB E XIV ELISA ASSAY FOR PARVOVIRUS ANTIGEN A sandwhich ELISA was conducted by coating a microwell plate with polyclonal rabbit antiserum made against cesium chloride- purified porcine parvovirus. Lysates of infected cells were added to the coated plates and reacted for 90 minutes. The wells were washed and reacted with a polyclonal mouse antiserum against poiccine parvovirus. A biotin/avidin anti-mouse IgG, conjugated to horse radish peroxidase, was then added and the reaction was read at 405 nm. TABLE XV * Challenge administred on day 56 ** Pigs were added to the study at the time of chal Lymphocytes negative for PPV + Lymphocytes positive for, PPV -177- EXAMPLE 27 S-PRV-086 S-PRV-086 is a pseudorabies virus that has a deletion in the TK gene in the long unique region, a deletion in the repeat region and a deletion in the gpX coding region. A gene coding for a fusion protein between E.coli beta-galactosidase (lacZ gene) and the swine parvovirus A capsid was inserted into the deletion in the gpX coding region. This virus is an example of combining the unique method of expression of a foreign antigen described for PRV- 065 (Example 26) with increased safety and negative sero-logical marker described for PRV-013 (Example 6) . S-PRV-086 was constructed by homologous recombination using the DNA TRANSFECTION FOR GENERATING RECOMBINANT PRV. This procedure requires a parental virus DNA and a homologous recombination plasmid DNA. The parental virus DNA was from PRV-002 deposited under ATCC Accession No. VR2107 and described in U.S. Serial No. 773,403, filed September 6, 1985, and the homologous recombination plasmid was 244-49.2H (see fig. 43). The plasmid 244-49.2H contains an E.coli beta- galactosidase-swine parvovirus fusion gene flanked by PRV DNA homologous to the gpX region cloned in the plasmid vector pSP65. Several segments of DNA were linked together utilizing either naturally occurring restriction sites and/or synthetic linker DNA. The detailed structure of this gene is shown in fig. 43. The first segment of DNA (segment l in fig. 43) contains the gpX promoter including the first seven amino acids of the gpX coding region and was derived from a subclone of the PRV Bam HI number 10 fragment as an approximately 1400 base pair Eco RV to Bam HI fragment. The second segment of DNA (segment 2 in fig. 43) contains the E.coli beta-galactosidase coding region from amino acid 10 to amino acid 1024 and was derived from the plasmid pJF751 (obtained from Jim Hσch, Scripps Clinic and Research Foundation) as two fragments of DNA, an approximately 3000 base pair Bam HI to Nde I fragment followed by an approximately 55 base pair Nde I to Pvu II fragment. The third segment of DNA (segment 3 in fig. 43) contains the swine parvovirus capsid A coding region from .amino acid 64 to amino acid 729 and can be derived from swine parvovirus -plicative form DNA (68) as two fragments of DNA, an approximately 1600 base pair Pvu II to Nde I fragment followed by an approximately 450 base pair Nde I to RSA I fragment. The fourth segment (segment 4 in fig. 43) contains the gpX poly A addition signal and was derived from a sub-clone of the PRV Bam HI fragment number 7 as an approximately 1800 base pair Nde I to Stu I fragment. These segments were assembled as indicated in fig. 43. The recombinant virus resulting from this construction was purified by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS and confirmed by restriction analysis of viral DNA prepared from the purified virus. This virus was designated S-PRV-086 and has been deposited with the ATCC under Accession No. VR 2216. The structure of PRV-086 is shown in fig. 44. Expression of the parvovirus antigen was assayed in vitro utilizing the WESTERN BLOTTING PROCEDURE. Cell lysates were prepared as described in PREPARATION OF HERPESVIRUS CELL LYSATES. Fig. 42 shows that a band of the expected size (180 kilodaltons) for a beta- galactosidase-swine parvovirus capsid A fusion protein -179- reacts specifically with an antibody directed against beta-galactosidase. Based on comparisons to known amounts of purified beta-galactosidase protein it is estimated that -15 ng of parvovirus capsid A are produced from an infection of a 60 mm petri dish of vero cells with S-PRV-086. Results of an experiment in which weaned pigs were vaccinated with S-PRV-086 as shown in Table XVI, indicate that S-PRV-086 may be used as a vaccine to r.rotect swine against p rvovirus infection. Following vaccination all animals were free of adverse reactions and two out of three pigs developed serum neutralizing antibodies to swine parvovirus. After challenge vaccinated animals exhibited a significant reduction in viremia relative to non vaccinated control animals. TABLE XVI * Challenge administred on day 42 - Lymphocytes negative for PPV + Lymphocytes positive for PPV -181- EXAMPLE 28 S-PRV-040 S-PRV-040 is a pseudorabies virus that has a deletion in the TK gene in the long unique region and a deletion in the repeat region. A gene coding for a fusion protein between the pseudorabies gpX secretion signal sequence and the swine parvovirus A capsid was inserted into the repeat regions. This virus is an example of a unique method for expressing foreign antigens from a herpesvirus vector. This method involves the construction of herpesvirus containing a gene which codes for the foreign antigen as a carboxyl-terminai fusion to a herpesvirus secretion signal sequence. This method has several advantages over previously known approaches. First, this method often results in an increase in the absolute amount of antigen produced from the recombinant virus. Second, the method often results in the secretion of the foreign antigen from cells infected with the herpesvirus vector. Third, the secretion signal is often cleaved from the fusion protein resulting in a protein more closely resembling the unfused antigen. The DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was used to construct PRV-040. This procedure requires a parental virus DNA, a parental plasmid DNA, and a specific restriction enzyme. The parental virus DNA was from PRV-002 deposited under ATCC Accession No. VR2107 and described in U.S. Serial No. 773,403, filed September 6, 1985, the parental plasmid DNA was from 167-72.54G (see fig. 45) and the restriction enzyme used was Xba I. The plasmid 167-72.54G contains a PRV gpX secretion signal- swine parvovirus fusion gene as an Xba I fragment in the plasmid vector pSP65. Several segments of DNA were linked together utilizing either naturally occurring restriction sites and/or synthetic linker DNA. The detailed structure of this gene is shown in fig. 45. The first segment of DNA (segment 1 in fig. 45) contains the gpX promoter including the first twenty- seven amino acids of the gpX coding region and was derived from a subclone of the PRV Kpn J' frag__.3nt as an approximately 500 base pair Sal I to Sac I fragment. The second segment of DNA (segment 2 in fig. 45) contains the swine parvovirus capsid A coding region from amino acid 64 to amino acid 729 and can be derived from swine parvovirus replicative form DNA (68) as two fragments of DNA, an approximately 1600 base pair Pvu II to Nde I fragment followed by an approximately 450 base pair Nde I to Rsa I fragment. These segments were assembled as indicated in fig. 45. A recombinant virus transfection stock generated using the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was plated out. Twelve plaques were picked and analyzed for the presence of the approximately 2600 base pair parvovirus DNA containing Xba I fragment. Two of the viruses contained the expected Xba I fragment. One of these viruses was designated S-PRV-040 and has been deposited with the ATCC under Accession No. VR2214. The structure of PRV-040 is shown in fig 46. Results of an experiment in which weaned pigs were vaccinated with S-PRV-040 as shown in Table XVI indicate that S-PRV-040 may be used as a vaccine to protect swine against parvovirus infection. Following vaccination all animals were free of adverse reactions and two out of three pigs developed serum neutralizing antibodies to swine parvovirus. After chall enge vaccinated animals exhibited a significant reduction in viremia relative to non vaccinated control animals. EXAMPLE 29 S-PRV-098 S-PRV-098 is a pseudorabies virus that has a deletion in the TK gene in the long unique region, a deletion in the repeat region and a deletion in the gpX coding region. A gene coding for a fusion protein between E.coli beta-galactosidase (lacZ gene) and the swine parvovirus A capsid was inserted into the deletion in the gpX coding region. A second gene coding for a " fusion protei&. between the pseudorabies gpX secretion signal sequence and the swine parvovirus A capsid was inserted into the repeat regions. This virus is an example of combining the unique methods for expression of a foreign antigen described for PRV-065 (Example 26) and for PRV-040 (Example 28) with increased safety and negative sero-logical marker described for PRV-013 (Example 6) . The DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was used to construct PRV-098. This procedure requires a parental virus DNA, a parental plasmid DNA, and a specific restriction enzyme. The parental virus DNA was from PRV-086 (Example 27) , the parental plasmid DNA was from 167- 72.54G (see fig. 45) and the restriction enzyme used ' was Xba I. The plasmid 167-72.54G contains a PRV gpX secretion signal-swine parvovirus fusion gene as an Xba I fragment in the plasmid vector pSP65. A virus containing this Xbal insert was purified as- described ' for PRV-040 (Example 28) . This virus was designated S-PRV-098 and has been deposited with the -185- ATCC under Accession No. VR 2219. The structure of PRV-098 is shown in figure 47. Expression of the parvovirus antigen was assayed in vitro utilizing the ELISA ASSAY FOR PARVOVIRUS ANTIGEN. Table XIV shows that S-PRV-098 expresses the parvovirus antigen which reacts specifically with antibody directed against authentic parvovirus protein. EXAMPLE 30 S-PRV-066 S-PRV-066 is a pseudorabies virus that has a deletion in the TK gene in the long unique region, and a deletion in the repeat region. A gene coding for a fusion protein between the pseudorabies gpX secretion signal sequence and the plasmodium falciparum (P.fal.) circumsporozoite protein (CSP) was inserted into the repeat regions. This virus is an example of a unique " method for expressing foreign antigens from a herpesvirus vector. This method involves the construction of herpesvirus containing a gene which codes for the foreign antigen as a carboxy1-terminal fusion to a herpesvirus secretion signal sequence. This method has several advantages over previously known approaches. First, this method often results in an increase in the absolute amount of antigen produced from the recombinant virus. Second, the method often results in the secretion of the foreign antigen from cells infected with the herpesvirus vector. Third, the secretion signal is often cleaved from the fusion protein resulting in a protein more closely resembling the unfused antigen. The DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was used to construct PRV-066. This procedure requires a parental virus DNA, a parental plasmid DNA, and a specific restriction enzyme. The parental virus DNA was from PRV-002 deposited under ATCC Accession No. VR2107 and described in parent application U.S. Serial No. 773,403, filed -187- September 6, 1985, the parental plasmid DNA was from 181-42.2 (see fig. 48) and the restriction enzyme used was Xba I. The plasmid 181-42.2 contains a PRV gpX secretion signal-P.fal.CSP fusion gene as an Xba I fragment in the plasmid vector pSP18. Several segments of DNA were linked together utilizing either naturally occurring restriction sites and/or synthetic linker DNA. The detailed structure of this gene is sho#Λ in fig. 48. The first segment of DNA (segment 1 in fig. 48) • contains the gpX promoter including the first twenty-seven amino acids of the gpX coding region and was derived from a subclone of the PRV Kpn J' fragment as an approximately 500 base pair Sal I to Sac I fragment. The second segment of DNA (segment 2 in fig. 48) contains the P.fal. CSP coding region from amino acid 19 to amino acid 412 and was derived from plasmid pUC8/lambda mpf5 (obtained from Institute of Immunology, dept. of the Army, Walter Reed Army Institute of Research) as an approximately 1200 base pair Stu I to Rsa I fragment. The third segment of DNA (segment 3 in fig. 48) contains the herpes simplex virus (HSV) thymidine kinase (TK) poly A addition signal and was derived form plasmid D 5'-0.20 (68) as an approximately 600 base pair Sma I to Pvu II fragment. These segments were assembled as indicated in fig. 48 and used in the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. A virus containing the expected Xba I insert was purified as described for PRV-040 (Example 28) . This virus was designated S-PRV-066. The structure of PRV-066 shown in figure 49. Expression of the CSP antigen was assayed _in vitro utilizing the WESTERN BLOTTING PROCEDURE. Cell lysates were prepared as described in PREPARATION OF HERPESVIRUS CELL LYSATES. Fig. 50 shows that a band of the expected size (-46 kilodaltons) for a gpX secretion signal sequence-P.fal. CSP fusion protein reacts specifically with an antibody directed against the repeat portion of the CSP protein. Based on comparisons to known amounts of purified CSP protein it is estimated that -2 ng of CSP are produced from an infection of a 60 mm petri dish of vero cells with S- PRV-066. ne potential for PRV-06 , to induce an immune response in vivo was assayed. Three weaned pigs were vaccinated, and on day 21 post infection one of the pigs demonstrated a clear sero-conversion to the CSP antigen based on ELISA titers (69) . This experiment demonstrates the utility of this expression approach to induce an immune response to the CSP antigen in a host animal. -189- EXAMPLE 31 S-PRV-088 •r- S-PRV-088 is a pseudorabies virus that has a deletion in the TK gene in the long unique region, a deletion in the repeat region and i deletion in the gpX coding region. A gene for E.coli beta-galactosidase (lacZ gene) was inserted into the deletion in the gpX coding region. A second gene coding for an embedded fusion 10 protein 1 itween the PRV gpX and the P.fal.CSP "was. inserted into the repeat regions. This virus is an example of a unique method for expression of the antigenic determinate of a foreign 15 antigen. This method involves the construction of a herpesvirus containing a gene which codes for a herpesvirus protein in which an antigenic determinate of the herpesvirus protein has been replaced with an antigenic determinant from the foreign antigen. Such a 20 gene contains the foreign determinate as an embedded fusion in the herpesvirus protein. This method has several advantages over previously known approaches. First, this method often results in a dramatic (as much as 5000 fold) increase in the absolute amount of 25 antigenic determinant produced from the recombinant virus. Second, the foreign antigenic determinate often acquires advantageous properties of the herpesvirus protein, such as localization (secreted, surface, or intracellular) and stimulation of the host immune 30 system. Third, the high level of expression of this construct in vitro makes it feasible to purify this antigen from tissue culture for use as a subunit vaccine. 35 -190- The DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was used to construct PRV-088. This procedure requires a parental virus DNA, a parental plasmid DNA, and a specific restriction enzyme. The parental virus DNA was from PRV-013 (example 2) , the parental plasmid DNA was from PSY1373 (see fig. 51) and the restriction enzyme used was Hind III. The plasmid PSY1373 contains a PRV gpX-P.fal.CSP embedded fusion gene as a Hind III fragment in the plasmid vector pSP65. The antigenic determinate to be replaced in gpX .as identified by computer analysis of the gpX amino acid sequence. The site was confirmed by raising rabbit anti-serum against a chemically- synthesized peptide (peptide 85.12 amino acids 299 to 316) and showed that anti-strum to react specifically with the naturally synthesized gpX protein (see example 2, fig 4). The antigenic determinant of the P.fal.CSP was determined by Dame, et al. (69) and is composed of tandem repeats of the tetrapeptide asn-ala-asn-pro. In order to construct the appropriate embedded fusion several segements of DNA were linked together utilizing either naturally occurring restriction sites and/or synthetic linker DNA. The detailed structure of this gene is shown in fig. 51. The first segment of DNA (segment 1 in fig. 51) contains the gpX promoter and the first two hundred and sixty-nine amino acids of the gpX coding region and was derived from a subclone of the PRV Kpn J' fragment as an approximately 12000 base pair Sal I to BstE II fragment. The second segment of DNA (segment 2 in fig. 51) contains the P.fal. antigenic determinate as -32 tandem repeats of the tetrapeptide and can be derived from plasmid pUC8/lambda mpf5 (obtained from Institute of Immunology, Dept. of the Army, Walter Reed Army Institute of Research) as two copies of approximately 200 base pair Xho II to Xho II fragment of DNA (note this fragment when ligated at its Xho II ends in the same translational orientation retains the reading frame of the CSP) . The third segment (segment 3 in fig. 51) contains the C-terminal region of gpX (amino acids 356 to 498) including the poly A addition signal and can be derived from a subclone of the PRV BAM HI number 10 fragment as an approximately 1100 base pair BstE II to Sal I fragment of DNA. These segments were assen..led as indicated in fig. 31A and used in the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. A virus containing the expected Hind III insert was purified as described for PRV-040 (Example 28) . This virus was designated S- PRV-088 and has been deposited with the ATCC under Accession No. VR 2217. The structure of PRV-088 is shown in figure 52. Expression of CSP antigen was assayed .in vitro utilizing the WESTERN BLOTTING PROCEDURE. Cell lysates were prepared as described in PREPARATION OF HERPESVIRUS CELL LYSATES. Fig. 50 shows that a band of the expected size (-60 kilodaltons) for the gpX-P.fal. CSP embedded fusion protein reacts specifically with an antibody directed against the repeat portion of the CSP protein. Based on comparisons to known amounts of purified CS protein it is estimated that -25 lg of CSP are produced from an infection of a 60 mm petri dish of vero cells with S-PRV-088. EXAMPLE 32 S-PRV-093 S-PRV-093 is a pseudorabies virus that has a deletion in the TK gene in the long unique region, a deletion in the repeat region and a deletion in the gpX coding region. A gene for E.coli beta-galactosidase (lacZ gene) was inserted into the deletion in the gpX coding region. A second gene coding for a hybrid protein between vhe PRV gpX and the P.fal CSP was inserted into the repeat regions. This virus is an example of a unique method for expression of a foreign antigen. This method involves the construction of a herpesvirus containing a gene which codes for a hybrid protein the amino terminal portion of which is a herpesvirus protein and the carboxyl-terminal portion of which is the foreign antigen. This method has several advantages over previously known approaches. First, this method often results in an increase in the absolute amount of antigen produced from the recombinant virus. Second, the foreign antigen often has advantageous properties of both the herpesvirus protein and the foreign antigen. These properties may include localization (secreted, surface, or intracellular) and stimulation of the host immune system. The DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was used to construct PRV-093. This procedure requires a parental virus DNA was from PRV-013 (Example 2), the parental plasmid DNA was from 181-66.26 (see fig. 53) and the restriction enzyme used was Hind III. The plasmid 181-66.26 contains a PRV gpX-P.fal.CSP hybrid gene as a HIND III fragment in the plasmid vector pSP65. In order to construct the appropriate hybrid fusion several segments of DNA were linked together utilizing either naturally occurring restriction sites and/or synthetic linker DNA. The detailed structure of this gene is shown in fig. 53. The first segment of DNA (segment 1 in fig. 53) contains the gpX promoter and the first two hundred and sixty-nine amino acids of the gpX coding region and was derived from a subclone of the PRV Kpn J' fragment as an approximataJ" 12000 " base pair Sal to BstE II fragment. The second segment of DNA (segment 2 in fig 53) contains the P.fal.CSP coding region from amino acid 19 to amino acid 412 and was derived from plasmid pUC8/lambda mpf5 (obtained from Institute of Immunology, Dept. of the Army, Walter Reed Army Institute of Research) as an approximately 1200 base pair Stu I to Rsa I fragment. The third segment (segment 3 in fig. 53) contains the gpX poly A addition signal and can be derived from a subclone of the PRV Bam HI number 10 fragment as an approximately 1100 base pair BstE II to Sal I fragment of DNA. These segments were assembled as indicated in fig. 53 and used in the DIRECT LIGATIOr. PROCEDURE FOR GENERATING RECOMBINANT HEPESVIRUS. A virus containing the expected Hind III insert was purified as described for S-PRV-040 -(example 28) . This virus was designated S-PRV-093 and has been deposited with the ATCC under Acession No. VR 2218. The structure of PRV-093 is shown in figure 54. Expression of the CSP antigen was assayed in vitro utilizing the WESTERN BLOTTING PROCEDURE. Cell lysates were prepared as described in PREPARATION OF HERPESVIRUS CELL LYSATES. Fig. 50 shows that a band of the expected size (-72 kilodaltons) for the gpX-P.fal. CSP hybid protein reacts specifically with an antibody directed against the repeat portion of the CSP protein. Based on comparisons to known amounts of purified CS protein it is estimated that -600 ng of CSP are produced from an infection of a 60 mm petri dish of vero cells with S-PRV-093. -195- References 1. Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1982) . 2. S.L. Mansour, et al.. Proceeding of the National Academy of Sciences U.S.A. 82, 1359-1363 (1985). 3. C. Thummel, et al., Cell, 33, 455-464 (1983). 4. D. Scolnick, Cell, 24, 135-1*3 (1981). 5. C. Thummel et al.. Cell, 23, 825-836 (1981). 6. M. Mackett et al., Proc. Natl. Acad. Sci. USA, 79, 7415-7419 (1982). 7. D. Panicali and E. Paoletti, Proc. Natl. Acad. Sci. USA, 79, 4927-4931 (1982) . 8. E. Paoletti et al., Proc. Natl. Acad. Sci. USA, 81, 193-197 (1984). 9. G.L. Smith et al.. Nature, 302, 490-495 (1983). 10. " D. Pancicali et al., Proc. Natl. Acad. Sci. USA, 80, 5364-5368 (1983). 11. G.L. Smith et al., Proc. Natl. Acad. Sci. USA, 80, 7155-7159 (1983). 12. G.L. Smith et al.. Science, 224, 397-399 (1984). 13. M. Mackett et al.. Science, 227, 433-435 (1985). 14. D.M. Knipe et al., Proc. Natl. Acad. Sci. USA, 75, 3896-3900 (1978). 15. E.S. Mocarski et al.. Cell, 22, 243-255 (1980). 16. L.E. Post et al., Cell, 24, 555-5<55 v '1981) . 17. L.E. Post and B. Roizman, Cell, 25, 227-232 (1981) . 18. K.L. Poffenberger et al., Proc. Natl. Acad. Sci. USA, 80, 2690-2694 (1981). 19. M.G. Gibson and P.G. Spear, Journal of Virology, 48, 396-404 (1983). 20. G. T.-Y. Lee et al., Proc. Natl. Acad. Sci. USA, 79, 6612-6616 (1982). 21. M. -F. Shih et a.1., Proc. Natl. Acad. Sci. USA, 81, 5867-5870 (ι984). 22. R. Desrosiers et al.. Ninth Annual Herpesviru Meeting, Seattle, Abstract #280 (1984) . 23. T.J. Rea, et al.. Journal of Virology 54: 21-2 (1984) . 24. S. Ihara et al.. Virology, 122, 268-278 (1982). 25. S. Kit et al., American Journal of Veterinary Research 46, 1359-1367 (1985). 26. A. Berns et al., J. Virology, 53, 89-93 (1985). 27. B. Lomniczi et al., J. Virology, 49, 970-979 (1984) . 28. Y. Haj-Ahmed and F.L. Graham, J. Virology, 57, 267-274 (1986) . 29. J.H. Gillespie et al., J. Clin. Microbiology, 23, 283-288 (1986). 30. M. Arsenakis and B. Roizman, in "The High Technol¬ ogy Route to Virus Vaccines", American Society f-r Microbiology, Washington, D.C., 1985 (Proceedings of the First Annual Southwest Foundation for Bio- medical Research Internatinal Symposium, Houston, Texas, 8-10 November 1984) . 31. L.E. Post et al., Tenth International Herpesvirus Workshop, Ann Arbor, August, 1985. 32. F.L. Graham and A. Van der Eb, Virology, 52, 556- 567, 1973. 33. P.A. Norton and J.M. Coffin, Molecular and Cellu¬ lar Biology 5, 281-290, 1985. 34. ' T. Igarashi, et al., 10th International Herpesvi¬ rus Workshop, Abstract No. 17, Ann Arbor, Mcihigan, August 1985. 35. J. Campione - Piccardo, et al., J. Virology 31, 281-287, 1979. 36. L. Villarreal and P. Berg, Science 196, 183-185 5 (1977). 37. S.B. Mohanty and S.K. Dutta, Veterinary Virology, Lea and Febiger, pubs., Philadelphia (1981). Q 38. R. Crandell in Current Veterinary Therapy, pages 543-546, W.B. Saunders, pubs., Philadelphia (1981). 39. H. Ludwig in The Herpesviruses, Vol. 2, B. 5 Roizman, ed. , Plenum Press .1983). 40. R.B. Tenser et al.,k J. Clinical Microbiol. 17; 122-127 (1983). 0 41. Y-C. Cheng et al., J. Virological Methods 5, 209- 217 (1982). 42. U.K. Laemmli, Nature 227, 680-685 (1970). 5 43. K. Fukuchi, et al., J. of Virology 51, 102-109, (1984) . 44. M.A. Richardson et al., J. Virology 51, 860, 1985. 0 45. R. W. Price and A. Kahn, Infection and Immunity 34, 571-580, 1981. 46. P.B. Tenser, et al.. Journal of General Virology 64, 1369-1373, 1983. 5 47. S. Kit., et al.. Ninth International Herpesvirus Workshop, Seattle, August 24-29, 1984. 48. Roizman, et al., Coldspring Harbor Conference on New Aproaches to Viral Vaccines, September, 1983. 49. R. L. Thompson, et al.. Virology 131, 180-192, 1983. 50. K. Fukuchi, et al., Proc. Natl. Acad. Sci. (USA) 82, 751-75^ 1985. 51. ' J. M. Koomey, et al.. Journal of Virology 50, 662- 665, 1984. 52. T. C. Holland, et al., Journal of Virology, 52, 566-574, 1984. 53. A. E. Churchill, et al., Journal of General Virology 4, 557-563, 1969. 54. M.W. Wathan and L.M.K. Wathan, Journal of Virology 58, 173-178, 1986. 55. T.C. Mettenleiter, et al.. Journal of Virology 56, 307-311, 1985. 56. J.T. Van Oirschot, et al.. Journal of General Virology 67, 1179-1182, 1986. 57. Gubler, U. , and Hoffman, B.J. , Gene 25, 263-269, 1983. 58. Hanahan, D., Molecular Biology 166, 557-580, 1983. 59. Hu, S., et al., in Modern Approaches to Vaccines, R.M. Chanock and R.A. Lerner, eds., 219-223, Col Spring Harbor Press (1984) . 60. N. Elango, et al.. Journal Of Virology, 57, 481 489 (1986). 61. M. . Spriggs and P.L. Collins, Journal o Virology, 59, 646-654 (1986). 62. B.M. Blumberg, et al.. Journal of Genera Virology, 66, 317-331 (1985). 63. P.J. Hudson, et al.. Nucleic Acid Research, 14, 5001-5012 (1986) . 64. McKnight, S.L. and Kingbury, R. , Science 217, 316 324. 65. Jagadish, M.N., et al., J. of Virol., 62, 1084 1087 (1988). 66. R.J. Isfort, et al., Ninth Internationa Herpesvirus Workshop, Abstract #146, Seattle, Washington, August 1984. 67. Miller, J.H. (Ed.), Experiments in Molecula Genetics, 352-355, Cold Spring Harbor Laborator Press (1972) . 68. Hirt, B., J. Mol. Biol. 26:365-369 (1967). 69. McKnight, S.L. and Gravis, E.R., Nucleic Acid Research, 8, 3931-3949 (1980). 70. Dame, J.B., et al.. Science 225, 593-599 (1984)

Claims: What is claimed is: 1. A recombinant fusion protein comprising an antigenic amino acid sequence fused to at least a portion of the gpX glycoprotein from pseudorabies virus. 2. A recombinant fusion protein of claim 1, wherein the portion of the gpX glycoprotein comprises the amino-terminal transmembrane signal sequence from the gpX glyc protein. 3. A recombinant fusion protein of claim 1, wherein the antigenic amino acid sequence is inserted into an internal portion of the gpX glycoprotein. 4. A recombinant fusion protein of claim 3, wherein the gpX/antigenic amino acid sequence boundary is in frame only on the amino terminal side. 5. A recombinant fusion protein of claim 3, wherein both gpX/antigenic acid sequence boundaries are in frame with each other. 6. A recombinant fusion protein of claim 1 which is delivered to an animal using a live herpesvirus vector adapted to express said fusion protein. 7. A recombinant fusion protein of claim 1, wherein the antigenic amino acid sequence is part of swine parvovirus capsid protein. 8. A recombinant fusion protein of claim 1, wherein . the antigenic amino acid sequence is part of the malaria CSP protein. -203- 9. A recombinant fusion protein of claim 1, wherein the antigenic amino acid sequence is part of the malaria CSP repeat region. 10. A recombinant fusion protein comprising the E. coli beta-galactosidase gene fused at its carboxy terminus to an antigenic amino acid sequence and delivered to an animal using a live herpesvirus vector adapted to express the fusion protein. 10 11. A vaccine which comprises an effective immunizing amount of the recombinant fusion protein of claim 1. 15 12. An infectious bovine rhinotracheitis virus which includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase and neomycin resistance genes, and the parainfluenzae -3, PI-3, virus hemagglutinin gene, HN. 20 13. An infectious bovine rhinotracheitis virus of claim 12, designated S-IBR-018 and deposited under ATCC Accession No. VR 2180. 25 14. An infectious bovine rhinotracheitis virus which includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase and neomycin resistance genes, and the parainfluenzae -3, PI-3, virus fusion gene, F. 30 15. An infectious bovine rhinotracheitis virus of claim 14, designated S-IBR-019. 35 16. A herpesvirus of turkeys which includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase gene and the infectious bursal disease virus, IBDV, large segment of RNA. 17. A herpesvirus of turkeys of claim 16, designated S-HVT-003 and deposited under ATCC Accession No. VR 2178. 18. A herpesvirus of turkeys which includes a foreign DNA sequence which encodes the Escherichia coli beta-galactosidase gene and the Marek's disease virus, MDV, glycoprotein A, gp A, gene. 19. A herpesvirus of turkeys of claim 18, designated S-HVT-004. 20. An attenuated, hybrid, nonprimate herpesvirus which comprises a pseudorabies virus from which has been deleted the TK gene and a portion of the repeat region, and into which has been inserted a foreign DNA sequence which encodes the trans¬ missible gastroenteritis, TGE, virus gpl95 gene. 21. An attenuated, hybrid, nonprimate herpesvirus of claim 20, designated S-PRV-055 and deposited under ATCC Accession No. VR 2179. 22. An attenuated, pseudorabies virus designated S- PRV-065 and deposited under ATCC Accession No. VR 2215. 23. An attenuated, hybrid, nonprimate herpesvirus designated S-PRV-086 and deposited under ATCC No. VR 2216. 24. An attenuated, hybrid, nonprimate herpesvirus designated S-PRV-040 and deposited under ATCC No. VR 2214. 25. An attenuated, hybrid, nonprimate herpesvirus designated S-PRV-098 and deposited under ATCC No. VR 2219. 26. An attenuated, hybrid, nonprimate herpesvirus designated S-PRV-066. 27. An attenuated, hybrid, nonprimate herpesvirus designated S-PRV-088 and deposited under ATCC No. VR 2217. 28. An attenuated, hybrid, nonprimate herpesvirus designated S-PRV-093 and deposited under ATCC No. VR 2218.

Inventors: CHIANG CHRISTINA H, COCHRAN MARK D, MACCONNELL WILLIAM P, MACDONALD RICHARD D, SHIH MENG-FU, CHIANG, CHRISTINA, H., COCHRAN, MARK, D., MACCONNELL, WILLIAM, P., MACDONALD, RICHARD, D., SHIH, MENG-FU
Applicants: SYNTRO CORP, SYNTRO CORPORATION
Application year: 1988
Main classification: C12N15
IPC codes: A61K39, C07K14, C07K19, C12N7, C12N15, C12P21, C12R1